

CITATION REPORT

List of articles citing

The protein kinase complement of the human genome

DOI: 10.1126/science.1075762
Science, 2002, 298, 1912-34.

Source: <https://exaly.com/paper-pdf/34790324/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2304	Phosphorylation or Mutation of the ERK2 Activation Loop Alters Oligonucleotide Binding.		
2303	Drug Discovery Maps, a Machine Learning Model That Visualizes and Predicts KinomeInhibitor Interaction Landscapes.		
2302	Molecular Signatures of Fusion Proteins in Cancer.		
2301	Predictive Models for Fast and Effective Profiling of Kinase Inhibitors.		
2300	.		
2299	Plasticity of the kinomes in monkey and rat tissues. 2002 , 2002, pe50		6
2298	PARKINSON'S DISEASE. 2002 , 927-960		
2297	Signal transduction in the liver: C/EBPbeta modulates cell proliferation and survival. 2003 , 37, 731-8		41
2296	Cloning and characterization of a novel cardiac-specific kinase that interacts specifically with cardiac troponin I. 2003 , 81, 297-304		47
2295	Never say never. The NIMA-related protein kinases in mitotic control. 2003 , 13, 221-8		189
2294	Protein structure: discovering selective protein kinase inhibitors. 2003 , 2, 101-108		7
2293	High-throughput structural genomics and proteomics: where are we now?. 2003 , 2, 201-207		2
2292	News in brief. 2003 , 8, 191-194		
2291	DAP-like kinase, a member of the death-associated protein kinase family, associates with centrosomes, centromeres, and the contractile ring during mitosis. 2003 , 82, 447-59		14
2290	Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. 2003 , 11, 1595-607		144
2289	Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression. 2003 , 33, 621-40		76
2288	CDK versus GSK-3 inhibition: a purple haze no longer?. 2003 , 10, 1144-6		19

2287	Receptor tyrosine kinases in normal and malignant haematopoiesis. 2003 , 17, 241-8	53
2286	Interdisciplinary sciences in the 21st century. 2003 , 14, 328-31	7
2285	Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis. 2003 , 13, 2985-8	41
2284	Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. 2003 , 13, 3049-53	52
2283	Alternative binding modes of an inhibitor to two different kinases. 2003 , 270, 3174-81	65
2282	Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. 2003 , 2, 28	1283
2281	Protein kinases conserved in herpesviruses potentially share a function mimicking the cellular protein kinase cdc2. 2003 , 13, 331-40	76
2280	Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. 2003 , 10, 168-74	194
2279	Phosphospecific proteolysis for mapping sites of protein phosphorylation. 2003 , 21, 1047-54	219
2278	A molecular switch controlling renal sodium and potassium excretion. 2003 , 35, 302-3	18
2277	Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. 2003 , 35, 148-57	397
2276	Issues and progress with protein kinase inhibitors for cancer treatment. 2003 , 2, 296-313	410
2275	Phosphatases in cell-matrix adhesion and migration. 2003 , 4, 700-11	99
2274	Post-translational modifications regulate microtubule function. 2003 , 4, 938-47	568
2273	Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. 2003 , 5, 609-20	116
2272	Protein kinase inhibitors as a therapeutic modality. 2003 , 36, 462-9	158
2271	Implications for RNase L in prostate cancer biology. 2003 , 42, 1805-12	122
2270	Exploring the nonlinear geometry of protein homology. 2003 , 12, 1604-12	10

2269	MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. 2003 , 22, 5090-101	145
2268	In search of the pathways for light-induced pacemaker resetting in the suprachiasmatic nucleus. 2003 , 18, 235-49	174
2267	Use of capillary electrophoresis and endogenous fluorescent substrate to monitor intracellular activation of protein kinase A. 2003 , 75, 3720-4	41
2266	Improved beta-elimination-based affinity purification strategy for enrichment of phosphopeptides. 2003 , 75, 6826-36	221
2265	Kinases, homology models, and high throughput docking. 2003 , 46, 4638-47	118
2264	Structure-based active site profiles for genome analysis and functional family subclassification. 2003 , 334, 387-401	52
2263	Repair of DNA double strand breaks by non-homologous end joining. 2003 , 85, 1161-73	299
2262	STI-571: an anticancer protein-tyrosine kinase inhibitor. 2003 , 309, 709-17	83
2261	Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. 2003 , 330, 925-34	65
2260	NDR family of AGC kinases--essential regulators of the cell cycle and morphogenesis. 2003 , 546, 73-80	85
2259	Protein kinase D: a family affair. 2003 , 546, 81-6	175
2258	Expression of the VRK (vaccinia-related kinase) gene family of p53 regulators in murine hematopoietic development. 2003 , 544, 176-80	40
2257	Functional homology between yeast piD261/Bud32 and human PRPK: both phosphorylate p53 and PRPK partially complements piD261/Bud32 deficiency. 2003 , 549, 63-6	30
2256	A myristoyl/phosphotyrosine switch regulates c-Abl. 2003 , 112, 845-57	332
2255	Mechanisms of TGF-beta signaling from cell membrane to the nucleus. 2003 , 113, 685-700	4695
2254	The human solute carrier SLC41A1 belongs to a novel eukaryotic subfamily with homology to prokaryotic MgtE Mg ²⁺ transporters. 2003 , 306, 718-24	66
2253	A genome-wide survey of the genes for planar polarity signaling or convergent extension-related genes in <i>Ciona intestinalis</i> and phylogenetic comparisons of evolutionary conserved signaling components. 2003 , 317, 165-85	19
2252	What is the relevance of bioinformatics to pharmacology?. 2003 , 24, 434-9	40

2251	Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction. 2003 , 24, 489-502	86
2250	Growth signalling pathways in Arabidopsis and the AGC protein kinases. 2003 , 8, 424-31	165
2249	High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases. 2003 , 1, 445-53	41
2248	Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. 2003 , 4, 111	197
2247	Versatile fluorescence probes of protein kinase activity. 2003 , 125, 14248-9	178
2246	Chapter 28. Recent development in cheminformatics and chemogenomics. 2003 , 38, 285-294	3
2245	Profiling the global tyrosine phosphorylation state. 2003 , 2, 215-33	66
2244	A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins. 2003 , 100, 10193-200	100
2243	Ligand structure-activity requirements and phospholipid dependence for the binding of phorbol esters to protein kinase D. 2003 , 64, 1342-8	21
2242	Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. 2003 , 24, 1291-300	114
2241	A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. 2003 , 278, 32662-72	83
2240	Heteromeric MAPPIT: a novel strategy to study modification-dependent protein-protein interactions in mammalian cells. 2003 , 31, e75	30
2239	Exploiting features of adenovirus replication to support mammalian kinase production. 2003 , 31, e128	9
2238	Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. 2003 , 23, 7732-41	77
2237	A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. 2003 , 278, 34897-909	128
2236	Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. 2003 , 372, 1-13	286
2235	The role of investigative molecular toxicology in early stage drug development. 2003 , 2, 147-59	9
2234	Nonlinear elasticity, proteinquakes, and the energy landscapes of functional transitions in proteins. 2003 , 100, 12570-5	433

2233	An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. 2003 , 100, 15434-9	317
2232	Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. 2003 , 100, 4287-92	138
2231	Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, autophosphorylation, and interaction with Hck. 2003 , 278, 47713-23	58
2230	Mutational analysis of the tyrosine kinome in colorectal cancers. <i>Science</i> , 2003 , 300, 949	33.3 392
2229	Determination of the substrate-docking site of protein tyrosine kinase C-terminal Src kinase. 2003 , 100, 14707-12	71
2228	Mechanism of Ca ²⁺ -mediated regulation of NDR protein kinase through autophosphorylation and phosphorylation by an upstream kinase. 2003 , 278, 6710-8	71
2227	Amino acids determining enzyme-substrate specificity in prokaryotic and eukaryotic protein kinases. 2003 , 100, 4463-8	77
2226	Signal transduction-related bioinformatics services. 2003 , 4, 325-31	
2225	A bioinformatics-based approach for the prediction and identification of novel proteins potentially involved in phosphorylation signalling pathways. 2003 , 12, 391	
2224	G protein-coupled receptor kinase interaction with Hsp90 mediates kinase maturation. 2003 , 278, 50908-14	42
2223	Structural insights into AGC kinase inhibition. 2004 , 14, 267-78	10
2222	Fluorescence assays for high-throughput screening of protein kinases. 2003 , 6, 313-20	41
2221	Mutational profiling in the human genome. 2003 , 68, 23-9	6
2220	SRC family kinases: potential targets for the treatment of human cancer and leukemia. 2003 , 9, 2043-59	105
2219	The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. 2003 , 23, 2068-82	89
2218	Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery. 2003 , 8, 349-358	5
2217	Chemical libraries towards protein kinase inhibitors. 2003 , 6, 661-72	4
2216	Novel Protein Kinase Inhibitors: SMART Drug Design Technology. 2003 , 34, S2-S15	12

2215	. 2004 ,	28
2214	Chemical Kinomics. 2004 , 167-190	3
2213	. 2004 ,	10
2212	Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. 2004 , 5, 69-77	34
2211	Novel oncogenic protein kinase inhibitors for cancer therapy. 2004 , 4, 449-55	26
2210	Minireview: RET: normal and abnormal functions. 2004 , 145, 5448-51	134
2209	Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. 2004 , 10, 1083-91	22
2208	Proteomics: current techniques and potential applications to lung disease. 2004 , 287, L1-23	88
2207	Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). 2004 , 10, 1757-66	21
2206	Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. 2004 , 4, 13-28	210
2205	Cyclin dependent kinase 11 in RNA transcription and splicing. 2004 , 77, 263-88	32
2204	High-throughput structural biology in drug discovery: protein kinases. 2004 , 10, 1069-82	46
2203	Assessing cellular protein phosphorylation: high throughput drug discovery technologies. 2004 , 2, 225-35	23
2202	Substrate capacity considerations in developing kinase assays. 2004 , 2, 131-40	7
2201	Comparison of on-chip and off-chip microfluidic kinase assay formats. 2004 , 2, 121-9	42
2200	A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. 2004 , 18, 8-30	251
2199	Applications of fluorescent polymer superquenching to high throughput screening assays for protein kinases. 2004 , 2, 183-92	30
2198	Miniaturized, ultra-high throughput screening of tyrosine kinases using homogeneous, competitive fluorescence immunoassays. 2004 , 2, 141-51	22

2197	WNK1 activates ERK5 by an MEKK2/3-dependent mechanism. 2004 , 279, 7826-31	129
2196	Two simple and generic antibody-independent kinase assays: comparison of a bioluminescent and a microfluidic assay format. 2004 , 9, 409-16	30
2195	Phosphoproteomic analysis of the developing mouse brain. 2004 , 3, 1093-101	299
2194	Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein. 2004 , 279, 23806-12	62
2193	Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. 2004 , 24, 5039-49	43
2192	Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase. 2004 , 9, 309-21	11
2191	Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. 2004 , 15, 1212-22	75
2190	Roscovitin inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors. 2004 , 78, 9352-65	43
2189	Gleevec: prototype or outlier?. 2004 , 2004, pe12	14
2188	S6K1(-)/S6K2(-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. 2004 , 24, 3112-24	623
2187	Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. 2004 , 101, 12288-93	375
2186	Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy. 2004 , 13, 2505-18	53
2185	Origins, lineage-specific expansions, and multiple losses of tyrosine kinases in eukaryotes. 2004 , 21, 828-40	62
2184	Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. 2004 , 24, 2614-26	200
2183	MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. 2004 , 167, 99-110	193
2182	Comparative analysis of the receptor-like kinase family in Arabidopsis and rice. 2004 , 16, 1220-34	772
2181	Microarray transfection analysis of transcriptional regulation by cAMP-dependent protein kinase. 2004 , 3, 770-9	30
2180	Purification and identification of protein-tyrosine kinase-binding proteins using synthetic phosphopeptides as affinity reagents. 2004 , 3, 887-95	5

2179	Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. 2004 , 3, 1181-93	69
2178	The AMP-activated protein kinase pathway--new players upstream and downstream. 2004 , 117, 5479-87	935
2177	Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins. 2004 , 101, 7187-92	112
2176	Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. 2004 , 109, 1196-205	114
2175	The protein kinase C inhibitor bisindolyl maleimide 2 binds with reversed orientations to different conformations of protein kinase A. 2004 , 279, 23679-90	35
2174	Smurf1: a link between cell polarity and ubiquitination. 2004 , 3, 391-2	39
2173	Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. 2004 , 95, 1091-9	121
2172	The promise of genomics to identify novel therapeutic targets. 2004 , 8, 587-96	45
2171	Kinase selectivity profiling by inhibitor affinity chromatography. 2004 , 1, 303-15	7
2170	New lead generation strategies for protein kinase inhibitors - fragment based screening approaches. 2004 , 4, 301-11	31
2169	Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. 2004 , 50, 490-9	268
2168	The mouse kinome: discovery and comparative genomics of all mouse protein kinases. 2004 , 101, 11707-12	248
2167	Characterization of three paralogous members of the Mammalian vaccinia related kinase family. 2004 , 279, 7934-46	106
2166	Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells. 2004 , 279, 32716-27	33
2165	p53 Stabilization and accumulation induced by human vaccinia-related kinase 1. 2004 , 24, 10366-80	105
2164	Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. 2004 , 279, 18262-9	70
2163	The phosphorylation of subunits of complex I from bovine heart mitochondria. 2004 , 279, 26036-45	133
2162	Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. 2004 , 279, 8808-19	41

2161	Metal ion-mediated polymer superquenching for highly sensitive detection of kinase and phosphatase activities. 2004 , 101, 15295-300	129
2160	Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. 2004 , 279, 55262-70	52
2159	Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. 2004 , 101, 17300-5	227
2158	Human vaccinia-related kinase 1 (VRK1) activates the ATF2 transcriptional activity by novel phosphorylation on Thr-73 and Ser-62 and cooperates with JNK. 2004 , 279, 27458-65	92
2157	A tobacco calcium/calmodulin-binding protein kinase functions as a negative regulator of flowering. 2004 , 279, 31483-94	29
2156	Kinase peptide specificity: improved determination and relevance to protein phosphorylation. 2004 , 101, 13744-9	81
2155	Inhibition of spliceosome assembly by the cell cycle-regulated protein kinase MELK and involvement of splicing factor NIPP1. 2004 , 279, 8642-7	70
2154	Identification of kinase inhibitors by an ATP depletion method. 2004 , 2, 161-9	34
2153	Evaluation of kinase inhibitor selectivity by chemical proteomics. 2004 , 2, 215-24	42
2152	Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. 2004 , 2, 431-41	68
2151	Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. 2004 , 279, 35298-305	176
2150	MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. 2004 , 279, 5915-23	110
2149	High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. 2004 , 78, 3502-13	57
2148	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
2147	Prediction of phosphorylation sites using SVMs. 2004 , 20, 3179-84	190
2146	Kinase inhibitors in cancer therapy. 2004 , 2, 177-93	22
2145	Control of vesicle fusion by a tyrosine phosphatase. 2004 , 6, 831-9	91
2144	Treating cancer's kinase 'addiction'. 2004 , 10, 786-7	52

2143	A rapid method for determining protein kinase phosphorylation specificity. 2004 , 1, 27-9	284
2142	Eph-ephrin promiscuity is now crystal clear. 2004 , 7, 417-8	125
2141	Switching on kinases: oncogenic activation of BRAF and the PDGFR family. 2004 , 4, 718-27	142
2140	Strategies to overcome resistance to targeted protein kinase inhibitors. 2004 , 3, 1001-10	276
2139	Regulation of the c-Abl and Bcr-Abl tyrosine kinases. 2004 , 5, 33-44	380
2138	LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. 2004 , 23, 833-43	1055
2137	PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. 2004 , 23, 3303-13	78
2136	Scaffolding by ERK3 regulates MK5 in development. 2004 , 23, 4770-9	93
2135	c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). 2004 , 23, 8950-8	83
2134	Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. 2004 , 11, 1192-7	511
2133	Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. 2004 , 90, 815-21	139
2132	Astronomy: where are Procyon's quakes?. 2004 , 430, 29-30	10
2131	Cancer: understanding the target. 2004 , 430, 30	12
2130	Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. 2004 , 12, 1303-11	156
2129	Crystal structure of A. fulgidus Rio2 defines a new family of serine protein kinases. 2004 , 12, 1585-94	66
2128	LKB1 tumor suppressor protein: PARTaker in cell polarity. 2004 , 14, 312-9	108
2127	Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation. 2004 , 29, 136-42	82
2126	Identifying protein kinase substrates: hunting for the organ-grinder's monkeys. 2004 , 29, 227-32	45

2125	Signal transduction in cancer chemoprevention. 2004 , 555, 1-2	8
2124	'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). 2004 , 14, 33-40	55
2123	Can mouse models for brain tumors inform treatment in pediatric patients?. 2004 , 14, 71-7	1
2122	Quantitative analysis of signaling networks. 2004 , 86, 5-43	163
2121	Protein kinases in drug discovery and development. 2004 , 9, 16-7	4
2120	Utility of homology models in the drug discovery process. 2004 , 9, 659-69	233
2119	The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. 2004 , 328, 254-65	36
2118	Alpha-kinases: analysis of the family and comparison with conventional protein kinases. 2004 , 85, 1-32	100
2117	Phospho.ELM: a database of experimentally verified phosphorylation sites in eukaryotic proteins. 2004 , 5, 79	282
2116	Protein kinases of the human malaria parasite <i>Plasmodium falciparum</i> : the kinome of a divergent eukaryote. 2004 , 5, 79	376
2115	Sequence and structural analysis of kinase ATP pocket residues. 2004 , 59, 759-65	66
2114	The EF-Handome: combining comparative genomic study using FamDBtool, a new bioinformatics tool, and the network of expertise of the European Calcium Society. 2004 , 1742, 179-83	11
2113	The novel functions of ubiquitination in signaling. 2004 , 16, 119-26	359
2112	Counting on mitogen-activated protein kinases--ERKs 3, 4, 5, 6, 7 and 8. 2004 , 16, 1345-54	107
2111	Tyrosine kinase receptors as attractive targets of cancer therapy. 2004 , 50, 23-38	140
2110	Profiling of generic anti-phosphopeptide antibodies and kinases with peptide microarrays using radioactive and fluorescence-based assays. 2004 , 8, 291-9	50
2109	Protein kinase inhibitors: insights into drug design from structure. <i>Science</i> , 2004 , 303, 1800-5	33.3 1035
2108	<i>Arabidopsis</i> kinome: after the casting. 2004 , 4, 163-87	94

2107	Isoindolinone ureas: a novel class of KDR kinase inhibitors. 2004 , 14, 4505-9	27
2106	Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. 2004 , 14, 5793-7	58
2105	Tyrosine kinase inhibitors in cancer therapy. 2004 , 37, 618-35	161
2104	Regulation of bone morphogenetic proteins in early embryonic development. 2004 , 91, 519-34	59
2103	A genomic perspective of protein kinases in Plasmodium falciparum. 2005 , 58, 180-9	121
2102	PhosphaBase: an ontology-driven database resource for protein phosphatases. 2005 , 58, 290-4	13
2101	Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. 2004 , 60, 240-5	137
2100	Protein kinase A phosphorylation characterized by tandem Fourier transform ion cyclotron resonance mass spectrometry. 2004 , 4, 970-81	75
2099	PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation. 2004 , 4, 1551-61	453
2098	Identification of regulated genes during permanent focal cerebral ischaemia: characterization of the protein kinase 9b5/MARKL1/MARK4. 2004 , 88, 1114-26	33
2097	High-content peptide microarrays for deciphering kinase specificity and biology. 2004 , 43, 2671-4	75
2096	High-Content Peptide Microarrays for Deciphering Kinase Specificity and Biology. 2004 , 116, 2725-2728	16
2095	Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. 2004 , 23, 540-5	485
2094	MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. 2004 , 112, 986-93	50
2093	NMR backbone assignment of a protein kinase catalytic domain by a combination of several approaches: application to the catalytic subunit of cAMP-dependent protein kinase. 2004 , 5, 1508-16	50
2092	Isolation of phosphopeptides using solid phase enrichment. 2004 , 45, 91-93	24
2091	Tyrosine kinases in AML: where do they fit in?. 2004 , 28, 217-8	2
2090	A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. 2004 , 11, 211-23	103

2089	Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. 2004 , 11, 691-701	114
2088	ADP-specific sensors enable universal assay of protein kinase activity. 2004 , 11, 499-508	78
2087	Characterization of protein kinase A phosphorylation: multi-technique approach to phosphate mapping. 2004 , 324, 204-18	9
2086	Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. 2004 , 1697, 89-101	210
2085	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. 2004 , 1697, 17-27	110
2084	Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. 2004 , 1697, 243-57	151
2083	PKA: a portrait of protein kinase dynamics. 2004 , 1697, 259-69	247
2082	The Janus kinases (Jaks). 2004 , 5, 253	400
2081	Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD?. 2004 , 18, 167-80	14
2080	The Contribution of Molecular Informatics to Chemogenomics. Knowledge-Based Discovery of Biological Targets and Chemical Lead Compounds. 2004 , 137-166	1
2079	Anti-sulfonylbenzoate antibodies as a tool for the detection of nucleotide-binding proteins for functional proteomics. 2004 , 3, 1184-90	8
2078	PfPKB, a novel protein kinase B-like enzyme from Plasmodium falciparum: I. Identification, characterization, and possible role in parasite development. 2004 , 279, 24255-64	38
2077	Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3',5'-adenosine monophosphate-dependent protein kinase catalytic subunit. 2004 , 43, 85-96	32
2076	Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production. 2004 , 47, 2724-7	110
2075	Quantitative methods for the analysis of protein phosphorylation in drug development. 2004 , 1, 327-41	70
2074	Fishing for targets: novel approaches using small molecule baits. 2004 , 1, 9-15	17
2073	Chemical kinomics - a target gene family approach in chemical biology. 2004 , 1, 25-34	4
2072	Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. 2004 , 47, 935-46	308

2071	Overview of protein structural and functional folds. 2004 , Chapter 17, Unit 17.1	6
2070	The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt. 2004 , 13, 787-97	37
2069	The BCR-ABL story: bench to bedside and back. 2004 , 22, 247-306	303
2068	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. 2004 , 13, 1-19	46
2067	Analysis of the LKB1-STRAD-MO25 complex. 2004 , 117, 6365-75	117
2066	A mechanism-based cross-linker for the identification of kinase-substrate pairs. 2004 , 126, 9160-1	68
2065	Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. 2004 , 13, 2059-77	116
2064	A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. 2004 , 4, 268-74	27
2063	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. 2004 , 47, 6239-47	151
2062	Chemical Probes in Biology. 2004 ,	1
2061	Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry. 2004 , 76, 2763-72	198
2060	Protein tyrosine phosphatases in the human genome. 2004 , 117, 699-711	1492
2059	Initiating cellular stress responses. 2004 , 118, 9-17	574
2058	DNA damage-induced activation of ATM and ATM-dependent signaling pathways. 2004 , 3, 889-900	366
2057	Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. 2004 , 328, 135-42	72
2056	Cloning, genomic organization, alternative splicing and expression analysis of the human gene WNK3 (PRKWINK3). 2004 , 335, 109-19	49
2055	Src proteins/src genes: from sponges to mammals. 2004 , 342, 251-61	13
2054	O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. 2004 , 1673, 13-28	319

2053	Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. 2004 , 318, 882-92	136
2052	The ErbB/HER receptor protein-tyrosine kinases and cancer. 2004 , 319, 1-11	309
2051	Src protein-tyrosine kinase structure and regulation. 2004 , 324, 1155-64	385
2050	GPS: a novel group-based phosphorylation predicting and scoring method. 2004 , 325, 1443-8	126
2049	Specific PKC isoforms regulate blastocoel formation during mouse preimplantation development. 2004 , 274, 384-401	43
2048	Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. 2004 , 295, 9-24	33
2047	Bruton tyrosine kinase-like protein, BtkSD, is present in the marine sponge Suberites domuncula. 2004 , 83, 743-5	18
2046	Characterization of the cAMP-dependent protein kinase catalytic subunit Cgamma expressed and purified from sf9 cells. 2004 , 35, 156-69	9
2045	Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. 2004 , 44, 595-600	1860
2044	Protein kinases linked to the pathogenesis of Parkinson's disease. 2004 , 44, 575-7	43
2043	Reassessing the MAP3K and MAP4K relationships. 2004 , 9, 123-9	64
2042	A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. 2004 , 15, 485-9	113
2041	WNK1 phosphorylates synaptotagmin 2 and modulates its membrane binding. 2004 , 15, 741-51	70
2040	Regulation of protein kinases; controlling activity through activation segment conformation. 2004 , 15, 661-75	814
2039	Jak3 and the pathogenesis of severe combined immunodeficiency. 2004 , 41, 727-37	92
2038	Protein tyrosine phosphatases in T cell physiology. 2004 , 41, 687-700	76
2037	Single cell proteomics for personalised medicine. 2004 , 10, 574-7	33
2036	Unexpected Hedgehog-Wnt interactions in epithelial differentiation. 2004 , 10, 577-80	42

2035	The slowpoke channel binding protein Slob from <i>Drosophila melanogaster</i> exhibits regulatable protein kinase activity. 2004 , 365, 33-8	12
2034	Effect of hypoxia on protein tyrosine kinase activity in cortical membranes of newborn piglets--the role of nitric oxide. 2004 , 372, 114-8	9
2033	Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1. 2004 , 337, 115-28	45
2032	Crystal structure of a cAMP-dependent protein kinase mutant at 1.26Å: new insights into the catalytic mechanism. 2004 , 336, 473-87	69
2031	Target specificity analysis of the Abl kinase using peptide microarray data. 2004 , 336, 307-11	68
2030	Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. 2004 , 116, 855-67	2142
2029	Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position. 2004 , 556, 26-34	22
2028	Receptor kinase signalling in plants. 2004 , 82, 1-15	42
2027	Common and distinct elements in cellular signaling via EGF and FGF receptors. <i>Science</i> , 2004 , 306, 1506-333	344
2026	Intermediate filaments: molecular structure, assembly mechanism, and integration into functionally distinct intracellular Scaffolds. 2004 , 73, 749-89	546
2025	Eph receptors, ephrins, and synaptic function. 2004 , 10, 304-14	77
2024	Assaying protein kinase activity. 2004 , 284, 79-90	7
2023	Toward a pharmacophore for kinase frequent hitters. 2004 , 47, 5616-9	55
2022	The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. 2004 , 2004, re15	273
2021	The importance of intrinsic disorder for protein phosphorylation. 2004 , 32, 1037-49	1043
2020	Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. 2004 , 378, 569-77	81
2019	Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. 2004 , 380, 371-84	21
2018	Structural Aspects of Kinases and Their Inhibitors. 2004 , 191-219	5

2017	Comparison of Modulation of Kv1.3 Channel by Two Receptor Tyrosine Kinases in Olfactory Bulb Neurons of Rodents. 2004 , 10, 25-36	4
2016	Somatic mutations in human cancer: insights from resequencing the protein kinase gene family. 2005 , 70, 43-9	21
2015	Inhibitors of PKA and Related Protein Kinases. 2005 , 85-124	3
2014	Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. 2005 , 70, 499-515	24
2013	Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity. 2005 , 295-317	8
2012	Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. 2005 , 14, 3477-92	376
2011	Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration. 2005 , 38, 381-402	18
2010	Applied Bioinformatics for Drug Discovery and Development. 353-382	
2009	Posttranslational modification of proteins. 2005 ,	
2008	MSK1 activity is controlled by multiple phosphorylation sites. 2005 , 387, 507-17	132
2007	Generation of protein kinase Ck1alpha mutants which discriminate between canonical and non-canonical substrates. 2005 , 391, 417-24	24
2006	Comparative Modeling and Structural Proteomics. 2005 , 109-136	
2005	Targeted Therapy with Imatinib: An Exception or a Rule?. 2005 , 361-389	4
2004	The RIO kinases: an atypical protein kinase family required for ribosome biogenesis and cell cycle progression. 2005 , 1754, 14-24	81
2003	Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. 2005 , 1754, 3-13	121
2002	Protein kinases as drug targets in trypanosomes and Leishmania. 2005 , 1754, 151-9	159
2001	Dynamics of signaling by PKA. 2005 , 1754, 25-37	184
2000	Crystallography for protein kinase drug design: PKA and SRC case studies. 2005 , 1754, 38-49	11

1999	Zinc ion acts as a cofactor for serine/threonine kinase MST3 and has a distinct role in autophosphorylation of MST3. 2005 , 99, 1306-13	19
1998	Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. 2005 , 12, 1211-9	104
1997	The kinome is not enough. 2005 , 12, 1057-8	3
1996	Small molecules driving myotube fission. 2005 , 12, 1058-60	3
1995	Functional identification of kinases essential for T-cell activation through a genetic suppression screen. 2005 , 96, 129-45	15
1994	Single-molecule observation of the catalytic subunit of cAMP-dependent protein kinase binding to an inhibitor peptide. 2005 , 12, 109-20	64
1993	A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. 2005 , 12, 1103-15	31
1992	Peptide inhibitors of protein kinases-discovery, characterisation and use. 2005 , 1754, 79-99	56
1991	Substrate specificity of protein kinases and computational prediction of substrates. 2005 , 1754, 200-9	80
1990	Bisubstrate analog probes for the insulin receptor protein tyrosine kinase: molecular yardsticks for analyzing catalytic mechanism and inhibitor design. 2005 , 33, 285-97	21
1989	Crystal structure of the E230Q mutant of cAMP-dependent protein kinase reveals an unexpected apoenzyme conformation and an extended N-terminal A helix. 2005 , 14, 2871-9	28
1988	The ERK cascade: a prototype of MAPK signaling. 2005 , 31, 151-74	319
1987	Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening. 2005 , 48, 121-33	96
1986	Overview of signal transduction. 2006 , Chapter 2, Unit2.1	1
1985	FLT3 tyrosine kinase inhibitors. 2005 , 82, 100-7	62
1984	The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. 2005 , 28, 508-14	71
1983	A small molecule-kinase interaction map for clinical kinase inhibitors. 2005 , 23, 329-36	1569
1982	Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. 2005 , 7, 591-600	469

1981	Assignment of protein function in the postgenomic era. 2005 , 1, 130-42	116
1980	A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. 2005 , 37, 590-2	289
1979	To affinity and beyond. 2005 , 2, 243-243	
1978	Kinase chemical genomics--a new rule for the exceptions. 2005 , 2, 411-2	11
1977	Perturbing interactions. 2005 , 2, 412-4	6
1976	MPS-1 is a K ⁺ channel beta-subunit and a serine/threonine kinase. 2005 , 8, 1503-9	26
1975	Integrin-linked kinase: a cancer therapeutic target unique among its ILK. 2005 , 5, 51-63	495
1974	Finding new tricks for old drugs: an efficient route for public-sector drug discovery. 2005 , 4, 1005-14	171
1973	Protein tyrosine phosphatases and the immune response. 2005 , 5, 43-57	273
1972	Reconstruction of cellular signalling networks and analysis of their properties. 2005 , 6, 99-111	408
1971	The phosphoinositide-3-OH-kinase-related kinases of <i>Arabidopsis thaliana</i> . 2005 , 6, 723-8	28
1970	Induction of centrosome and chromosome aberrations by imatinib in vitro. 2005 , 19, 1573-8	57
1969	Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. 2005 , 436, 78-86	523
1968	Colorectal cancer: mutations in a signalling pathway. 2005 , 436, 792	452
1967	Structural characterization of Ca ²⁺ /CaM in complex with the phosphorylase kinase PhK5 peptide. 2005 , 272, 1511-22	9
1966	Autophosphorylation of <i>Archaeoglobus fulgidus</i> Rio2 and crystal structures of its nucleotide-metal ion complexes. 2005 , 272, 2800-10	39
1965	Structure and activity of the atypical serine kinase Rio1. 2005 , 272, 3698-713	45
1964	Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. 2005 , 272, 4884-98	26

1963	Characterization of testis-specific serine-threonine kinase 3 and its activation by phosphoinositide-dependent kinase-1-dependent signalling. 2005 , 272, 6310-23	15
1962	Molecular basis of ataxia telangiectasia and related diseases. 2005 , 26, 897-907	38
1961	Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. 2005 , 203, 127-42	107
1960	Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. 2005 , 7, 387-97	2353
1959	Protein serine/threonine phosphatases: life, death, and sleeping. 2005 , 17, 197-202	131
1958	New roles for the LKB1-->AMPK pathway. 2005 , 17, 167-73	223
1957	The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. 2005 , 17, 675-89	425
1956	Pathophysiological roles of G-protein-coupled receptor kinases. 2005 , 17, 917-28	109
1955	Individual C1 domains of PKD3 in phorbol ester-induced plasma membrane translocation of PKD3 in intact cells. 2005 , 17, 1397-411	11
1954	Molecular cloning and expression of cDNA coding for four spliced isoforms of casein kinase Ialpha in goldfish oocytes. 2005 , 1727, 75-80	4
1953	Interaction of casein kinase 1 delta (CK1 delta) with the light chain LC2 of microtubule associated protein 1A (MAP1A). 2005 , 1745, 196-206	32
1952	Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept?. 2005 , 70, 1707-16	25
1951	Kinomics: characterizing the therapeutically validated kinase space. 2005 , 10, 839-46	153
1950	The druggable genome: an update. 2005 , 10, 1607-10	346
1949	Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. 2005 , 13, 541-50	76
1948	Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. 2005 , 13, 1131-41	67
1947	Structural basis for glycogen recognition by AMP-activated protein kinase. 2005 , 13, 1453-62	163
1946	Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site. 2005 , 13, 1559-68	48

1945	Incomplete protein packing as a selectivity filter in drug design. 2005 , 13, 1829-36	23
1944	Chemical approaches for investigating phosphorylation in signal transduction networks. 2005 , 15, 502-10	120
1943	The RIP kinases: crucial integrators of cellular stress. 2005 , 30, 151-9	314
1942	WNK kinases and the control of blood pressure. 2005 , 106, 221-31	38
1941	Detailed protein sequence alignment based on Spectral Similarity Score (SSS). 2005 , 6, 105	6
1940	The yeast kinome displays scale free topology with functional hub clusters. 2005 , 6, 271	9
1939	Cyclic nucleotide binding proteins in the Arabidopsis thaliana and Oryza sativa genomes. 2005 , 6, 6	54
1938	Systematic analysis of human kinase genes: a large number of genes and alternative splicing events result in functional and structural diversity. 2005 , 6 Suppl 4, S20	56
1937	Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. 2005 , 6, 127	262
1936	Diversity in domain architectures of Ser/Thr kinases and their homologues in prokaryotes. 2005 , 6, 129	59
1935	GeneSeer: a sage for gene names and genomic resources. 2005 , 6, 134	6
1934	The role of protein kinase activity expressed by the UL13 gene of herpes simplex virus 1: the activity is not essential for optimal expression of UL41 and ICP0. 2005 , 341, 301-12	40
1933	Basic region of residues 228-231 of protein kinase CK1alpha is involved in its interaction with axin: binding to axin does not affect the kinase activity. 2005 , 94, 217-24	15
1932	Cytokine and growth factor receptors in the nucleus: what's up with that?. 2005 , 95, 478-87	21
1931	Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis. 2005 , 95, 817-26	19
1930	Protein posttranslational modifications: the chemistry of proteome diversifications. 2005 , 44, 7342-72	1009
1929	Posttranslationale Proteinmodifikation: die Chemie der Proteomdiversifizierung. 2005 , 117, 7508-7539	74
1928	The Eukaryotic Protein Kinase Domain. 2005 , 181-209	2

1927	Defining mitogen-activated protein kinase pathways with mass spectrometry-based approaches. 2005 , 24, 847-64	7
1926	Structure-aided optimization of kinase inhibitors derived from alsterpaullone. 2005 , 6, 541-9	35
1925	Classifying "kinase inhibitor-likeness" by using machine-learning methods. 2005 , 6, 558-66	40
1924	Target-family-oriented focused libraries for kinases--conceptual design aspects and commercial availability. 2005 , 6, 500-5	35
1923	The target discovery process. 2005 , 6, 468-79	26
1922	The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography. 2005 , 6, 506-12	36
1921	High-throughput screening for kinase inhibitors. 2005 , 6, 481-90	106
1920	PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. 2005 , 6, 550-7	50
1919	Drug discovery process for kinase inhibitors. 2005 , 6, 455-9	58
1918	Fluorescence-based cloning of a protein tyrosine kinase with a yeast tribrid system. 2005 , 6, 1442-8	5
1917	Function and pharmacology of TRPM cation channels. 2005 , 371, 307-14	116
1916	Genetic analysis of the kinome and phosphatome in cancer. 2005 , 62, 2092-9	47
1915	A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. 2005 , 338, 136-42	68
1914	The mammalian melastatin-related transient receptor potential cation channels: an overview. 2005 , 451, 204-11	125
1913	Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. 2005 , 446, 442-50	110
1912	Phosphoproteome analysis. 2005 , 25, 33-44	52
1911	Evidence for proximal cysteine and lysine residues at or near the active site of arginine kinase of <i>stichopus japonicus</i> . 2005 , 70, 24-39	
1910	Molecular mechanisms of hormonal activity. I. receptors. neuromediators. systems with second messengers. 2005 , 70, 24-39	0

1909	Molecular mechanisms of hormonal activity. II. Kinase systems. Systems with intracellular receptors. Transactivation of STS. 2005 , 70, 391-405	2
1908	High-throughput kinase assays with protein substrates using fluorescent polymer superquenching. 2005 , 5, 16	11
1907	Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor. 2005 , 5, 1299-307	26
1906	Automated immobilized metal affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites. 2005 , 19, 57-71	85
1905	Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. 2005 , 10, 1205-20	51
1904	Chronic peritoneal sepsis: myocardial dysfunction, endothelin and signaling mechanisms. 2005 , 10, 3183-205	10
1903	Identification and characterization of a novel alpha-kinase with a von Willebrand factor A-like motif localized to the contractile vacuole and Golgi complex in Dictyostelium discoideum. 2005 , 16, 2248-62	24
1902	Receptor tyrosine kinases as targets for anticancer therapeutics. 2005 , 12, 1773-81	13
1901	MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. 2005 , 12, 2979-94	207
1900	Kinases as drug discovery targets in hematologic malignancies. 2005 , 5, 625-42	26
1899	A NIMA-related protein kinase is essential for completion of the sexual cycle of malaria parasites. 2005 , 280, 31957-64	111
1898	Regulation of NDR protein kinase by hydrophobic motif phosphorylation mediated by the mammalian Ste20-like kinase MST3. 2005 , 25, 11019-29	128
1897	Structural evolution of the protein kinase-like superfamily. 2005 , 1, e49	191
1896	Strategies for the design of potent and selective kinase inhibitors. 2005 , 11, 1845-63	54
1895	Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. 2005 , 5, 1017-29	147
1894	Transcription profiling of signal transduction-related genes in sugarcane tissues. 2005 , 12, 27-38	68
1893	Phosphoproteomics in analyzing signaling pathways. 2005 , 2, 117-28	28
1892	Revisiting the Cdk-Centric View of the Mammalian Cell Cycle. 2005 , 4, 209-213	28

1891	An evolutionary proteomics approach identifies substrates of the cAMP-dependent protein kinase. 2005 , 102, 13933-8	183
1890	Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase. 2005 , 280, 42219-26	36
1889	Somatic mutations of the protein kinase gene family in human lung cancer. 2005 , 65, 7591-5	392
1888	A liquid chromatography/mass spectrometry-based method for the selection of ATP competitive kinase inhibitors. 2005 , 10, 447-55	17
1887	Exceptional disfavor for proline at the P + 1 position among AGC and CAMK kinases establishes reciprocal specificity between them and the proline-directed kinases. 2005 , 280, 10743-8	44
1886	Cell signalling in the cardiovascular system: an overview. 2005 , 91, 1366-74	34
1885	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. 2005 , 42, e65	141
1884	Regulation of microfilament organization by Kaposi sarcoma-associated herpes virus-cyclin.CDK6 phosphorylation of caldesmon. 2005 , 280, 35844-58	18
1883	Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species. 2005 , 25, 8520-30	195
1882	Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention and Cancer Therapy. 2005 , 33, 804-804	
1881	Development of a microplate-based, electrophoretic fluorescent protein kinase a assay: comparison with filter-binding and fluorescence polarization assay formats. 2005 , 10, 329-38	8
1880	GPS: a comprehensive www server for phosphorylation sites prediction. 2005 , 33, W184-7	182
1879	Phosphoproteome profiling of transforming growth factor (TGF)-beta signaling: abrogation of TGFbeta1-dependent phosphorylation of transcription factor-II-I (TFII-I) enhances cooperation of TFII-I and Smad3 in transcription. 2005 , 16, 4765-80	42
1878	The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. 2005 , 4, 1349-57	145
1877	A family portrait of the RIO kinases. 2005 , 280, 37297-300	73
1876	The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3. 2005 , 47-64	5
1875	Active kinase proteome screening reveals novel signal complexity in cardiomyopathy. 2005 , 4, 673-82	8
1874	Substrate specificity and activity regulation of protein kinase MELK. 2005 , 280, 40003-11	78

1873	Generation and characterization of p38beta (MAPK11) gene-targeted mice. 2005 , 25, 10454-64	204
1872	Protein kinase C-independent effects of protein kinase D3 in glucose transport in L6 myotubes. 2005 , 67, 152-62	76
1871	Integration of the extranuclear and nuclear actions of estrogen. 2005 , 19, 1951-9	598
1870	A single pair of acidic residues in the kinase major groove mediates strong substrate preference for P-2 or P-5 arginine in the AGC, CAMK, and STE kinase families. 2005 , 280, 36372-9	41
1869	Protein kinase specificity. A strategic collaboration between kinase peptide specificity and substrate recruitment. 2005 , 4, 52-6	51
1868	Chapter 13 Targeting the Kinome with Computational Chemistry. 2005 , 185-202	2
1867	Understanding signal transduction through functional proteomics. 2005 , 2, 103-16	4
1866	The transcription factor NF-kappaB as drug target. 2005 , 43, 137-88	9
1865	Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy. 2005 , 9, 515-32	16
1864	Potential of proteomics towards the investigation of the IGF-independent actions of IGFBP-3. 2005 , 2, 71-86	7
1863	Inflammatory pathway analysis using a high content screening platform. 2005 , 3, 261-71	36
1862	Consequences of lysine 72 mutation on the phosphorylation and activation state of cAMP-dependent kinase. 2005 , 280, 8800-7	61
1861	A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. 2005 , 280, 15013-9	131
1860	Physiological role for casein kinase 1 in glutamatergic synaptic transmission. 2005 , 25, 6601-9	47
1859	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. 2005 , 102, 11011-6	487
1858	Alzheimer's Disease. 2005 ,	7
1857	Structure and substrate specificity of the Pim-1 kinase. 2005 , 280, 41675-82	147
1856	Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. 2005 , 280, 24715-22	96

1855	Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. 2005 , 201, 925-35	300
1854	Molecular motions of human cyclin-dependent kinase 2. 2005 , 280, 13993-4005	39
1853	Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation. 2005 , 102, 8114-9	36
1852	Nicotinic acetylcholine receptor subunits and associated proteins in human sperm. 2005 , 280, 25928-35	58
1851	Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. 2005 , 280, 6130-7	203
1850	Inhibition of integrin-mediated cell adhesion but not directional cell migration requires catalytic activity of EphB3 receptor tyrosine kinase. Role of Rho family small GTPases. 2005 , 280, 923-32	86
1849	Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics. 2005 , 5, 561-71	12
1848	Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. 2005 , 23, 3614-21	158
1847	Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. 2005 , 65, 9751-61	133
1846	Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells. 2005 , 118, 5811-23	30
1845	Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. 2005 , 102, 14344-9	125
1844	Multisite protein phosphorylation makes a good threshold but can be a poor switch. 2005 , 102, 14617-22	214
1843	CVAK104 is a novel poly-L-lysine-stimulated kinase that targets the beta2-subunit of AP2. 2005 , 280, 21539-44	29
1842	Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. 2005 , 202, 1587-97	44
1841	Charge screening by internal pH and polyvalent cations as a mechanism for activation, inhibition, and rundown of TRPM7/MIC channels. 2005 , 126, 499-514	102
1840	Role of the regulatory domain of protein kinase D2 in phorbol ester binding, catalytic activity, and nucleocytoplasmic shuttling. 2005 , 16, 4375-85	50
1839	Phosphorylation site prediction with a modified k-nearest neighbor algorithm and BLOSUM62 matrix. 2005 , 2005, 6075-8	4
1838	Identification of an inactivating cysteine switch in protein kinase Cepsilon, a rational target for the design of protein kinase Cepsilon-inhibitory cancer therapeutics. 2005 , 65, 10478-85	14

1837	Unraveling kinase signaling pathways with chemical genetic and chemical proteomic approaches. 2005 , 4, 434-7	8
1836	Structural bioinformatics-based design of selective, irreversible kinase inhibitors. <i>Science</i> , 2005 , 308, 1318-21	333 407
1835	The genome sequence of <i>Trypanosoma cruzi</i> , etiologic agent of Chagas disease. <i>Science</i> , 2005 , 309, 409-15	1085
1834	Structure/function studies of Ser/Thr and Tyr protein phosphorylation in <i>Mycobacterium tuberculosis</i> . 2005 , 9, 167-81	89
1833	The detection of MAPK signaling. 2005 , Chapter 14, Unit 14.3	1
1832	The Proteomics Protocols Handbook. 2005 ,	204
1831	Challenges facing the development and use of protein chips to analyze the phosphoproteome. 2005 , 2, 487-97	7
1830	Lanthanide-mediated phosphoester hydrolysis and phosphate elimination from phosphopeptides. 2005 , 5426-8	13
1829	Raf: a strategic target for therapeutic development against cancer. 2005 , 23, 6771-90	230
1828	Mining the tumor phosphoproteome for cancer markers. 2005 , 11, 3163-9	74
1827	Second-generation kinase inhibitors. 2005 , 9, 975-93	48
1826	Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. 2005 , 9, 715-36	62
1825	Toward Protein Structure Analysis with Self-Organizing Maps. 2005 ,	1
1824	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. 2005 , 23, 2445-59	613
1823	Pyrazolones as therapeutics for kinase-mediated inflammatory disorders. 2005 , 15, 1617-1623	4
1822	Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. 2005 , 5, 35-43	3
1821	Using bioinformatics for drug target identification from the genome. 2005 , 5, 387-96	25
1820	Nanovolume kinase inhibition assay using a sol-gel-derived multicomponent microarray. 2005 , 77, 8013-9	24

1819	Cdk2: a genuine protein kinase client of Hsp90 and Cdc37. 2005 , 44, 15287-95	52
1818	Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. 2005 , 44, 8533-42	50
1817	Real-time protein kinase assay. 2005 , 77, 2043-9	24
1816	cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. 2005 , 280, 6094-100	166
1815	Phosphoproteomics for oncology discovery and treatment. 2005 , 9, 851-60	9
1814	Protein kinase B/Akt at a glance. 2005 , 118, 5675-8	256
1813	Toward a global analysis of the human pituitary proteome by multiple gel-based technology. 2005 , 77, 5324-31	25
1812	Mapping sites of protein phosphorylation by mass spectrometry utilizing a chemical-enzymatic approach: characterization of products from alpha-S1 casein phosphopeptides. 2005 , 4, 424-34	7
1811	Predicting the phosphorylation sites using hidden Markov models and machine learning methods. 2005 , 45, 1147-52	25
1810	Global Analysis of the <i>Hortaea werneckii</i> proteome: studying steroid response in yeast. 2005 , 4, 2043-51	11
1809	Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). 2005 , 4, 1661-71	108
1808	Increasing the kinase specificity of k252a by protein surface recognition. 2005 , 7, 1695-8	49
1807	Comparison of the ATP binding sites of protein kinases using conformationally diverse bisindolylmaleimides. 2005 , 127, 11699-708	28
1806	Bio-orthogonal affinity purification of direct kinase substrates. 2005 , 127, 5288-9	87
1805	Proximity-induced catalysis by the protein kinase ERK2. 2005 , 127, 10494-5	41
1804	Identification of a molecular recognition role for the activation loop phosphotyrosine of the SRC tyrosine kinase. 2005 , 127, 1600-1	6
1803	On-bead fluorescence assay for serine/threonine kinases. 2005 , 7, 5565-8	25
1802	Global phosphoproteome of HT-29 human colon adenocarcinoma cells. 2005 , 4, 1339-46	102

1801	Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. 2005 , 348, 183-93	118
1800	Catalytic independent functions of a protein kinase as revealed by a kinase-dead mutant: study of the Lys72His mutant of cAMP-dependent kinase. 2005 , 351, 1110-22	64
1799	Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component?. 2005 , 351, 956-72	122
1798	Crystal structure of the catalytic domain of human atypical protein kinase C- ι reveals interaction mode of phosphorylation site in turn motif. 2005 , 352, 918-31	82
1797	High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. 2005 , 352, 1134-56	38
1796	Crystal structures of active SRC kinase domain complexes. 2005 , 353, 222-31	66
1795	Therapeutic promise of JNK ATP-noncompetitive inhibitors. 2005 , 11, 232-9	39
1794	The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. 2005 , 53, 291-302	38
1793	Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFR α , and PDGFR β in ovarian cancers. 2005 , 36, 242-9	62
1792	Src kinase regulation by phosphorylation and dephosphorylation. 2005 , 331, 1-14	442
1791	The repertoire of solute carriers of family 6: identification of new human and rodent genes. 2005 , 336, 175-89	54
1790	Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor. 2005 , 338, 1307-15	246
1789	Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37. 2005 , 338, 1447-54	16
1788	Mutational analysis of gene families in human cancer. 2005 , 15, 5-12	40
1787	Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. 2005 , 357, 180-3	34
1786	Putative homologues of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and other components of the non-homologous end joining machinery in Dictyostelium discoideum. 2005 , 4, 1061-5	21
1785	Resistance to tyrosine kinase inhibitors: calling on extra forces. 2005 , 8, 119-29	33
1784	The Ran binding protein RanBPM interacts with Axl and Sky receptor tyrosine kinases. 2005 , 37, 2344-56	37

1783	Stress kinase signaling in cancer: fact or fiction?. 2005 , 217, 1-9	36
1782	Identification of the sucrose non-fermenting related kinase SNRK, as a novel LKB1 substrate. 2005 , 579, 1417-23	115
1781	Identification of cancer genes by mutational profiling of tumor genomes. 2005 , 579, 1884-90	20
1780	Drosophila RET contains an active tyrosine kinase and elicits neurotrophic activities in mammalian cells. 2005 , 579, 3789-96	20
1779	Phosphorylation of serine residues in histidine-tag sequences attached to recombinant protein kinases: a cause of heterogeneity in mass and complications in function. 2005 , 44, 121-9	22
1778	Functional Genomics meets neurodegenerative disorders. Part II: application and data integration. 2005 , 76, 169-88	36
1777	Computational analysis of protein tyrosine phosphatases: practical guide to bioinformatics and data resources. 2005 , 35, 90-114	31
1776	Analysis of protein phosphorylation by mass spectrometry. 2005 , 35, 256-64	107
1775	The Protein Kinase Resource: everything you always wanted to know about protein kinases but were afraid to ask. 2005 , 97, 113-8	12
1774	Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity. 2005 , 48, 4332-45	88
1773	A chemical model for redox regulation of protein tyrosine phosphatase 1B (PTP1B) activity. 2005 , 127, 10830-1	80
1772	Role of tyrosine kinases and phosphatases in polycythemia vera. 2005 , 42, 221-9	21
1771	Mutated kinases as targets for cancer drugs. 2005 , 2, 139-144	7
1770	Phospho-specific flow cytometry in drug discovery. 2005 , 2, 295-302	10
1769	Absence of fatty liver in familial hypobetalipoproteinemia linked to chromosome 3p21. 2005 , 54, 682-8	23
1768	Rapid computational identification of the targets of protein kinase inhibitors. 2005 , 48, 4138-52	45
1767	Synthesis and isozyme selectivity of small molecule protein kinase C inhibitors: a review of patents. 2005 , 15, 1691-1701	2
1766	Inhibitors of Protein Kinase CK2: Structural Aspects. 2005 , 125-155	4

1765	Imidazole-4,5-dicarboxamide derivatives with antiproliferative activity against HL-60 cells. 2005 , 48, 5955-65	28
1764	Identification of an acquired JAK2 mutation in polycythemia vera. 2005 , 280, 22788-92	477
1763	Inhibitors of Protein Kinases and Protein Phosphates. 2005 ,	1
1762	Comparative Genomics. 2005 ,	1
1761	Nanoliter homogenous ultra-high throughput screening microarray for lead discoveries and IC50 profiling. 2005 , 3, 177-87	35
1760	Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. 2005 , 48, 710-22	78
1759	Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. 2005 , 5, 259-65	52
1758	New Challenges and Strategies for Multiple Sequence Alignment in the Proteomics Era. 2005 , 475-492	
1757	Chemical Genomics. 2005 ,	2
1756	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. 2005 , 23, 2556-68	525
1755	Caged phosphoproteins. 2005 , 127, 846-7	59
1754	Microarray-based detection of protein binding and functionality by gold nanoparticle probes. 2005 , 77, 5770-4	146
1753	Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. 2005 , 11, 1-68	45
1752	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. 2005 , 7, R1186-98	164
1751	Protein Tyrosine Kinases. 2006 ,	4
1750	Kinase-catalyzed modification of gold nanoparticles: a new approach to colorimetric kinase activity screening. 2006 , 128, 2214-5	252
1749	Kidney cancer therapy: new perspectives and avenues. 2006 , 7, 2481-93	13
1748	The proteomes of neurotransmitter receptor complexes form modular networks with distributed functionality underlying plasticity and behaviour. 2006 , 2, 2006.0023	94

1747	Analgesia. 2006 ,		1
1746	The genome of the sea urchin <i>Strongylocentrotus purpuratus</i> . <i>Science</i> , 2006 , 314, 941-52	33.3	886
1745	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. 2006 , 281, 260-8		179
1744	Improved immobilized metal affinity chromatography for large-scale phosphoproteomics applications. 2006 , 5, 2789-99		109
1743	Protein tyrosine phosphatases in human disease. 2006 , 584, 53-72		7
1742	Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor. 2006 , 49, 7549-53		26
1741	Prediction of multiple binding modes of the CDK2 inhibitors, anilino-pyrazoles, using the automated docking programs GOLD, FlexX, and LigandFit: an evaluation of performance. 2006 , 46, 2552-62		31
1740	Purification and kinase assay of PKN. 2006 , 406, 234-50		9
1739	Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. 2006 , 16, 713-8		10
1738	Targeting the PTPome in human disease. 2006 , 10, 157-77		84
1737	Lymphocyte Signal Transduction. 2006 ,		
1736	Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. 2006 , 7, 73-86		15
1735	Applications of protein arrays for small molecule drug discovery and characterization. 2006 , 22, 197-211		2
1734	Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. 2006 , 66, 11100-5		229
1733	Tyrphostins and other tyrosine kinase inhibitors. 2006 , 75, 93-109		180
1732	Biomolecular interaction analysis in functional proteomics. 2006 , 113, 1015-32		42
1731	Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. 2006 , 49, 1006-15		54
1730	[Not Available]. 2006 , 2 Suppl 2, S9-S12		

1729	Phosphoproteomics toolbox: computational biology, protein chemistry and mass spectrometry. 2006 , 580, 4764-70	45
1728	Targeting tyrosine kinases in cancer: the second wave. <i>Science</i> , 2006 , 312, 1175-8	333 380
1727	Phosphoprotein analysis: from proteins to proteomes. 2006 , 4, 15	100
1726	Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis. 2006 , 45, 643-61	37
1725	LKB1-dependent signaling pathways. 2006 , 75, 137-63	614
1724	Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. 2006 , 4, 597-607	148
1723	Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. 2006 , 49, 6443-50	53
1722	Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. 2006 , 3, 207-17	44
1721	Elucidation of characteristic structural features of ligand binding sites of protein kinases: a neural network approach. 2006 , 46, 2158-66	8
1720	Profiling the kinome for drug discovery. 2006 , 3, 269-76	3
1719	Changing the course of oncogenesis: The development of tyrosine kinase inhibitors. 2006 , 4, 14-20	2
1718	Phosphopeptide modification and enrichment by oxidation-reduction condensation. 2006 , 1, 697-701	21
1717	Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations. 2006 , 49, 5141-53	37
1716	The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. 2006 , 281, 23167-79	75
1715	Mechanism-based profiling of enzyme families. 2006 , 106, 3279-301	490
1714	Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin. 2006 , 8, 1893-6	35
1713	Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. 2006 , 103, 4234-9	151
1712	Protein and proteome phosphorylation stoichiometry analysis by element mass spectrometry. 2006 , 78, 1987-94	70

1711	Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs. 2006 , 8, 5299-302	42
1710	A new functional, chemical proteomics technology to identify purine nucleotide binding sites in complex proteomes. 2006 , 5, 3438-45	28
1709	Selective ion tracing and MSn analysis of peptide digests from FSBA-treated kinases for the analysis of protein ATP-binding sites. 2006 , 5, 2019-24	7
1708	Transcreener: screening enzymes involved in covalent regulation. 2006 , 10, 179-90	36
1707	Design of a protein kinase-inducible domain. 2006 , 128, 5590-1	51
1706	Mitochondrial matrix phosphoproteome: effect of extra mitochondrial calcium. 2006 , 45, 2524-36	213
1705	Discovery of protein phosphatase 2C inhibitors by virtual screening. 2006 , 49, 1658-67	60
1704	Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. 2006 , 49, 7150-9	53
1703	A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. 2006 , 124, 1283-98	1340
1702	Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. 2006 , 3, 393-402	520
1701	Protein kinase C regulatory domains: the art of decoding many different signals in membranes. 2006 , 1761, 633-54	97
1700	The complex formation of PKCdelta through its C1- and C2-like regions in H2O2-stimulated cells. 2006 , 341, 101-7	6
1699	Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. 2006 , 342, 1263-72	61
1698	BRSK2 is activated by cyclic AMP-dependent protein kinase A through phosphorylation at Thr260. 2006 , 347, 867-71	13
1697	Chemical genetic approaches to the development of cancer therapeutics. 2006 , 16, 85-91	3
1696	Genome-wide comparative analyses of domain organisation of repertoires of protein kinases of Arabidopsis thaliana and Oryza sativa. 2006 , 380, 1-13	41
1695	ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 2006 , 237, 89-94	39
1694	Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. 2006 , 17, 295-304	201

1693	Hyperphosphorylation of tau induces local polyproline II helix. 2006 , 45, 5527-37	71
1692	A critical assessment of docking programs and scoring functions. 2006 , 49, 5912-31	1258
1691	A brief introduction to the protein phosphatase families. 2007 , 365, 9-22	28
1690	From the similarity analysis of protein cavities to the functional classification of protein families using cavbase. 2006 , 359, 1023-44	79
1689	The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. 2006 , 22, 851-868	231
1688	Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity?. 2006 , 18, 254-60	16
1687	RTK and TGF-beta signaling pathways genes in the sea urchin genome. 2006 , 300, 132-52	124
1686	The sea urchin kinome: a first look. 2006 , 300, 180-93	74
1685	Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. 2006 , 88, 779-790	125
1684	Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. 2006 , 40, 303-12	134
1683	Ischemia-specific phosphorylation and myofilament translocation of heat shock protein 27 precedes alpha B-crystallin and occurs independently of reactive oxygen species in rabbit myocardium. 2006 , 40, 761-74	32
1682	Integration of calcium with the signaling network in cardiac myocytes. 2006 , 41, 183-214	42
1681	Analyzing protein kinase dynamics in living cells with FRET reporters. 2006 , 40, 279-86	65
1680	Production of active recombinant mitogen-activated protein kinases through transient transfection of 293T cells. 2006 , 46, 468-74	6
1679	The familial Parkinsonism gene LRRK2 regulates neurite process morphology. 2006 , 52, 587-93	483
1678	LRRK2 in Parkinson's disease: protein domains and functional insights. 2006 , 29, 286-93	390
1677	. 2006 ,	56
1676	Role of Protein Kinases, Phosphatases and 14-3-3 Proteins in the Control of Primary Plant Metabolism. 121-149	3

1675 Signaling Networks. 74-86

1674 . **2006**, 5

1673 . **2006**, 19

1672 Bibliography. 299-316

1671 Biological Regulation by Protein Phosphorylation. **2006**,

1670 Protein kinase CK2: a newcomer in the 'druggable kinome'. **2006**, 34, 1303-6 62

1669 Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. **2006**, 4, 955-66 14

1668 Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. **2006**, 290, L492-500 14

1667 The ubiquitin-associated domain of AMPK-related kinases regulates conformation and LKB1-mediated phosphorylation and activation. **2006**, 394, 545-55 80

1666 Current status of virtual screening as analysed by target class. **2006**, 2, 89-112 21

1665 Signal Transduction Therapy for Cancer - Whither Now?. **2006**, 1, 1-12 11

1664 Protein Kinase Assays for Drug Discovery. 189-201

1663 Construction of a Homogeneous and Informative In vitro Profiling Database for Anticipating the Clinical Effects of Drugs. **2006**, 175-206 6

1662 Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. **2006**, 7, 1 147

1661 Systematic characterization of phosphorylation sites in NFATc2 by linear ion trap mass spectrometry. **2006**, 6 Suppl 1, S16-27 14

1660 Phosphoproteomics strategies for the functional analysis of signal transduction. **2006**, 6, 4047-56 120

1659 Plant phosphoproteomics: a long road ahead. **2006**, 6, 5517-28 74

1658 Protein kinase resource: an integrated environment for phosphorylation research. **2006**, 63, 78-86 42

1657	Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity. 2007 , 66, 912-29	17
1656	Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single-cell level. 2006 , 210, 208-28	81
1655	Phosphoproteomics as a tool to unravel plant regulatory mechanisms. 2006 , 126, 110-119	36
1654	Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. 2006 , 97 Suppl 1, 16-23	349
1653	Tau-tubulin kinase 1 (TTBK1), a neuron-specific tau kinase candidate, is involved in tau phosphorylation and aggregation. 2006 , 98, 1573-84	97
1652	How nutrition and exercise maintain the human musculoskeletal mass. 2006 , 208, 451-8	34
1651	The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines. 2006 , 273, 2487-504	56
1650	Structural study of the catalytic domain of PKCzeta using infrared spectroscopy and two-dimensional infrared correlation spectroscopy. 2006 , 273, 3273-86	9
1649	A kinase-focused compound collection: compilation and screening strategy. 2006 , 67, 385-94	15
1648	SPAK and OSR1, key kinases involved in the regulation of chloride transport. 2006 , 187, 103-13	54
1647	Isolation and Characterization of GmSTY1, a Novel Gene Encoding a Dual-Specificity Protein Kinase in Soybean (<i>Glycine max</i> L.). 2006 , 48, 857-866	6
1646	Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. 2006 , 27, 641-50	35
1645	Regulation of cytotoxin expression by converging eukaryotic-type and two-component signalling mechanisms in <i>Streptococcus agalactiae</i> . 2006 , 62, 941-57	85
1644	Expression patterns of polo-like kinase 1 in human gastric cancer. 2006 , 97, 271-6	40
1643	Rational design of inhibitors that bind to inactive kinase conformations. 2006 , 2, 358-64	854
1642	Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates. 2006 , 5, 581-9	490
1641	Highly selective enrichment of phosphorylated peptides using titanium dioxide. 2006 , 1, 1929-35	509
1640	ILK, PINCH and parvin: the tIPP of integrin signalling. 2006 , 7, 20-31	547

1639	MAPKAP kinases - MKs - two's company, three's a crowd. 2006 , 7, 120-30	350
1638	NDR kinases regulate essential cell processes from yeast to humans. 2006 , 7, 253-64	269
1637	Identification of a novel human MAST4 gene, a new member of human microtubule associated serine/threonine kinase family. 2006 , 40, 724-731	12
1636	Mechanisms of drug inhibition of signalling molecules. 2006 , 441, 457-62	257
1635	The second wave in kinase cancer drugs. 2006 , 24, 127-30	51
1634	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. 2006 , 14, 322-31	134
1633	Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. 2006 , 25, 4020-32	59
1632	Protein kinase WNK3 increases cell survival in a caspase-3-dependent pathway. 2006 , 25, 4172-82	35
1631	Optimal Sox-based fluorescent chemosensor design for serine/threonine protein kinases. 2006 , 352, 198-207	62
1630	Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. 2006 , 356, 273-81	66
1629	In situ phosphorylation of immobilized receptors on biosensor surfaces: application to E-cadherin/beta-catenin interactions. 2006 , 357, 277-88	21
1628	Two-dimensional expression pattern analysis of protein kinases after separation by MicroRotofor/SDS-PAGE. 2006 , 359, 271-3	21
1627	Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. 2006 , 10, 20-7	32
1626	A general strategy for creating "inactive-conformation" abl inhibitors. 2006 , 13, 779-86	132
1625	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification. 2006 , 14, 1792-804	45
1624	Induction of acid phosphatase activity during germination of maize (<i>Zea mays</i>) seeds. 2006 , 44, 467-73	14
1623	Kinase inhibitor recognition by use of a multivariable QSAR model. 2006 , 24, 278-95	9
1622	Molecular modelling. 2006 , 2, 660-81	8

1621	Protein kinases as potential targets for the treatment of pathological pain. 2007 , 359-89	63
1620	Selectivity and potency of cyclin-dependent kinase inhibitors. 2006 , 8, E204-21	49
1619	Identification of potent, selective protein kinase C inhibitors based on a phorbol skeleton. 2006 , 1, 314-21	8
1618	ERK1/2 MAP kinases in cell survival and apoptosis. 2006 , 58, 621-31	446
1617	Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival. 2006 , 45, 303-15	44
1616	Bull testicular haploid germ cells express a messenger encoding for a truncated form of the protein tyrosine kinase HCK. 2006 , 73, 520-30	14
1615	Novel frequenin-modulated Ca ²⁺ -signaling membrane guanylate cyclase (ROS-GC) transduction pathway in bovine hippocampus. 2006 , 291, 187-204	12
1614	Protein kinases controlling the onset of mitosis. 2006 , 63, 781-95	49
1613	Structural biology of protein tyrosine kinases. 2006 , 63, 2608-25	70
1612	Starch-binding domains in the post-genome era. 2006 , 63, 2710-24	125
1611	[Molecular targeted therapy]. 2006 , 77, 1118-25	3
1610	Neutrons reveal how nature uses structural themes and variation in biological regulation. 2006 , 385-386, 825-830	6
1609	Protein kinases and phosphatases as therapeutic targets in cancer. 2006 , 8, 153-60	65
1608	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. 2006 , 1, 151	2
1607	Bad patients meet good drugs. 2006 , 8, 225-7	1
1606	Sensing extracellular matrix: an update on discoidin domain receptor function. 2006 , 18, 1108-16	264
1605	Kinase inhibitors and airway inflammation. 2006 , 533, 118-32	108
1604	Chemogenomics: structuring the drug discovery process to gene families. 2006 , 11, 880-8	65

1603	Dusty protein kinases: primary structure, gene evolution, tissue specific expression and unique features of the catalytic domain. 2006 , 1759, 562-72	11
1602	The flexible evolutionary anchorage-dependent Pardee's restriction point of mammalian cells: how its deregulation may lead to cancer. 2006 , 1765, 38-66	13
1601	Emerging applications for phospho-proteomics in cancer molecular therapeutics. 2006 , 1766, 230-41	12
1600	Lining the pockets of kinases and phosphatases. 2006 , 16, 693-701	66
1599	Protein-protein interactions in the allosteric regulation of protein kinases. 2006 , 16, 702-9	89
1598	Docking interactions in protein kinase and phosphatase networks. 2006 , 16, 676-85	145
1597	Structure of the catalytic and ubiquitin-associated domains of the protein kinase MARK/Par-1. 2006 , 14, 173-83	66
1596	Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. 2006 , 14, 1835-44	106
1595	Complexity of the TOR signaling network. 2006 , 16, 206-12	163
1594	Emerging roles of pseudokinases. 2006 , 16, 443-52	414
1593	Mitochondrial modulation: reversible phosphorylation takes center stage?. 2006 , 31, 26-34	200
1592	The where's and when's of kinase anchoring. 2006 , 31, 316-23	119
1591	Charging it up: global analysis of protein phosphorylation. 2006 , 22, 545-54	116
1590	An intracellular kinase signal-responsive gene carrier for disordered cell-specific gene therapy. 2006 , 110, 431-436	45
1589	Protein phosphatase modulation of the intercellular junctional communication: importance in cardiac myocytes. 2006 , 90, 225-48	26
1588	Multipolar representation of protein structure. 2006 , 7, 242	14
1587	Multiple lineage specific expansions within the guanylyl cyclase gene family. 2006 , 6, 26	35
1586	Diversity-oriented synthesis of pochonins and biological evaluation against a panel of kinases. 2006 , 12, 8819-34	36

1585	Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3. 2006 , 7, 1443-50	101
1584	A genetically encoded pore for the stochastic detection of a protein kinase. 2006 , 7, 1923-7	47
1583	NMR characterization of kinase p38 dynamics in free and ligand-bound forms. 2006 , 45, 993-7	129
1582	Neuroproteomics - the tasks lying ahead. 2006 , 27, 2819-29	37
1581	Phospho-proteomic analysis of cellular signaling. 2006 , 27, 2676-86	47
1580	Can MM-PBSA calculations predict the specificities of protein kinase inhibitors?. 2006 , 27, 1990-2007	49
1579	Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. 2006 , 27, 1060-1	73
1578	The role of mass spectrometry in plant systems biology. 2006 , 25, 173-214	123
1577	Fragment-based Lead Discovery and Optimization Using X-Ray Crystallography, Computational Chemistry, and High-throughput Organic Synthesis. 2006 , 215-248	26
1576	LC/MS Analysis of Proteins and Peptides in Drug Discovery. 2006 , 837-899	1
1575	Charakterisierung der Dynamik der Kinase p38 in freiem und ligandgebundenem Zustand durch NMR-Spektroskopie. 2006 , 118, 1008-1012	17
1574	The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. 2006 , 5, 1136-41	57
1573	Regulatory molecular biology. 2006 , 5, 846-52	11
1572	Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors. 2006 , 7, 327-43	13
1571	Druggable signaling proteins. 2007 , 361, 1-24	13
1570	Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?. 2006 , 6, 175-86	14
1569	Phosphorylation of the protein phosphatase type 1 inhibitor protein CPI-17 by protein kinase C. 2007 , 365, 209-23	18
1568	Aurora A and B kinases as targets for cancer: will they be selective for tumors?. 2006 , 6, 109-20	63

1567	Statistical challenges with gene expression studies. 2006 , 7, 511-9	2
1566	Systemic mastocytosis. 2006 , 89, 169-243	25
1565	A microfluidics-based mobility shift assay to discover new tyrosine phosphatase inhibitors. 2006 , 11, 996-1004	19
1564	The Parkinson disease gene LRRK2: evolutionary and structural insights. 2006 , 23, 2423-33	128
1563	Targeting cancer: the challenges and successes of structure-based drug design against the human purinome. 2006 , 6, 1129-59	16
1562	Identification of a novel putative mitogen-activated kinase cascade on human chromosome 21 by computational approaches. 2006 , 22, 775-8	12
1561	The vaccinia-related kinases phosphorylate the N' terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. 2006 , 17, 2451-64	169
1560	Tyrosine phosphatases epsilon and alpha perform specific and overlapping functions in regulation of voltage-gated potassium channels in Schwann cells. 2006 , 17, 4330-42	27
1559	Proteomic and computational methods in systems modeling of cellular signaling. 2006 , 7, 135-45	4
1558	Structure selection for protein kinase docking and virtual screening: homology models or crystal structures?. 2006 , 7, 437-57	46
1557	Herpes simplex viruses in antiviral drug discovery. 2006 , 12, 1357-70	20
1556	The use of anticancer drugs in antiparasitic chemotherapy. 2006 , 6, 131-43	43
1555	Computational approaches to model ligand selectivity in drug design. 2006 , 6, 41-55	34
1554	The dictyostelium kinome--analysis of the protein kinases from a simple model organism. 2006 , 2, e38	127
1553	High-throughput mutational analysis of the human cancer genome. 2006 , 7, 597-612	13
1552	Recent developments in focused library design: targeting gene-families. 2006 , 6, 19-29	42
1551	Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. 2006 , 7, 185-98	2
1550	Plant and animal pathogen recognition receptors signal through non-RD kinases. 2006 , 2, e2	198

1549	Filopodia formation via a specific Eph family member and PI3K in immortalized cholangiocytes. 2006 , 291, G812-9	12
1548	Clathrin-dependent association of CVAK104 with endosomes and the trans-Golgi network. 2006 , 17, 4513-25	26
1547	A dithio-coupled kinase and ATPase assay. 2006 , 11, 844-53	5
1546	Peptide microarray analysis of substrate specificity of the transmembrane Ser/Thr kinase KPI-2 reveals reactivity with cystic fibrosis transmembrane conductance regulator and phosphorylase. 2006 , 5, 2124-30	36
1545	Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. 2006 , 70, 1061-95	417
1544	Conserved domains subserve novel mechanisms and functions in DKF-1, a <i>Caenorhabditis elegans</i> protein kinase D. 2006 , 281, 17815-26	12
1543	Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. 2006 , 281, 25110-23	81
1542	A quantitative results-driven approach to analyzing multisite protein phosphorylation: the phosphate-dependent phosphorylation profile of the transcription factor Pho4. 2006 , 5, 2019-30	26
1541	Phosphorylation analysis by mass spectrometry: myths, facts, and the consequences for qualitative and quantitative measurements. 2006 , 5, 172-81	287
1540	The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. 2006 , 15, 223-32	393
1539	Label-free and real-time cell-based kinase assay for screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array. 2006 , 11, 634-43	56
1538	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. 2006 , 103, 690-5	351
1537	Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. 2006 , 5, 995-1006	176
1536	Homogeneous and nonradioactive high-throughput screening platform for the characterization of kinase inhibitors in cell lysates. 2006 , 11, 1015-26	25
1535	Molecular identification and characterization of a family of kinases with homology to Ca ²⁺ /calmodulin-dependent protein kinases I/IV. 2006 , 281, 20427-39	36
1534	Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. 2006 , 13 Suppl 1, S77-88	21
1533	Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands. 2006 , 12, 373-83	62
1532	Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity. 2006 , 281, 24818-30	28

1531	Inhibitors of signal transduction protein kinases as targets for cancer therapy. 2006 , 12, 153-223	17
1530	Inhibition of cell migration by autophosphorylated mammalian sterile 20-like kinase 3 (MST3) involves paxillin and protein-tyrosine phosphatase-PEST. 2006 , 281, 38405-17	58
1529	Steady-state kinetic mechanism of PDK1. 2006 , 281, 21670-21681	19
1528	Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. 2006 , 17, 293-320	64
1527	Kinase and phosphatase: the cog and spring of the circadian clock. 2006 , 250, 47-72	30
1526	p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop. 2006 , 26, 4782-93	45
1525	Packing defects as selectivity switches for drug-based protein inhibitors. 2006 , 103, 323-8	8
1524	Comparison of kinome profiles of Barrett's esophagus with normal squamous esophagus and normal gastric cardia. 2006 , 66, 11605-12	68
1523	EphB2 and ephrin-B1 expressed in the adult kidney regulate the cytoarchitecture of medullary tubule cells through Rho family GTPases. 2006 , 119, 559-70	45
1522	New assignments for multitasking signal transduction inhibitors. 2006 , 69, 1510-2	7
1521	Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. 2006 , 103, 3563-8	63
1520	Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. 2006 , 19, 219-29	57
1519	The cysteine-rich domain protein KCP is a suppressor of transforming growth factor beta/activin signaling in renal epithelia. 2006 , 26, 4577-85	39
1518	A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5'-diphosphate accumulation. 2006 , 11, 390-9	53
1517	Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. 2006 , 5, 1571-6	4
1516	JNK/SAPK and p38 SAPK-2 mediate mechanical stretch-induced apoptosis via caspase-3 and -9 in NRK-52E renal epithelial cells. 2006 , 102, e49-61	32
1515	New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. 2006 , 26, 7086-102	53
1514	Ca ²⁺ /calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation. 2006 , 26, 5497-508	81

1513	Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. 2006 , 17, 4459-72	80
1512	Structure of the ternary signaling complex of a TGF-beta superfamily member. 2006 , 103, 7643-8	204
1511	Docking-based substrate recognition by the catalytic domain of a protein tyrosine kinase, C-terminal Src kinase (Csk). 2006 , 281, 8183-9	28
1510	Characterization of a novel protein kinase D: <i>Caenorhabditis elegans</i> DKF-1 is activated by translocation-phosphorylation and regulates movement and growth in vivo. 2006 , 281, 17801-14	19
1509	A functional interaction between sprouty proteins and caveolin-1. 2006 , 281, 29201-12	16
1508	Automated identification and quantification of protein phosphorylation sites by LC/MS on a hybrid triple quadrupole linear ion trap mass spectrometer. 2006 , 5, 337-46	97
1507	Epstein-Barr virus protein kinase BGLF4 is a virion tegument protein that dissociates from virions in a phosphorylation-dependent process and phosphorylates the viral immediate-early protein BZLF1. 2006 , 80, 5125-34	62
1506	Cardiovascular Proteomics. 2006 , 3, 147-170	6
1505	Kinase drug discovery by affinity selection/mass spectrometry (ASMS): application to DNA damage checkpoint kinase Chk1. 2006 , 11, 755-64	27
1504	Calcium:magnesium ratio in local groundwater and incidence of acute myocardial infarction among males in rural Finland. 2006 , 114, 730-4	31
1503	Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases. 2006 , 22, 1846-54	14
1502	VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. 2006 , 108, 2624-31	147
1501	Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease. 2006 , 3, 437-45	22
1500	Protein Microarrays. 2006 ,	
1499	Target Discovery and Validation Reviews and Protocols. 2006 ,	1
1498	Intracellular signal-responsive artificial gene regulation. 2006 , 14, 456-64	7
1497	Crystal structure of the FERM domain of focal adhesion kinase. 2006 , 281, 252-9	97
1496	Regulation of cell adhesion by protein-tyrosine phosphatases. I. Cell-matrix adhesion. 2006 , 281, 15593-6	48

1495	Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. 2006 , 281, 24322-35	20
1494	VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. 2006 , 4, 177-85	58
1493	Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. 2006 , 26, 3378-89	38
1492	The detection of MAPK signaling. 2006 , Chapter 18, Unit 18.12	3
1491	Microarrays for the functional analysis of the chemical-kinase interactome. 2006 , 11, 48-56	38
1490	Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. 2006 , 66, 6050-62	162
1489	Frequent alterations in the expression of serine/threonine kinases in human cancers. 2006 , 66, 8147-54	121
1488	Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. 2006 , 20, 1982-91	79
1487	Hsp90 recognizes a common surface on client kinases. 2006 , 281, 14361-9	177
1486	The first armadillo repeat is involved in the recognition and regulation of beta-catenin phosphorylation by protein kinase CK1. 2006 , 103, 19725-30	34
1485	Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics. 2006 , 281, 7271-81	40
1484	PKCalpha: a versatile key for decoding the cellular calcium toolkit. 2006 , 174, 521-33	55
1483	Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. 2006 , 26, 7529-38	133
1482	Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (MARK) 1 and MARK2. 2006 , 281, 27586-99	45
1481	Smad Signal Transduction. 2006 ,	11
1480	Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. 2007 , 282, 36177-89	127
1479	The Ste20-like kinase Svka of Dictyostelium discoideum is essential for late stages of cytokinesis. 2007 , 120, 4345-54	18
1478	Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. 2007 , 282, 34663-71	68

1477	Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. 2007 , 27, 7273-83	54
1476	The hallmark of AGC kinase functional divergence is its C-terminal tail, a cis-acting regulatory module. 2007 , 104, 1272-7	172
1475	A network-based analysis of polyanion-binding proteins utilizing human protein arrays. 2007 , 282, 10153-63	24
1474	A novel tyrosine phosphorylation site in protein kinase D contributes to oxidative stress-mediated activation. 2007 , 282, 31873-81	62
1473	Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-activated protein kinase 5 and requires PKA-induced nuclear export of MK5. 2007 , 282, 37232-43	48
1472	Identification of ChChd3 as a novel substrate of the cAMP-dependent protein kinase (PKA) using an analog-sensitive catalytic subunit. 2007 , 282, 14952-9	34
1471	Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition and promotes interaction with the adjacent kinase domain. 2007 , 104, 14336-41	39
1470	The DNA-dependent protein kinase catalytic subunit is phosphorylated in vivo on threonine 3950, a highly conserved amino acid in the protein kinase domain. 2007 , 27, 1581-91	100
1469	Cutting Edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. 2007 , 178, 2641-5	56
1468	Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. 2007 , 73, 288-97	117
1467	Highly Efficient Phosphopeptide Enrichment by Calcium Phosphate Precipitation Combined with Subsequent IMAC Enrichment. 2007 , 6, 2032-42	103
1466	Proteomics of lung cell biology and pulmonary disease. 2007 , 1, 255-69	4
1465	Probing the membrane targeting C1 subdomains of PKC with bivalent ligands. 2007 , 7, 355-62	4
1464	Derepression of pathological cardiac genes by members of the CaM kinase superfamily. 2007 , 73, 667-77	97
1463	Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. 2007 , 7, 311-40	232
1462	Protein kinase D selectively targets cardiac troponin I and regulates myofilament Ca ²⁺ sensitivity in ventricular myocytes. 2007 , 100, 864-73	88
1461	Fluorescence resonance energy transfer in quantum dot-protein kinase assemblies. 2007 , 2007, 18081	6
1460	Epidermal growth factor receptor phosphorylates protein kinase C {delta} at Tyr332 to form a trimeric complex with p66Shc in the H ₂ O ₂ -stimulated cells. 2008 , 143, 31-8	22

1459	Finding drug targets through analysis of the platelet transcriptome. 2007 , 13, 2662-7	3
1458	Protein kinase inhibitors: structural insights into selectivity. 2007 , 13, 2751-65	45
1457	CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. 2007 , 13, 3765-70	56
1456	Relevance of Protein Isoforms in Proteomic Studies. 2007 , 4, 235-252	7
1455	Targeting protein multiple conformations: a structure-based strategy for kinase drug design. 2007 , 7, 1394-407	31
1454	Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. 2007 , 23, 1919-26	19
1453	Molecular basis for specificity in the druggable kinome: sequence-based analysis. 2007 , 23, 563-72	50
1452	The role of halogen bonding in inhibitor recognition and binding by protein kinases. 2007 , 7, 1336-48	142
1451	Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. 2007 , 28, 318-26	38
1450	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. 2007 , 7, 1408-22	55
1449	A chemogenomic analysis of the human proteome: application to enzyme families. 2007 , 12, 972-82	23
1448	Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. 2007 , 2007, pe22	36
1447	Structure-based approaches to drug discovery against tuberculosis. 2007 , 8, 365-75	16
1446	Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. 2007 , 178, 155-65	89
1445	Meeting report: targeting the kinome--20 years of tyrosine kinase inhibitor research in Basel. 2007 , 2007, pe8	8
1444	In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells. 2007 , 6, 980-7	14
1443	Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress. 2007 , 282, 28395-28407	47
1442	Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy. 2007 , 383-405	4

1441	The rice kinase database. A phylogenomic database for the rice kinome. 2007 , 143, 579-86	116
1440	Designing in vitro assays for drug discovery: a study with the human MAP3 kinase COT. 2007 , 2, 909-15	2
1439	Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. 2008 , 29, 629-37	66
1438	Structural basis for the specific inhibition of protein kinase G, a virulence factor of <i>Mycobacterium tuberculosis</i> . 2007 , 104, 12151-6	131
1437	The Par-1/MARK family of protein kinases: from polarity to metabolism. 2007 , 6, 1966-9	53
1436	Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. 2007 , 4, 783-92	20
1435	The alliance for cellular signaling plasmid collection: a flexible resource for protein localization studies and signaling pathway analysis. 2007 , 6, 413-24	13
1434	Protein Kinases and Protein Phosphatases in Signal Transduction Pathways. 2007 , 959-992	2
1433	Synthesis and characterization of 5'-p-fluorosulfonylbenzoyl-2' (or 3')-(biotinyl)adenosine as an activity-based probe for protein kinases. 2007 , 12, 126-32	13
1432	Properties, regulation, and in vivo functions of a novel protein kinase D: <i>Caenorhabditis elegans</i> DKF-2 links diacylglycerol second messenger to the regulation of stress responses and life span. 2007 , 282, 31273-88	35
1431	TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. 2007 , 67, 919-29	238
1430	Signalling through kinase-defective domains: the prevalence of atypical receptor-like kinases in plants. 2007 , 58, 3503-11	76
1429	Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. 2007 , 67, 11368-76	71
1428	Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. 2007 , 12, 1404-15	99
1427	The serine/threonine/tyrosine phosphoproteome of the model bacterium <i>Bacillus subtilis</i> . 2007 , 6, 697-707	309
1426	PepCyber:P~PEP: a database of human protein protein interactions mediated by phosphoprotein-binding domains. 2008 , 36, D679-83	38
1425	Expression of serine/threonine protein-kinases and related factors in normal monkey and human retinas: the mechanistic understanding of a CDK2 inhibitor induced retinal toxicity. 2007 , 35, 972-83	13
1424	Plant Proteomics. 2007 ,	6

1423	Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. 2007 , 6, 537-47	92
1422	Development of a Transcreeper kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. 2007 , 12, 578-84	35
1421	KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. 2007 , 35, W588-94	285
1420	Neuroproteomics and the Detection of Regulatory Phosphosites. 2007 , 4, 209-222	8
1419	An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. 2007 , 67, 4408-17	607
1418	Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. 2007 , 6, 2828-42	22
1417	Drug discovery and delivery in the 21st century. 2007 , 16, 1-14	22
1416	Mitogen-activated protein kinases in heart development and diseases. 2007 , 116, 1413-23	228
1415	Large-scale phosphorylation analysis of mouse liver. 2007 , 104, 1488-93	627
1414	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. 2007 , 104, 20523-8	286
1413	c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages. 2007 , 282, 18980-90	52
1412	BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. 2007 , 401, 29-38	234
1411	Identification of novel phosphorylation sites in MSK1 by precursor ion scanning MS. 2007 , 402, 491-501	44
1410	LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. 2007 , 405, 307-17	414
1409	Protein kinases, from B to C. 2007 , 35, 1013-7	34
1408	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. 2007 , 110, 323-33	38
1407	Signaling by AMP-activated Protein Kinase. 303-338	5
1406	Characterization and Evolution of the Cell Cycle-Associated Mob Domain-Containing Proteins in Eukaryotes. 2007 , 3, 117693430700300	10

1405	Vascular signaling through cholesterol-rich domains: implications in hypertension. 2007 , 16, 90-104	37
1404	Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. 2007 , 8, 205-16	25
1403	Subject Index To Volume 5. 2007 , 6, 3-6	
1402	Editorial [Hot Topic: Kinase Targets and Inhibitors in Inflammation (Guest Editors: Khusru Asadullah and Matthias Gaestel)]. 2007 , 6, 1-1	
1401	Hela γ -CaD undergoes a DNA replication-associated switch in localization from the cytoplasm to the nuclei of endothelial cells/endothelial progenitor cells in human tumor vasculature. 2007 , 6, 886-90	10
1400	Using phosphoproteomics to reveal signalling dynamics in plants. 2007 , 12, 404-11	60
1399	Distribution analysis of nonsynonymous polymorphisms within the human kinase gene family. 2007 , 90, 49-58	23
1398	Kinase inhibitors for cardiovascular disease. 2007 , 42, 1-11	22
1397	From five- to six-membered rings: 3,4-diarylquinolinone as lead for novel p38MAP kinase inhibitors. 2007 , 50, 1213-21	40
1396	Identification of a dominant epitope in human vaccinia-related kinase 1 (VRK1) and detection of different intracellular subpopulations. 2007 , 465, 219-26	33
1395	Plant protein phosphorylation monitored by capillary liquid chromatography--element mass spectrometry. 2007 , 355, 89-96	28
1394	The carboxyl terminal tyrosine 417 residue of NOK has an autoinhibitory effect on NOK-mediated signaling transductions. 2007 , 356, 444-9	7
1393	Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. 2007 , 356, 323-8	295
1392	The role of protein kinases in pancreatic carcinogenesis. 2007 , 381, 56-62	
1391	Systematic discovery of in vivo phosphorylation networks. 2007 , 129, 1415-26	611
1390	Two kinase family dramas. 2007 , 129, 1037-8	5
1389	Elucidation of a universal size-control mechanism in Drosophila and mammals. 2007 , 130, 1120-33	1695
1388	Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). 2007 , 401, 38-45	66

1387	Gene expression profiling reveals complex changes following MEK-EE expression in cardiac myocytes. 2007 , 39, 349-65	3
1386	Getting connected: analysis and principles of biological networks. 2007 , 21, 1010-24	380
1385	Evolved to be active: sulfate ions define substrate recognition sites of CK2alpha and emphasise its exceptional role within the CMGC family of eukaryotic protein kinases. 2007 , 370, 427-38	51
1384	A novel phosphatase family, structurally related to dual-specificity phosphatases, that displays unique amino acid sequence and substrate specificity. 2007 , 374, 899-909	17
1383	Novel homeodomain-interacting protein kinase family member, HIPK4, phosphorylates human p53 at serine 9. 2007 , 581, 5649-57	40
1382	Kinase Inhibitors for Cancer. 2007 , 183-220	1
1381	Using chemical genetics and ATP analogues to dissect protein kinase function. 2007 , 2, 299-314	57
1380	Detection of in vitro kinase generated protein phosphorylation sites using gamma[18O4]-ATP and mass spectrometry. 2007 , 79, 7603-10	23
1379	Antimalarial drug discovery: targeting protein kinases. 2007 , 11, 279-90	65
1378	Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. 2007 , 25, 1035-44	864
1377	Tethering small molecules to a phage display library: discovery of a selective bivalent inhibitor of protein kinase A. 2007 , 129, 13812-3	57
1376	VEGF/VEGFR signalling as a target for inhibiting angiogenesis. 2007 , 16, 83-107	138
1375	Apoptosis, Senescence, and Cancer. 2007 ,	6
1374	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. 2007 , 8, R215	230
1373	Unequal evolutionary conservation of human protein interactions in interologous networks. 2007 , 8, R95	244
1372	A systematic comparative and structural analysis of protein phosphorylation sites based on the mtcPTM database. 2007 , 8, R90	53
1371	Cancer. 2007 ,	4
1370	Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. 2007 , 46, 9551-63	89

1369	Kinases and Phosphatases and Human Disorders: The First Drugs. 2007 ,	
1368	AMP-activated protein kinase as a drug target. 2007 , 47, 185-210	345
1367	Comparative thermodynamic analysis of cyclic nucleotide binding to protein kinase A. 2007 , 388, 163-72	19
1366	Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. 2007 , 9, 1-24	138
1365	Electron capture dissociation in the analysis of protein phosphorylation. 2007 , 4, 149-59	30
1364	Recent progress in the discovery of Akt inhibitors as anticancer agents. 2007 , 17, 1077-1130	34
1363	Parkinson's disease: animal models. 2007 , 83, 265-87	9
1362	Mitochondria in the etiology of Parkinson's disease. 2007 , 83, 479-91	7
1361	Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. 2007 , 17, 1035-1045	54
1360	O-GlcNAc modification in diabetes and Alzheimer's disease. 2007 , 3, 766-72	195
1359	Cellulose-bound peptide arrays: preparation and applications. 2007 , 24, 31-106	27
1358	Tyrosine kinase inhibitors in pediatric malignancies. 2007 , 25, 606-12	7
1357	FRET-based biosensors for protein kinases: illuminating the kinome. 2007 , 3, 759-65	109
1356	An integrated chemical, mass spectrometric and computational strategy for (quantitative) phosphoproteomics: application to Drosophila melanogaster Kc167 cells. 2007 , 3, 275-86	73
1355	Electrochemical detection of kinase-catalyzed thiophosphorylation using gold nanoparticles. 2007 , 5019-21	45
1354	Role of type 2C protein phosphatases in growth regulation and in cellular stress signaling. 2007 , 42, 437-61	123
1353	Mining phosphopeptide signals in liquid chromatography-mass spectrometry data for protein phosphorylation analysis. 2007 , 6, 1812-21	22
1352	Comprehensive phosphorylation site analysis of individual phosphoproteins applying scoring schemes for MS/MS data. 2007 , 79, 7439-49	15

1351	Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. 2007 , 50, 5773-9	179
1350	Prediction of Kinase-Specific Phosphorylation Sites by One-Class SVMs. 2007 ,	1
1349	Quantitative proteomic approaches for studying phosphotyrosine signaling. 2007 , 4, 13-23	40
1348	Microarray-based kinase inhibition assay by gold nanoparticle probes. 2007 , 79, 773-7	53
1347	Mechanistic investigations of the dehydration reaction of lactacin 481 synthetase using site-directed mutagenesis. 2007 , 46, 5991-6000	57
1346	Label-free electrical sensing of small-molecule inhibition on tyrosine phosphorylation. 2007 , 79, 6881-5	58
1345	A pharmacophore map of small molecule protein kinase inhibitors. 2007 , 47, 2374-82	37
1344	Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains. 2007 , 18, 1294-302	10
1343	Subdomain switching reveals regions that harbor substrate specificity and regulatory properties of protein tyrosine kinases. 2007 , 46, 10162-9	2
1342	Functional interrogation of the kinome using nucleotide acyl phosphates. 2007 , 46, 350-8	346
1341	Substrate and docking interactions in serine/threonine protein kinases. 2007 , 107, 5065-81	101
1340	A 10,000 member PNA-encoded peptide library for profiling tyrosine kinases. 2007 , 2, 810-8	31
1339	Fragment-based ligand discovery meets phage display. 2007 , 2, 779-82	9
1338	Analysis of protein phosphorylation in the regions of consecutive serine/threonine residues by negative ion electrospray collision-induced dissociation. Approach to pinpointing of phosphorylation sites. 2007 , 79, 3476-86	26
1337	Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas. 2007 , 58, 303-9	28
1336	Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. 2007 , 55, 467-76	79
1335	[Biologic therapy: current and future applications in oncology]. 2007 , 129, 184-93	3
1334	Intrinsic fluctuations, robustness, and tunability in signaling cycles. 2007 , 92, 4473-81	42

1333	FLT3 kinase inhibitors in the management of acute myeloid leukemia. 2007 , 8 Suppl 1, S24-34	22
1332	Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. 2007 , 5, 3963-70	14
1331	1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel. 2007 , 50, 2011-29	26
1330	Molecular/Targeted Therapy of Cancer. 2007 , 236-274	
1329	A dinoflagellate CDK5-like cyclin-dependent kinase. 2007 , 99, 531-40	5
1328	HIPK2: a multitalented partner for transcription factors in DNA damage response and development. 2007 , 85, 411-8	102
1327	Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. 2007 , 50, 409-24	416
1326	Proteomic studies of PP2A-B56gamma1 phosphatase complexes reveal phosphorylation-regulated partners in cardiac local signaling. 2007 , 6, 3433-42	10
1325	Protein kinases as targets for cancer treatment. 2007 , 8, 1005-16	60
1324	Biological Fingerprints. 2007 , 807-818	4
1323	Degeneration of the olfactory guanylyl cyclase D gene during primate evolution. 2007 , 2, e884	44
1322	Conservation, variability and the modeling of active protein kinases. 2007 , 2, e982	41
1321	Library Design: Reactant and Product-Based Approaches. 2007 , 337-378	
1320	NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor. 2007 , 2, 117739010700200	17
1319	Apoptotic cardiomyocyte hypertrophy during sepsis and septic shock results from prolonged exposure to endothelin precursor. 2007 , 12, 3052-60	4
1318	Diversity versus Focus in Choosing Targets and Therapeutic Areas. 2007 , 753-770	0
1317	Genomics. 2007 , 1-25	
1316	Kinases as Drug Targets in Inflammation: In Vitro and In Vivo Target Validation and Expression Profiling. 2007 , 6, 19-27	

1315	Progress in the Development of Agents to Control the Cell Cycle. 2007 , 207-291	5
1314	. 2007 ,	14
1313	Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview. 2007 , 6, 3-4	1
1312	Structural Aspects of Drugability and Selectivity of Protein Kinases in Inflammation. 2007 , 6, 5-17	7
1311	Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. 2007 , 8, 129-39	104
1310	A multiplexed protein kinase assay. 2007 , 8, 933-42	28
1309	Measurement of homogeneous kinase activity for cell lysates based on the aggregation of gold nanoparticles. 2007 , 8, 875-9	71
1308	The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules. 2007 , 8, 1804-9	86
1307	In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. 2007 , 85, 333-48	23
1306	Phosphate recognition in structural biology. 2007 , 46, 338-52	229
1305	Polymeric nanoparticles as imaging probes for protein kinase activity in cells. 2007 , 46, 8744-6	11
1304	Molekulare Erkennung von Phosphaten in der Strukturbiologie. 2007 , 119, 342-357	33
1303	Polymernanopartikel für die Bildgebung der Proteinkinaseaktivität in Zellen. 2007 , 119, 8898-8900	1
1302	Beyond Natural Products: Synthetic Analogues of Bryostatin 1. 125-162	1
1301	Nanoparticle Self-Assembly Directed by Antagonistic Kinase and Phosphatase Activities. 2007 , 19, 3579-3583	41
1300	Targeting cell signaling pathways for drug discovery: an old lock needs a new key. 2007 , 102, 580-92	107
1299	Novel biochemical pathways of endoglin in vascular cell physiology. 2007 , 102, 1375-88	103
1298	Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line. 2007 , 28, 2027-34	22

1297	Are MAP kinases drug targets? Yes, but difficult ones. 2007 , 2, 1116-40	34
1296	Functional classification of protein kinase binding sites using Cavbase. 2007 , 2, 1432-47	57
1295	Mass spectrometry-based "omics" technologies in cancer diagnostics. 2007 , 26, 403-31	87
1294	Caged O-phosphorothioyl amino acids as building blocks for Fmoc-based solid phase peptide synthesis. 2007 , 63, 6185-6190	10
1293	Annotating the human proteome: beyond establishing a parts list. 2007 , 1774, 175-91	26
1292	Carbocyclic 3'-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. 2007 , 17, 5336-9	15
1291	Selective sampling of multiply phosphorylated peptides by capillary electrophoresis for electrospray ionization mass spectrometry analysis. 2007 , 1156, 101-10	19
1290	An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1. 2007 , 367, 179-89	9
1289	Liquid chromatographic analysis of phosphoamino acids at femtomole level using chemical derivatization with N-hydroxysuccinimidyl fluorescein-O-acetate. 2007 , 601, 118-24	7
1288	Thienopyridine urea inhibitors of KDR kinase. 2007 , 17, 1246-9	40
1287	Expression, purification and crystallization of a human tau-tubulin kinase 2 that phosphorylates tau protein. 2007 , 63, 602-4	29
1286	p90 Ribosomal S6 kinases- eclectic members of the human kinome. 2007 , 7, 225-239	1
1285	Dlk/ZIP kinase, a novel Ser/Thr-specific protein kinase with multiple functions. 2007 , 7, 248-259	5
1284	Modelling of the ABL and ARG proteins predicts two functionally critical regions that are natively unfolded. 2007 , 67, 1-11	4
1283	Classification and functional annotation of eukaryotic protein kinases. 2007 , 68, 893-914	121
1282	Prediction of kinase-specific phosphorylation sites with sequence features by a log-odds ratio approach. 2008 , 70, 404-14	37
1281	Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets. 2007 , 1, 1042-57	38
1280	Neuroproteomics and its applications in research on nicotine and other drugs of abuse. 2007 , 1, 1406-27	9

1279	A la carte proteomics with an emphasis on gel-free techniques. 2007 , 7, 2698-718	79
1278	Analysis of protein phosphorylation on a proteome-scale. 2007 , 7, 2751-68	146
1277	The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. 2007 , 26, 6469-87	633
1276	Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. 2007 , 26, 6071-81	59
1275	AOP-1 interacts with cardiac-specific protein kinase TNNT3K and down-regulates its kinase activity. 2007 , 72, 1199-204	13
1274	The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. 2007 , 8, 1227-35	103
1273	The reverse in-gel kinase assay to profile physiological kinase substrates. 2007 , 4, 957-62	14
1272	Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. 2007 , 6, 464-79	310
1271	Flying under the radar: the new wave of BCR-ABL inhibitors. 2007 , 6, 834-48	246
1270	The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. 2007 , 6, 636-49	264
1269	Emerging roles of nuclear protein phosphatases. 2007 , 8, 234-44	293
1268	Mechanisms of specificity in protein phosphorylation. 2007 , 8, 530-41	977
1267	Mitochondrial dysfunction in Parkinson's disease. 2007 , 14, 1261-6	127
1266	TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. 2007 , 26, 3957-67	407
1265	Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. 2007 , 26, 4619-33	41
1264	Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. 2007 , 445, 437-41	770
1263	Patterns of somatic mutation in human cancer genomes. 2007 , 446, 153-8	2400
1262	The biological impact of mass-spectrometry-based proteomics. 2007 , 450, 991-1000	564

1261	Protein phosphorylation in plant mitochondria. 2007 , 129, 90-103	17
1260	Enteropathogenic Escherichia coli Tir is an SH2/3 ligand that recruits and activates tyrosine kinases required for pedestal formation. 2007 , 63, 1748-68	53
1259	ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. 2007 , 98, 1638-42	118
1258	Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. 2007 , 102, 93-102	72
1257	Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers. 2007 , 103, 2401-7	14
1256	Purification of phosphoproteins by immobilized metal affinity chromatography and its application to phosphoproteome analysis. 2007 , 274, 1576-87	43
1255	ProCKSI: a decision support system for Protein (structure) Comparison, Knowledge, Similarity and Information. 2007 , 8, 416	42
1254	Statistical analysis of genomic protein family and domain controlled annotations for functional investigation of classified gene lists. 2007 , 8 Suppl 1, S14	2
1253	The complement of protein kinases of the microsporidium Encephalitozoon cuniculi in relation to those of Saccharomyces cerevisiae and Schizosaccharomyces pombe. 2007 , 8, 309	59
1252	Signal transduction-related responses to phytohormones and environmental challenges in sugarcane. 2007 , 8, 71	110
1251	Atypical mitogen-activated protein kinases: structure, regulation and functions. 2007 , 1773, 1376-87	172
1250	Characterization of the activity of human MAP kinase-interacting kinase Mnk1b. 2007 , 1773, 1416-27	17
1249	Protein kinase D 3 is localized in vesicular structures and interacts with vesicle-associated membrane protein 2. 2007 , 19, 867-79	25
1248	Data reduction and representation in drug discovery. 2007 , 12, 45-53	18
1247	Insights for the development of specific kinase inhibitors by targeted structural genomics. 2007 , 12, 365-72	57
1246	A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. 2007 , 12, 622-33	143
1245	Dissecting kinase signaling pathways. 2007 , 12, 717-24	13
1244	The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. 2007 , 313, 3658-70	170

1243	Mitochondrial ROS--radical detoxification, mediated by protein kinase D. 2007 , 17, 13-8	109
1242	Molecular chaperones and protein kinase quality control. 2007 , 17, 87-92	149
1241	Activation segment exchange: a common mechanism of kinase autophosphorylation?. 2007 , 32, 351-6	78
1240	Editorial: role of cyclin-dependent kinase-5 (Cdk5) in the central nervous system. 2007 , 2, 914-5	3
1239	In silico binding free energy predictability by using the linear interaction energy (LIE) method: bromobenzimidazole CK2 inhibitors as a case study. 2007 , 47, 572-82	29
1238	Cyclin-Dependent Kinase 5. 2006 , 81-100	
1237	Chapter 18:The Impact of Protein Kinase Structures on Drug Discovery. 2007 , 349-365	1
1236	Molecular Modelling. 2007 , 54-96	
1235	Functional flexibility of human cyclin-dependent kinase-2 and its evolutionary conservation. 2008 , 17, 22-33	28
1234	A 2D NMR method to study peptide phosphorylation. 2007 , 389, 2161-5	4
1233	The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins. 2007 , 8, 107-19	55
1232	The cancer cell's "power plants" as promising therapeutic targets: an overview. 2007 , 39, 1-12	125
1231	Evaluation of the utility of homology models in high throughput docking. 2007 , 13, 897-905	40
1230	Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. 2007 , 8, 95-102	34
1229	Opinion: alternative views of AMP-activated protein kinase. 2007 , 47, 321-31	5
1228	Identification of proteins directly phosphorylated by UL13 protein kinase from herpes simplex virus 1. 2007 , 9, 1434-8	34
1227	Peptide-mediated interactions in biological systems: new discoveries and applications. 2008 , 19, 344-50	185
1226	Estrogen receptors outside the nucleus in breast cancer. 2008 , 108, 351-61	138

1225	Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis. 2008 , 27, 193-203	10
1224	An unusual member of the Cdk family: Cdk5. 2008 , 28, 351-69	133
1223	Emerging approaches for the syntheses of bicyclic imidazo[1,2-x]-heterocycles. 2008 , 12, 1-15	82
1222	Structure and dynamic regulation of Src-family kinases. 2008 , 65, 3058-73	131
1221	The three-fingered protein domain of the human genome. 2008 , 65, 3481-93	43
1220	A cell-based screening method for specifically detecting kinase activity. 2008 , 390, 343-8	2
1219	Prediction of PK-specific phosphorylation site based on information entropy. 2008 , 51, 12-20	7
1218	Targeted therapy des metastasierten Nierenzellkarzinoms (mRCC). 2008 , 1, 82-90	
1217	Glycomic Approaches to Study GlcNAcylation: Protein Identification, Site-mapping, and Site-specific O-GlcNAc Quantitation. 2008 , 4, 5-13	23
1216	Regulatory phosphorylation of cyclin-dependent kinase 2: insights from molecular dynamics simulations. 2008 , 14, 761-8	10
1215	Aging leads to increased levels of protein O-linked N-acetylglucosamine in heart, aorta, brain and skeletal muscle in Brown-Norway rats. 2008 , 9, 139	59
1214	Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. 2008 , 130, 465-71	38
1213	A shotgun phosphoproteomics analysis of embryos in germinated maize seeds. 2008 , 228, 1029-41	33
1212	Quantifying information transfer by protein domains: analysis of the Fyn SH2 domain structure. 2008 , 8, 43	28
1211	Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. 2008 , 3, 3	90
1210	Prediction of kinase inhibitors cross-reaction on the basis of kinase ATP cavity similarities: a study using PKSIM protein similarity score. 2008 , 2,	78
1209	The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin. 2008 , 9, 25	22
1208	Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays. 2008 , 8, 1980-6	33

1207	Quantitative phosphoproteomics--an emerging key technology in signal-transduction research. 2008 , 8, 4416-32	55
1206	Sensitive detection of phosphopeptides by matrix-assisted laser desorption/ionization mass spectrometry: use of alkylphosphonic acids as matrix additives. 2008 , 22, 1109-16	32
1205	Proteomic insights into cardiac cell death and survival. 2008 , 2, 837-44	0
1204	[Protein tyrosine kinases as drug targets. An important group of intracellular regulators]. 2008 , 37, 370-80	
1203	[Medical chemistry and molecular mechanisms of tyrosine kinase inhibitors. The viewpoint of pharmaceutical research]. 2008 , 37, 382-92	1
1202	Analysis of the protein kinome of <i>Entamoeba histolytica</i> . 2008 , 71, 995-1006	40
1201	A simple and fuzzy method to align and compare druggable ligand-binding sites. 2008 , 71, 1755-78	83
1200	Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors. 2008 , 73, 795-801	6
1199	Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. 2008 , 28, 372-412	107
1198	Flavonoids as RTK inhibitors and potential anticancer agents. 2008 , 28, 715-45	73
1197	A multi-angular mass spectrometric view at cyclic nucleotide dependent protein kinases: in vivo characterization and structure/function relationships. 2008 , 27, 331-53	24
1196	Mass spectrometry in systems biology: an overview. 2008 , 27, 635-60	76
1195	Enzymatic glycosylation of peptide arrays on gold surfaces. 2008 , 9, 883-7	60
1194	An improved mechanism-based cross-linker for multiplexed kinase detection and inhibition in a complex proteome. 2008 , 9, 1883-8	15
1193	Phosphate selective uranyl photo-affinity cleavage of proteins. Determination of phosphorylation sites. 2008 , 9, 2377-81	9
1192	Chemical biology approaches to probe the proteome. 2008 , 9, 2913-9	11
1191	Probing kinase activities by electrochemistry, contact-angle measurements, and molecular-force interactions. 2008 , 14, 7774-81	45
1190	Indeno[1,2-d]pyrido[1,2-a]pyrimidines: a new class of receptor tyrosine kinase inhibitors. 2008 , 3, 429-33	9

1189	Systemic cancer therapy: evolution over the last 60 years. 2008 , 113, 1857-87	42
1188	Src kinase induces tumor formation in the c-SRC C57BL/6 mouse. 2008 , 122, 2665-73	15
1187	What controls TOR?. 2008 , 60, 483-96	34
1186	Src-Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation. 2008 , 104, 840-9	53
1185	ERK5 regulation in naïve T-cell activation and survival. 2008 , 38, 2534-47	19
1184	Biomarker discovery in psychiatric disorders. 2008 , 29, 2884-90	27
1183	Peptide microarray for high-throughput determination of phosphatase specificity and biology. 2008 , 47, 1698-702	60
1182	Peptide Microarray for High-Throughput Determination of Phosphatase Specificity and Biology. 2008 , 120, 1722-1726	11
1181	Atmospheric pressure thermal dissociation of phospho- and sulfopeptides. 2008 , 19, 1897-905	13
1180	Mycobacterial Ser/Thr protein kinases and phosphatases: physiological roles and therapeutic potential. 2008 , 1784, 193-202	142
1179	Analogous regulatory sites within the alphaC-beta4 loop regions of ZAP-70 tyrosine kinase and AGC kinases. 2008 , 1784, 27-32	17
1178	Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. 2008 , 43, 1469-77	50
1177	Array-based fluorescence assay for serine/threonine kinases using specific chemical reaction. 2008 , 16, 7788-94	20
1176	Development of a novel fluorescent probe for fluorescence correlation spectroscopic detection of kinase inhibitors. 2008 , 18, 3752-5	12
1175	Discovery of amido-benzisoxazoles as potent c-Kit inhibitors. 2008 , 18, 5115-7	8
1174	High-throughput colorimetric detection of tyrosine kinase inhibitors based on the aggregation of gold nanoparticles. 2008 , 373, 161-3	29
1173	Staurosporine-based binding assay for testing the affinity of compounds to protein kinases. 2008 , 373, 197-206	10
1172	Evaluation of protein kinase activities of cell lysates using peptide microarrays based on surface plasmon resonance imaging. 2008 , 375, 223-31	43

1171	In vitro protein kinase activity measurement by flow cytometry. 2008 , 383, 180-5	7
1170	Doing more than just the structure-structural genomics in kinase drug discovery. 2008 , 12, 40-5	36
1169	The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. 2008 , 15, 111-7	82
1168	Molecular basis of drug resistance in aurora kinases. 2008 , 15, 552-62	98
1167	Mammalian NDR protein kinases: from regulation to a role in centrosome duplication. 2008 , 1784, 3-15	51
1166	Src family kinases: regulation of their activities, levels and identification of new pathways. 2008 , 1784, 56-65	238
1165	Predicting kinase selectivity profiles using Free-Wilson QSAR analysis. 2008 , 48, 1851-67	33
1164	High incidence of distal vaginal atresia in mice lacking Tyro3 RTK subfamily. 2008 , 75, 1775-82	7
1163	Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. 2008 , 77, 383-414	890
1162	7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. 2008 , 51, 3777-87	44
1161	Linear motif atlas for phosphorylation-dependent signaling. 2008 , 1, ra2	342
1160	Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. 2008 , 130, 15764-5	181
1159	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. 2008 , 51, 7898-914	139
1158	Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. 2008 , 51, 1214-22	83
1157	Function-oriented synthesis, step economy, and drug design. 2008 , 41, 40-9	931
1156	Complex kinase requirements for Chlamydia trachomatis Tarp phosphorylation. 2008 , 289, 233-40	40
1155	Therapeutic targeting of Janus kinases. 2008 , 223, 132-42	190
1154	Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH. 2008 , 275, 449-57	1

1153	Membrane localization of the MAK-V protein kinase. 2008 , 73, 278-82	2
1152	CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. 2008 , 27, 5797-807	139
1151	A quantitative analysis of kinase inhibitor selectivity. 2008 , 26, 127-32	1908
1150	Killing two kinase families with one stone. 2008 , 4, 648-9	26
1149	Development, validation and implementation of immobilized metal affinity for phosphochemicals (IMAP)-based high-throughput screening assays for low-molecular-weight compound libraries. 2008 , 3, 1350-63	31
1148	Peptide microarrays for high-throughput studies of Ser/Thr phosphatases. 2008 , 3, 1485-93	21
1147	Targeting the oncogene and kinome chaperone CDC37. 2008 , 8, 491-5	97
1146	Immunobiology of the TAM receptors. 2008 , 8, 327-36	586
1145	Identification of new kinase clusters required for neurite outgrowth and retraction by a loss-of-function RNA interference screen. 2008 , 15, 283-98	75
1144	The plant WNK gene family and regulation of flowering time in Arabidopsis. 2008 , 10, 548-62	66
1143	Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. 2008 , 99, 677-82	28
1142	Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. 2008 , 13, 233-44	32
1141	Palmitoylation-dependent endosomal localization of AATYK1A and its interaction with Src. 2008 , 13, 949-64	18
1140	A versatile strategy to define the phosphorylation preferences of plant protein kinases and screen for putative substrates. 2008 , 55, 104-17	95
1139	Alignment of protein structures in the presence of domain motions. 2008 , 9, 352	41
1138	Prediction of specificity-determining residues for small-molecule kinase inhibitors. 2008 , 9, 491	17
1137	A novel method for high accuracy sumoylation site prediction from protein sequences. 2008 , 9, 8	60
1136	Comparative kinomics of human and chimpanzee reveal unique kinship and functional diversity generated by new domain combinations. 2008 , 9, 625	9

1135	Short Linear Motifs recognized by SH2, SH3 and Ser/Thr Kinase domains are conserved in disordered protein regions. 2008 , 9 Suppl 2, S26	54
1134	Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. 2008 , 9 Suppl 2, S9	40
1133	The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. 2008 , 582, 3811-6	122
1132	HIPKs: Jack of all trades in basic nuclear activities. 2008 , 1783, 2124-9	43
1131	Fifty years of Biochemical Pharmacology: the discipline and the journal. 2008 , 76, 1-10	1
1130	Expression of the MAST family of serine/threonine kinases. 2008 , 1195, 12-9	37
1129	Biosignaling of mammalian Ste20-related kinases. 2008 , 20, 1237-47	106
1128	Protein kinase D2 regulates chromogranin A secretion in human BON neuroendocrine tumour cells. 2008 , 20, 925-34	21
1127	Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. 2008 , 100, 617-31	109
1126	Protein kinases of malaria parasites: an update. 2008 , 24, 570-7	92
1125	Structure of the human protein kinase MPSK1 reveals an atypical activation loop architecture. 2008 , 16, 115-24	30
1124	Pellino proteins splitting up the FHAMily!. 2008 , 16, 1752-4	1
1123	Endosomal trafficking of Src tyrosine kinase. 2008 , 18, 322-9	88
1122	Non-functional phosphorylations?. 2008 , 33, 351-2	110
1121	Characterization of Plasmodium falciparum protein kinase 2. 2008 , 162, 87-95	16
1120	Time to Search for Protein Kinase Substrates. 485-498	2
1119	Colorimetric enzymatic activity assay based on noncrosslinking aggregation of gold nanoparticles induced by adsorption of substrate peptides. 2008 , 9, 2301-8	57
1118	Tuning a three-component reaction for trapping kinase substrate complexes. 2008 , 130, 17568-74	54

1117	Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. 2008 , 3, 1409-25	71
1116	Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. 2008 , 51, 7921-32	142
1115	Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. 2008 , 51, 487-501	72
1114	Protein kinase CK2 as a druggable target. 2008 , 4, 889-94	98
1113	Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. 2008 , 7, 47	17
1112	Tv-RIO1 - an atypical protein kinase from the parasitic nematode <i>Trichostrongylus vitrinus</i> . 2008 , 1, 34	7
1111	The selectivity of inhibitors of protein kinase CK2: an update. 2008 , 415, 353-65	193
1110	Proteomics. 839-865	2
1109	Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. 2008 , 7, 5314-26	119
1108	Target therapy in metastatic renal cell carcinoma. 2008 , 6, 38-41	1
1107	Structural And Functional Organization Of The Synapse. 2008 ,	3
1106	Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors. 2008 , 4, 542-50	7
1105	Vascular Complications in Human Disease. 2008 ,	
1104	Identification of CDK2 substrates in human cell lysates. 2008 , 9, R149	120
1103	Plant Growth Signaling. 2008 ,	2
1102	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
1101	Identification of protein kinase substrates by proteomic approaches. 2008 , 5, 497-505	9
1100	The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity. 2008 , 10, 3331-4	52

1099	Protein kinases: starting a molecular systems view of endocytosis. 2008 , 24, 501-23	31
1098	Advances in the analysis of protein phosphorylation. 2008 , 7, 1809-18	140
1097	Checkpoint Responses in Cancer Therapy. 2008 ,	1
1096	Recent advances in the study of genes involved in non-syndromic premature ovarian failure. 2008 , 282, 101-11	57
1095	Transforming growth factor-beta (TGF-beta) and brain tumours. 2008 , 15, 845-55	32
1094	Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. 2008 , 31, 438-48	495
1093	The JAK kinases: not just another kinase drug discovery target. 2008 , 19, 319-28	70
1092	Targeted deletion of Tsk1 and 2 causes male infertility due to haploinsufficiency. 2008 , 319, 211-22	66
1091	Proteome-wide prediction of PKA phosphorylation sites in eukaryotic kingdom. 2008 , 92, 457-63	22
1090	EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. 2008 , 24, 27-33	9
1089	Chemicals that modulate stem cell differentiation. 2008 , 105, 7467-71	43
1088	Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region. 2008 , 51, 4122-49	73
1087	TOR regulation of AGC kinases in yeast and mammals. 2008 , 410, 19-37	166
1086	Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. 2008 , 1782, 259-70	46
1085	A tightly regulated Pol III promoter for synthesis of miRNA genes in tandem. 2008 , 1779, 773-9	20
1084	Tyrosine kinase activity of a Ca ²⁺ /calmodulin-dependent protein kinase II catalytic fragment. 2008 , 377, 648-652	3
1083	Nuclear localization of SNARK; its impact on gene expression. 2008 , 377, 1062-6	14
1082	Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. 2008 , 410, 147-53	19

1081	CASK Functions as a Mg ²⁺ -independent neurexin kinase. 2008 , 133, 328-39	204
1080	Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. 2008 , 133, 537-48	150
1079	Rethinking pseudokinases. 2008 , 133, 204-5	33
1078	Rewiring the specificity of two-component signal transduction systems. 2008 , 133, 1043-54	365
1077	Structural basis for the recognition of c-Src by its inactivator Csk. 2008 , 134, 124-34	93
1076	A history of cancer chemotherapy. 2008 , 68, 8643-53	984
1075	Peptide biosensors for the electrochemical measurement of protein kinase activity. 2008 , 80, 9395-401	78
1074	Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. 2008 , 295, E17-28	195
1073	Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. 2008 , 51, 3124-32	36
1072	Role of Src-family kinases in formation of the cortical actin cap at the dorsal cell surface. 2008 , 314, 2040-54	20
1071	Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors. 2008 , 51, 3814-24	72
1070	Peptides and Peptidomimetics as Cancer Therapy Sensitizing Agents. 2008 , 279-303	
1069	Prediction of cancer driver mutations in protein kinases. 2008 , 68, 1675-82	79
1068	Proteomics-based strategies in kinase drug discovery. 2007 , 1-28	13
1067	Drug Targets, Target identification, Validation and Screening. 2008 , 106-121	0
1066	Protein Crystallography and Drug Discovery. 2008 , 605-634	1
1065	Clinical Relevance: Cytokines in Alzheimer's Disease. 2008 , 6, 507-526	1
1064	Combined anti-proliferative and anti-angiogenic strategies for cancer. 2008 , 9, 701-15	14

1063	Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. 2008 , 3, 959-78	16
1062	Platelet protein interactions: map, signaling components, and phosphorylation groundstate. 2008 , 28, 1326-31	63
1061	Element mass spectrometry as a tool for high-resolution temporal dynamics investigations of peptide phosphorylation. 2008 , 6230-2	4
1060	Electrochemical detection of kinase-catalyzed phosphorylation using ferrocene-conjugated ATP. 2008 , 502-4	87
1059	Following protein kinase activity by electrochemical means and contact angle measurements. 2008 , 2376-8	32
1058	The evolutionarily conserved arrangement of domains in SRC family kinases is important for substrate recognition. 2008 , 47, 10871-80	10
1057	Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. 2008 , 47, 5017-27	22
1056	Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling. 2008 , 10, 843-89	129
1055	A new tool for G protein analysis. 2008 , 3, 24-6	
1054	Neurobiological applications of small molecule screening. 2008 , 108, 1774-86	13
1053	Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. 2008 , 51, 3065-8	33
1052	Characterization of polyubiquitin chain structure by middle-down mass spectrometry. 2008 , 80, 3438-44	86
1051	3-amino-7-phthalazinylbenzoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. 2008 , 51, 6280-92	23
1050	Niobium(V) oxide (Nb2O5): application to phosphoproteomics. 2008 , 80, 4606-13	116
1049	Global impact of oncogenic Src on a phosphotyrosine proteome. 2008 , 7, 3447-60	80
1048	Chip-Based Enrichment and NanoLC-MS/MS Analysis of Phosphopeptides from Whole Lysates. 2008 , 7, 1565-71	61
1047	Advances in the Discovery of IB Kinase Inhibitors. 2008 , 43, 155-170	8
1046	Separations in poly(dimethylsiloxane) microchips coated with supported bilayer membranes. 2008 , 80, 9756-62	21

1045	Phosphorylation of the human full-length protein kinase Ciota. 2008 , 7, 2928-35	8
1044	Recognition-domain focused chemosensors: versatile and efficient reporters of protein kinase activity. 2008 , 130, 12821-7	80
1043	Identification of functionally distinct regions that mediate biological activity of the protein kinase a homolog Tpk2. 2008 , 283, 1084-93	5
1042	Large-scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis. 2008 , 4, 193	302
1041	Breast Cancer. 2008 ,	3
1040	Targeting the unactivated conformations of protein kinases for small molecule drug discovery. 2008 , 3, 595-605	27
1039	Allosteric cooperativity in protein kinase A. 2008 , 105, 506-11	137
1038	GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. 2008 , 7, 1598-608	516
1037	Angiogenesis. 2008 ,	25
1036	The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. 2008 , 121, 3293-304	222
1035	Ca ²⁺ /calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. 2008 , 102, 695-702	124
1034	Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. 2008 , 28, 14511-21	69
1033	Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. 2008 , 68, 7362-70	32
1032	Meta-prediction of phosphorylation sites with weighted voting and restricted grid search parameter selection. 2008 , 36, e22	51
1031	Identification of early-flower-related ESTs in an early-flowering mutant of trifoliate orange (<i>Poncirus trifoliata</i>) by suppression subtractive hybridization and macroarray analysis. 2008 , 28, 1449-57	27
1030	Rho5p is involved in mediating the osmotic stress response in <i>Saccharomyces cerevisiae</i> , and its activity is regulated via Msi1p and Npr1p by phosphorylation and ubiquitination. 2008 , 7, 1441-9	19
1029	Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. 2008 , 118, 84-95	260
1028	Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. 2008 , 68, 767-76	86

1027	Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. 2008 , 8, 53-75	73
1026	Quantitative Proteomics in the Study of Phosphotyrosine-Mediated Signal Transduction Pathway. 2008 , 5, 146-156	2
1025	Understanding how kinase-targeted therapies work. 2008 , 7, 1560-3	2
1024	Evolutionary radiation pattern of novel protein phosphatases revealed by analysis of protein data from the completely sequenced genomes of humans, green algae, and higher plants. 2008 , 146, 351-67	128
1023	Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. 2008 , 7, 1769-75	51
1022	Characterization of a new family of protein kinases from Arabidopsis containing phosphoinositide 3/4-kinase and ubiquitin-like domains. 2008 , 409, 117-27	39
1021	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. 2008 , 7, 3129-40	1072
1020	Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling. 2008 , 283, 4612-21	21
1019	Activation of the SPS amino acid-sensing pathway in <i>Saccharomyces cerevisiae</i> correlates with the phosphorylation state of a sensor component, Ptr3. 2008 , 28, 551-63	53
1018	Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. 2008 , 283, 18873-82	67
1017	Mechanoenzymatics of titin kinase. 2008 , 105, 13385-90	280
1016	Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. 2008 , 283, 33516-26	104
1015	Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. 2008 , 283, 3743-50	51
1014	O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. 2008 , 283, 33935-41	120
1013	Fibronectin type I repeat is a nonactivating ligand for EphA1 and inhibits ATF3-dependent angiogenesis. 2008 , 283, 13148-55	9
1012	Prediction of phosphotyrosine signaling networks using a scoring matrix-assisted ligand identification approach. 2008 , 36, 3263-73	43
1011	Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. 2008 , 327, 610-9	67
1010	Cyclic nucleotide-dependent protein kinases inhibit binding of 14-3-3 to the GTPase-activating protein Rap1GAP2 in platelets. 2008 , 283, 2297-306	37

1009	An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro. 2008 , 14, 524-34	46
1008	Modulation of growth factor action by the extracellular matrix. 2008 , 49, 145-8	9
1007	Non-ATP-competitive kinase inhibitors - enhancing selectivity through new inhibition strategies. 2008 , 3, 761-74	13
1006	FERM control of FAK function: implications for cancer therapy. 2008 , 7, 2306-14	106
1005	Current in vitro kinase assay technologies: the quest for a universal format. 2008 , 5, 59-69	61
1004	Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C beta1 in the diabetic fat tissue. 2008 , 294, E1169-77	23
1003	Signal Transduction in the Cardiovascular System in Health and Disease. 2008 ,	
1002	PhosphoPOINT: a comprehensive human kinase interactome and phospho-protein database. 2008 , 24, i14-20	69
1001	Transcriptional profiling of native inner medullary collecting duct cells from rat kidney. 2008 , 32, 229-53	86
1000	Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. 2008 , 4, e1000051	63
999	Principles of Molecular Oncology. 2008 ,	1
998	PhosphoBlast, a computational tool for comparing phosphoprotein signatures among large datasets. 2008 , 7, 145-62	14
997	A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. 2008 , 295, H2541-50	62
996	Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection. 2008 , 4, e1000201	77
995	Regulation of Bcl-2 family proteins by posttranslational modifications. 2008 , 8, 102-18	81
994	Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. 2008 , 105, 13793-8	252
993	Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis. 2008 , 149, 2667-77	40
992	Congenital disease SNPs target lineage specific structural elements in protein kinases. 2008 , 105, 9011-6	55

991	Tony Hunter: kinase king. Interview by Ruth Williams. 2008 , 181, 572-3	2
990	The annotation of both human and mouse kinomes in UniProtKB/Swiss-Prot: one small step in manual annotation, one giant leap for full comprehension of genomes. 2008 , 7, 1409-19	37
989	Defining the specificity space of the human SRC homology 2 domain. 2008 , 7, 768-84	164
988	Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. 2008 , 68, 3844-53	94
987	Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. 2008 , 100, 1-33	126
986	Gas6 and the Tyro 3 receptor tyrosine kinase subfamily regulate the phagocytic function of Sertoli cells. 2008 , 135, 77-87	72
985	The protist, <i>Monosiga brevicollis</i> , has a tyrosine kinase signaling network more elaborate and diverse than found in any known metazoan. 2008 , 105, 9674-9	158
984	Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). 2008 , 13, 17-28	40
983	Protein kinase d in the cardiovascular system: emerging roles in health and disease. 2008 , 102, 157-63	94
982	The challenge of selecting protein kinase assays for lead discovery optimization. 2008 , 3, 607-621	142
981	Wealth of opportunity - the C1 domain as a target for drug development. 2008 , 9, 641-52	74
980	Prediction of kinase-specific phosphorylation sites using conditional random fields. 2008 , 24, 2857-64	53
979	Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities. 2008 , 7, 2199-214	31
978	Comparative conservation analysis of the human mitotic phosphoproteome. 2008 , 24, 1426-32	43
977	Potassium channel phosphorylation in excitable cells: providing dynamic functional variability to a diverse family of ion channels. 2008 , 23, 49-57	41
976	Involvement of protein kinase D in phosphorylation and increase of DNA binding of activator protein 2 alpha to downregulate ATP-binding cassette transporter A1. 2008 , 28, 2282-7	20
975	Alternative assay formats to identify diverse inhibitors of protein kinases. 2008 , 3, 819-31	3
974	CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. 2008 , 73, 684-90	39

973	SPAK and OSR1: STE20 kinases involved in the regulation of ion homoeostasis and volume control in mammalian cells. 2008 , 409, 321-31	170
972	Overexpression of TNNI3K, a cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and prevents myocardial infarction-induced injury. 2008 , 295, H708-16	25
971	Identification of Phosphorylation Sites Using SVMs. 2008 ,	
970	Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors. 2008 , 15, 673-7	11
969	Current status of HTRF() technology in kinase assays. 2008 , 3, 1461-74	13
968	Structure activity relationships of quinoxalin-2-one derivatives as platelet-derived growth factor-beta receptor (PDGFBeta R) inhibitors, derived from molecular modeling. 2008 , 56, 682-7	11
967	Chapter 13 Analysis of Protein-Tyrosine Phosphorylation by Mass Spectrometry. 2008 , 52, 297-526	1
966	Phosphoproteomic analysis of aged skeletal muscle. 2008 ,	10
965	Signaling in Auxin-Dependent Plant Development. 2008 , 155-178	
964	Selective binding of phorbol esters and diacylglycerol by individual C1 domains of the PKD family. 2008 , 411, 333-42	31
963	The effects of imatinib on pregnancy outcome. 2008 , 111, 5505-8	256
962	[Development of protein kinase inhibitors and their applications for chemical biology]. 2008 , 132, 22-5	
961	Personalizing protein-drug interactions. 2008 , 80, 1811-1820	1
960	Protein Kinase Inhibitors Highlight the Complexities of Drug-Target Non-Covalent Interactions. 2008 , 22, 772-777	
959	. 2008 ,	
958	MEKK1: Dual Function as a Protein Kinase and a Ubiquitin Protein Ligase. 2008 , 79-87	
957	Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. 2008 , 29, 431-40	77
956	Genomic cDNA and RNAi Functional Profiling and Its Potential Application to the Study of Mammalian Stem Cells. 83-107	

955	Sunitinib for advanced renal cell cancer. 2008 , 2, 97-105	8
954	EGFR expression in gallbladder carcinoma in North America. 2008 , 5, 285-91	27
953	Nutri� no p�-genoma: fundamentos e aplica�es de ferramentas �nicas. 2008 , 21, 757-766	8
952	Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs. 2008 , 1, 1-12	13
951	Signal Transduction by Growth Factor Receptors. 2008 , 155-168	
950	Development of a HTRF kinase assay for determination of Syk activity. 2008 , 1, 20-6	13
949	Protein Kinases as Substrates for SAPKs. 2007 , 243-260	1
948	Use of Broad Biological Profiling as a Relevant Descriptor to Describe and Differentiate Compounds: Structure� Vitro (Pharmacology�ADME)� Vivo (Safety) Relationships. 2008 , 23-52	8
947	The C/H3 domain of p300 is required to protect VRK1 and VRK2 from their downregulation induced by p53. 2008 , 3, e2649	19
946	Expression patterns of protein kinases correlate with gene architecture and evolutionary rates. 2008 , 3, e3599	17
945	Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases. 2008 ,	
944	Opposing forces in asthma: regulation of signaling pathways by kinases and phosphatases. 2009 , 29, 419-42	9
943	. 2009 ,	19
942	Approaches to Kinase Homology Modeling: Successes and Considerations for the Structural Kinome. 433-460	2
941	Mutational analysis of JAK1 gene in human hepatocellular carcinoma. 2009 , 56, 136-40	23
940	Loss of yata, a novel gene regulating the subcellular localization of APPL, induces deterioration of neural tissues and lifespan shortening. 2009 , 4, e4466	14
939	Ser/Thr/Tyr protein phosphorylation in the archaeon Halobacterium salinarum--a representative of the third domain of life. 2009 , 4, e4777	69
938	Identifying and characterizing a novel protein kinase STK35L1 and deciphering its orthologs and close-homologs in vertebrates. 2009 , 4, e6981	6

937	Sequence and structure signatures of cancer mutation hotspots in protein kinases. 2009 , 4, e7485	57
936	Neuroproteomics. 2009 , 971-981	1
935	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. 2009 , 1, CMT.S2122	
934	Targeting histone deacetylases for heart failure. 2009 , 13, 767-84	29
933	The emerging complexity of protein ubiquitination. 2009 , 37, 937-53	564
932	Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization. 2009 , 106, 20204-9	49
931	The transcriptome of human CD34+ hematopoietic stem-progenitor cells. 2009 , 106, 8278-83	26
930	Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation. 2009 , 182, 6187-94	31
929	KEA: kinase enrichment analysis. 2009 , 25, 684-6	147
928	An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. 2009 , 106, 2182-7	36
927	Transforming growth factor- β -inducible phosphorylation of Smad3. 2009 , 284, 9663-73	101
926	Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. 2009 , 284, 21327-37	103
925	Direct selection of monoclonal phosphospecific antibodies without prior phosphoamino acid mapping. 2009 , 284, 20791-5	19
924	Generation of a novel system for studying spleen tyrosine kinase function in macrophages and B cells. 2009 , 182, 988-98	8
923	A PGC-1 α -O-GlcNAc transferase complex regulates FoxO transcription factor activity in response to glucose. 2009 , 284, 5148-57	137
922	The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. 2009 , 284, 4921-35	86
921	A conserved protonation-dependent switch controls drug binding in the Abl kinase. 2009 , 106, 139-44	216
920	Advances in Genetics, Genomics and Control of Rice Blast Disease. 2009 ,	24

919	Phosphate-Affinity Gel Electrophoresis Using a Phos-Tag Molecule for Phosphoproteome Study. 2009 , 6, 104-121	16
918	Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases. 2009 , 37, 1297-307	43
917	Functional Characterization of the Canine Heme-Regulated eIF2alpha Kinase: Regulation of Protein Synthesis. 2009 , 2009, 251915	5
916	Classification of nonenzymatic homologues of protein kinases. 2009 , 365637	7
915	The novel protein kinase Vlk is essential for stromal function of mesenchymal cells. 2009 , 136, 2069-79	24
914	Regulation of the catalytic activity of herpes simplex virus 1 protein kinase Us3 by autophosphorylation and its role in pathogenesis. 2009 , 83, 5773-83	40
913	Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. 2009 , 186, 423-36	53
912	Structure and functional characterization of the atypical human kinase haspin. 2009 , 106, 20198-203	115
911	In silico analysis of phosphoproteome data suggests a rich-get-richer process of phosphosite accumulation over evolution. 2009 , 8, 1061-71	26
910	Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. <i>Science</i> , 2009 , 326, 1707-11	333 234
909	New insights into mTOR signaling: mTORC2 and beyond. 2009 , 2, pe27	148
908	Modelling the evolution of multi-gene families. 2009 , 18, 487-504	3
907	Protein Chips and Chromatin Immunoprecipitation I Emerging Technologies to Study Macromolecule Interactions in <i>M. grisea</i> . 2009 , 73-82	1
906	Drug target central. 2009 , 4, 857-72	13
905	The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. 2009 , 29, 1011-6	129
904	Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions. 2009 , 15, 3919-39	50
903	Quantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from <i>Listeria monocytogenes</i> . 2009 , 8, 2778-95	17
902	Chemical genetics identifies c-Src as an activator of primitive ectoderm formation in murine embryonic stem cells. 2009 , 2, ra64	24

901	DNA-PK: relaying the insulin signal to USF in lipogenesis. 2009 , 8, 1977-8	15
900	Wnt asymmetry and the terminal division of neuronal progenitors. 2009 , 8, 1973-4	9
899	Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?. 2009 , 9, 252-72	40
898	Protein phosphorylation by semisynthesis: from paper to practice. 2009 , 462, 1-24	21
897	Changing the clinical picture of challenging tumors: tales becoming reality?. 2009 , 5, 785-802	1
896	A rice kinase-protein interaction map. 2009 , 149, 1478-92	104
895	Dynamic visualization of cellular signaling. 2010 , 119, 79-97	9
894	A survey of the population genetic variation in the human kinome. 2009 , 54, 488-92	1
893	Progress towards the development of anti-inflammatory inhibitors of IKKbeta. 2009 , 9, 623-39	24
892	Successful structure-based design of recent p38 MAP kinase inhibitors. 2009 , 9, 655-76	37
891	ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor. 2009 , 7, e1000126	109
890	Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. 2009 , 5, e1000446	44
889	MoKCa database--mutations of kinases in cancer. 2009 , 37, D824-31	45
888	Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells. 2009 , 69, 2279-86	82
887	Kinomer v. 1.0: a database of systematically classified eukaryotic protein kinases. 2009 , 37, D244-50	74
886	Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample. 2009 , 34, 319-30	99
885	Challenges and opportunities in defining the essential cancer kinome. 2009 , 2, pe15	38
884	Eukaryotic protein domains as functional units of cellular evolution. 2009 , 2, ra76	97

883	Identification and specific localization of tyrosine-phosphorylated proteins in <i>Trypanosoma brucei</i> . 2009 , 8, 617-26	33
882	Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. 2009 , 5, e1000487	63
881	Hunting for the SNARK in metabolic disease. 2009 , 296, E969-72	6
880	Genome to kinome: species-specific peptide arrays for kinome analysis. 2009 , 2, pl1	68
879	Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. 2009 , 296, H13-28	118
878	Herpes simplex virus 1 protein kinase Us3 phosphorylates viral envelope glycoprotein B and regulates its expression on the cell surface. 2009 , 83, 250-61	62
877	Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazono)-ethyl]-phenyl}-amide]. 2009 , 331, 816-26	81
876	How Much Does It Cost?: Optimization of Costs in Sequence Analysis of Social Science Data. 2009 , 38, 197-231	44
875	EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. 2009 , 122, 243-55	90
874	A coated vesicle-associated kinase of 104 kDa (CVAK104) induces lysosomal degradation of frizzled 5 (Fzd5). 2009 , 284, 26716-24	21
873	Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice. 2009 , 138, 655-66	49
872	Mitochondrial diacylglycerol initiates protein-kinase D1-mediated ROS signaling. 2009 , 122, 919-28	47
871	Comparative analysis and unification of domain-domain interaction networks. 2009 , 25, 3020-5	22
870	Monitoring protein kinase activity in cell lysates using a high-density peptide microarray. 2009 , 14, 256-62	16
869	Large-scale proteomics analysis of the human kinome. 2009 , 8, 1751-64	236
868	A structural guide to proteins of the NF-kappaB signaling module. 2009 , 1, a000075	77
867	Loss of post-translational modification sites in disease. 2010 , 337-47	47
866	Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. 2009 , 15, 6327-40	78

865	SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. 2009 , 8, 3181-90	105
864	Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. 2009 , 106, 21608-13	241
863	The DNA Damage Response: Implications on Cancer Formation and Treatment. 2009 ,	3
862	An overview of the Babesia, Plasmodium and Theileria genomes: a comparative perspective. 2009 , 164, 1-8	41
861	Signaling mechanisms of the Mycobacterium tuberculosis receptor Ser/Thr protein kinases. 2009 , 19, 650-7	71
860	Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. 2009 , 17, 128-38	156
859	Mitotic phosphatases: from entry guards to exit guides. 2009 , 19, 531-41	110
858	The tau of MARK: a polarized view of the cytoskeleton. 2009 , 34, 332-42	162
857	Structure-based design of molecular cancer therapeutics. 2009 , 27, 315-28	57
856	Detection and characterization of 3D-signature phosphorylation site motifs and their contribution towards improved phosphorylation site prediction in proteins. 2009 , 10, 117	56
855	Extraction of human kinase mutations from literature, databases and genotyping studies. 2009 , 10 Suppl 8, S1	30
854	Transcriptional profiling of trait deterioration in the insect pathogenic nematode Heterorhabditis bacteriophora. 2009 , 10, 609	20
853	Functional diversity of human protein kinase splice variants marks significant expansion of human kinome. 2009 , 10, 622	19
852	Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects?. 2009 , 9, 225	11
851	Nuclear localization of Src-family tyrosine kinases is required for growth factor-induced euchromatinization. 2009 , 315, 1117-41	49
850	Revealing promiscuous drug-target interactions by chemical proteomics. 2009 , 14, 1021-9	106
849	Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. 2009 , 1793, 847-59	128
848	Nilotinib (AMN107, Tasisign) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. 2009 , 78, 153-61	179

847	A kinome of 2600 in the ciliate <i>Paramecium tetraurelia</i> . 2009 , 583, 3589-92	14
846	Enzymatic characteristics of a Ser/Thr protein kinase, SpkA, from <i>Myxococcus xanthus</i> . 2009 , 107, 10-5	1
845	The Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. 2009 , 16, 246-58	63
844	Structural biology contributions to tyrosine kinase drug discovery. 2009 , 21, 280-7	46
843	The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. 2009 , 21, 288-95	49
842	Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. 2009 , 21, 166-76	515
841	Tyrosine phosphorylation: thirty years and counting. 2009 , 21, 140-6	472
840	Protein phosphatases take the mitotic stage. 2009 , 21, 806-15	75
839	ICBP90 mediates the ERK1/2 signaling to regulate the proliferation of Jurkat T cells. 2009 , 257, 80-7	16
838	Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. 2009 , 21, 1717-26	95
837	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
836	MALDI-TOF mass-spectrometry-based versatile method for the characterization of protein kinases. 2009 , 15, 1413-21	17
835	Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases. 2009 , 15, 11498-506	56
834	Off-target decoding of a multitarget kinase inhibitor by chemical proteomics. 2009 , 10, 1163-74	14
833	A quantitative comparison of wild-type and gatekeeper mutant cdk2 for chemical genetic studies with ATP analogues. 2009 , 10, 1519-26	17
832	Protein conjugates of SH3-domain ligands and ATP-competitive inhibitors as bivalent inhibitors of protein kinases. 2009 , 10, 2445-8	2
831	Structure and function of VEGF receptors. 2009 , 61, 915-22	130
830	<i>Helicobacter pylori</i> activates protein kinase C delta to control Raf in MAP kinase signalling: role in AGS epithelial cell scattering and elongation. 2009 , 66, 874-92	19

829	Design, selection, and evaluation of a general kinase-focused library. 2009 , 4, 1273-8	14
828	Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. 2009 , 70, 125-144	24
827	Asator, a tau-tubulin kinase homolog in Drosophila localizes to the mitotic spindle. 2009 , 238, 3248-56	12
826	Two-dimensional phosphate-affinity gel electrophoresis for the analysis of phosphoprotein isotypes. 2009 , 30, 550-9	42
825	Phosphate-affinity electrophoresis on a microchip for determination of protein kinase activity. 2009 , 30, 3507-13	11
824	Autophosphorylation of carboxy-terminal residues inhibits the activity of protein kinase CK1alpha. 2009 , 106, 399-408	21
823	Loss of cell-cell contacts induces NF-kappaB via RhoA-mediated activation of protein kinase D1. 2009 , 106, 714-28	54
822	A review of current applications of mass spectrometry for neuroproteomics in epilepsy. 2010 , 29, 197-246	10
821	Binding of phosphorylated peptides and inhibition of their interaction with disease-relevant human proteins by synthetic metal-chelate receptors. 2010 , 23, 329-34	5
820	Phosphopeptide fragmentation and analysis by mass spectrometry. 2009 , 44, 861-78	290
819	Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. 2009 , 87, 1283-95	96
818	Monitoring Protein Kinases in Cellular Media with Highly Selective Chimeric Reporters. 2009 , 121, 6960-6963	15
817	Monitoring protein kinases in cellular media with highly selective chimeric reporters. 2009 , 48, 6828-31	41
816	Toward an in situ phospho-protein atlas: phospho- and site-specific antibody-based spatio-temporally systematized detection of phosphorylated proteins in vivo. 2009 , 31, 831-42	5
815	Phenotypic and transcriptomic analyses of Plasmodium falciparum protein kinase A catalytic subunit inhibition. 2009 , 105, 1691-9	12
814	Transmembrane helix of novel oncogene with kinase-domain (NOK) influences its oligomerization and limits the activation of RAS/MAPK signaling. 2009 , 27, 39-45	12
813	A computational approach for the classification of protein tyrosine kinases. 2009 , 28, 195-200	2
812	Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling. 2009 , 17, 6196-202	21

811	Robust optimization of scoring functions for a target class. 2009 , 23, 633-44	15
810	Sequence conservation between porcine and human LRRK2. 2009 , 36, 237-43	13
809	Pathways of metastasis suppression in bladder cancer. 2009 , 28, 327-33	19
808	Brought to life: targeted activation of enzyme function with small molecules. 2009 , 2, 1-9	23
807	Measuring and interpreting the selectivity of protein kinase inhibitors. 2009 , 2, 131-51	119
806	Cancer colorectal m̄astatique et th̄rapies cibl̄es. 2009 , 3, 230-238	
805	Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes. 2009 , 52, 2182-9	26
804	ERK/MAPK signalling pathway and tumorigenesis. 2020 , 19, 1997-2007	265
803	Knockdown of Tousled-like kinase 1 inhibits survival of glioblastoma multiforme cells. 2020 , 46, 685-699	5
802	Multiple functions of TBCK protein in neurodevelopment disorders and tumors. 2021 , 21, 17	5
801	FOXO1 regulates oncogenic PKC- β expression in melanoma inversely to c-Jun in an autocrine manner via IL-17E and ICAM-1 activation. 2018 ,	2
800	FOXO1 regulates oncogenic PKC- β expression in melanoma inversely to c-Jun in an autocrine manner via IL-17E and ICAM-1 activation. 2018 ,	2
799	EGFR and KRAS mutations in patients with adenocarcinoma of the lung. 2009 , 24, 48-54	56
798	The Green MAPKs. 2009 , 9, 1-10	20
797	Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage. 2020 , 15, 86-95	6
796	New genetic players in late-onset Alzheimer's disease: Findings of genome-wide association studies. 2018 , 148, 135-144	17
795	Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression. 2020 , 52, 1067-1083	2
794	Molecular Docking Studies of Myricetin and Its Analogues against Human PDK-1 Kinase as Candidate Drugs for Cancer. 2015 , 05, 20-33	5

793	Kinases: Understanding Their Role in HIV Infection. 2019 , 9, 142-160	1
792	Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology. 2020 , 12, 1553-1575	2
791	Synthesis and Pharmacologic Evaluation of Some Benzimidazole Acetohydrazide Derivatives as EGFR Inhibitors. 2017 , 14, 285-289	7
790	JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. 2015 , 6, 409-18	4
789	Design and Synthesis of an Anticancer Diarylurea Derivative with Multiple-Kinase Inhibitory Effect. 2012 , 33, 1571-1576	12
788	Descriptor-Based Profile Analysis of Kinase Inhibitors to Predict Inhibitory Activity and to Grasp Kinase Selectivity. 2013 , 34, 2680-2684	1
787	Synthesis, characterization, anticancer activity, optical spectroscopic and docking studies of novel thiophene-2-carboxaldehyde derivatives. 2016 , 7, 454-462	1
786	Quantitative Phosphoproteomics of the Human Neural Stem Cell Differentiation into Oligodendrocyte by Mass Spectrometry. 2012 , 3, 93-100	3
785	Isolation and characterization of mouse testis specific serine/threonine kinase 5 possessing four alternatively spliced variants. 2007 , 40, 749-56	9
784	Casein kinase 2 interacts with human mitogen- and stress-activated protein kinase MSK1 and phosphorylates it at multiple sites. 2009 , 42, 840-5	7
783	Chemical kinomics: a powerful strategy for target deconvolution. 2010 , 43, 711-9	6
782	Small-molecule probes elucidate global enzyme activity in a proteomic context. 2014 , 47, 149-57	8
781	c-Jun N-Terminal Kinase Signaling Inhibitors Under Development. 2008 , 24, 93-100	3
780	Evidence, hypotheses and significance of MAP kinase TNKI3K interacting with its partners. 2012 , 2, 22	2
779	Studying Side Effects of Tyrosine Kinase Inhibitors in a Juvenile Rat Model with Focus on Skeletal Remodeling.	2
778	Computational Biology and Bioinformatics: a tinge of Indian spice. 2006 , 1, 105-9	1
777	Insights into evolutionary interaction patterns of the 'Phosphorylation Activation Segment' in kinase. 2019 , 15, 666-677	3
776	Endpoint of cancer treatment: targeted therapies. 2014 , 15, 4395-403	16

775	Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. 2014 , 3, e02667	87
774	Ancestral resurrection reveals evolutionary mechanisms of kinase plasticity. 2014 , 3,	36
773	COMP-1 promotes competitive advantage of nematode sperm. 2015 , 4,	17
772	A secretory kinase complex regulates extracellular protein phosphorylation. 2015 , 4, e06120	76
771	Structure of protein O-mannose kinase reveals a unique active site architecture. 2016 , 5,	23
770	Endothelial PKA activity regulates angiogenesis by limiting autophagy through phosphorylation of ATG16L1. 2019 , 8,	15
769	ASPEN, a methodology for reconstructing protein evolution with improved accuracy using ensemble models. 2019 , 8,	3
768	Protein polyglutamylation catalyzed by the bacterial calmodulin-dependent pseudokinase SidJ. 2019 , 8,	33
767	An atypical DYRK kinase connects quorum-sensing with posttranscriptional gene regulation in. 2020 , 9,	15
766	Slo2 potassium channel function depends on RNA editing-regulated expression of a SCYL1 protein. 2020 , 9,	3
765	A perspective on HPK1 as a novel immuno-oncology drug target. 2020 , 9,	9
764	FRET kinase sensor development reveals SnRK2/OST1 activation by ABA but not by MeJA and high CO during stomatal closure. 2020 , 9,	19
763	DOSCHEDA: a web application for interactive chemoproteomics data analysis. 3, e129	2
762	Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree. 2013 , 1, e126	72
761	ksrMKL: a novel method for identification of kinase-substrate relationships using multiple kernel learning. 2017 , 5, e4182	3
760	Phosphoproteomic insights into processes influenced by the kinase-like protein DIA1/C3orf58. 2018 , 6, e4599	5
759	Phosphorylation/dephosphorylation response to light stimuli of proteins: specific light-induced dephosphorylation of an HSP-like 75 kDa protein from. 2019 , 7, e7406	2
758	Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. 2021 , 81, 1605-1626	5

757	Strategies for mass spectrometry-based phosphoproteomics using isobaric tagging. 2021 , 18, 795-807	2
756	Functional requirements of protein kinases and phosphatases in the development of the <i>Drosophila melanogaster</i> wing. 2021 , 11,	1
755	CDKL5 kinase controls transcription-coupled responses to DNA damage. 2021 , 40, e108271	1
754	Pathogenic role of mitogen activated protein kinases in protozoan parasites. 2021 ,	0
753	Virtual screening of natural compounds as selective inhibitors of polo-like kinase-1 at C-terminal polo box and N-terminal catalytic domain. 2021 , 1-19	3
752	The structural basis of PTEN regulation by multi-site phosphorylation. 2021 , 28, 858-868	5
751	Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways. 2021 , 12, 931	1
750	The Role of Kinase Inhibitors in Cancer Therapies.	
749	Complete genomes of the eukaryotic poultry parasite <i>Histomonas meleagridis</i> : linking sequence analysis with virulence / attenuation. 2021 , 22, 753	2
748	Molecular insight into the affinity, specificity and cross-reactivity of systematic hepatocellular carcinoma RALT interaction profile with human receptor tyrosine kinases. 2021 , 53, 1715-1728	
747	Stress Relief Techniques: p38 MAPK Determines the Balance of Cell Cycle and Apoptosis Pathways. 2021 , 11,	3
746	Tyrosine kinases: complex molecular systems challenging computational methodologies. 2021 , 94, 1	2
745	Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation. 2021 , 117, 105420	0
744	Jak3 and the Pathogenesis of Severe Combined Immunodeficiency. 2003 , 623-636	
743	Eukaryotic Kinomes: Genomic Cataloging of Protein Kinases and Their Evolution. 2003 , 373-377	
742	From Tyrphostins to Iressa and Gleevec: Signal Transduction Therapy from Concept to the Patient Bed. 2003 , 391-402	
741	Bioinformatics Tools. 2004 , 449-472	
740	Using a Neural Networking Method to Predict the Protein Phosphorylation Sites with Specific Kinase. 2006 , 682-689	

739 Development of High-Throughput Screening Assays in Scintillating Microplates (FlashPlates) to Identify Inhibitors of Kinase Activity. **2006**, 57-70

738 Protein Kinases in Drug Discovery: Rationale, Success, and Challenge. **2006**, 19-24

737 Introduction to molecular exercise physiology. **2006**, 121-163

736 Trafficking of Serine/Threonine Kinase Receptors and Smad Activation. **2006**, 177-191

1

735 IKK-2/NF- κ B-DEPENDENT TRANSCRIPTION. **2007**, 199-221

734 The Structural Bases of CDK5 Activity. **2008**, 191-210

733 Structure-function of EGFR kinase domain and its inhibitors. **2008**, 30-44

o

732 The Signaling Duel Between Virus and Host: Impact on Coxsackieviral Pathogenesis. **2008**, 267-284

731 Schizophrenia Biomarkers: A Means to Advance Disease Understanding, Diagnosis and Treatment. **2008**, 75-96

730 Angiopoietins and Tie Receptors. **2008**, 113-120

o

729 Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways. **2008**, 117-134

728 Molecular Dynamics in Cellular Signal Transduction Systems. **2008**, 111, 578-581

727 Intracellular Signaling. **2008**, 21-31

726 Protein Kinase Inhibitors. 47

725 Mitogen-activated Protein Kinases (MAPKs): ERKs, JNKs, and p38s. 1

724 Post-Translational Modifications that Regulate Kinetochore Activity. **2009**, 1-51

1

723 Cancer Genes, Genomes, and the Environment. **2009**, 808-817

722 Insights into the Three-Dimensional Organization of Ryanodine Receptors. **2009**, 463-486

721 Spatial and Temporal Control of Cell Signaling by A-Kinase Anchoring Proteins. **2010**, 183-197

720 Toxicology of the Endocrine System.

1

719 Small Molecules as Versatile Tools for Activity-Based Protein Profiling Experiments. **2010**, 603-639

718 Substrates of Cyclic Nucleotide-Dependent Protein Kinases. **2010**, 1489-1495

717 Wrapping Patterns as Universal Markers for Specificity in the Therapeutic Interference with Signaling Pathways. **2010**, 141-161

716 Posttranslational Modification of Proteins. **2010**, 528-559

715 Insulin and Growth Factor Signaling Pathways. **2010**, 38-82

714 PKC β Interplay in Cancer. **2010**, 287-303

713 Protein Kinase Inhibitors in Drug Discovery. 1

712 Msk1.

0

711 Target-Driven Drug Discovery. **2010**, 23-54

710 Targeted Therapy in Hematologic Malignancies. **2011**, 293-323

709 Encyclopedia of Cancer. **2011**, 3698-3702

708 The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL. **2011**, 203-219

707 Encyclopedia of Cancer. **2011**, 1031-1034

706 Cancer Signaling Network Analysis by Quantitative Mass Spectrometry. **2011**, 55-75

705 Encyclopedia of Cancer. **2011**, 3531-3534

704 Mitotic kinases regulate chromosome dynamics during mitosis. **2011**, 23, 81-89

- 703 Platelets and their Role in Thrombotic and Cardiovascular Disease: The Impact of Proteomic Analysis. 1-26 1
- 702 Eukaryote PTM as Phosphorylation: Normal State Studies. 99-146
- 701 Cell Signalling Through Covalent Modification and Allostery. **2012**, 87-92
- 700 DNA Damage Checkpoint Signaling Pathways in Human Cancer. **2012**, 23-37
- 699 Anti-Inflammatory/Analgesics: An In-Depth Look at p38 MAP Kinases. 1
- 698 Protein Kinase C: The Drug Target One Must See. **2012**, 2, 1
- 697 Signaling Pathways in Endometriosis (Eutopic/Ectopic). 164-172 1
- 696 Classification of Biological Sequences. **2012**, 111-135
- 695 Analysis of Kinase Inhibitors and Druggability of Kinase-Targets Using Machine Learning Techniques. **2012**, 155-165
- 694 Large-Scale Protein Phosphorylation Analysis by Mass Spectrometry-Based Phosphoproteomics. **2012**, 35-46
- 693 New Insights from a Focused Library Approach Aiming at Development of Inhibitors of Dual-Specificity Protein Phosphatases. **2012**, 69-81
- 692 Electrophysiological Technique for Analysis of Synaptic Function of PKN1 in Hippocampus. **2012**, 349-360
- 691 Imaging Oscillations of Protein Kinase C Activity in Cells. **2012**, 251-257
- 690 The Role of Chemical Biology in Drug Discovery. 1
- 689 The Role of Chemical Biology in Drug Discovery. 1-21
- 688 Introduction. **2013**, 1-3
- 687 Classification of Biological Sequences. **2013**, 1019-1042
- 686 Intracellular Message Chains. **2013**, 97-130

685 Comprehensive Genomic Alterations in Common Cancer Cell Lines Revealed by Exome Sequencing. **2013**, 165-182

684 CHAPTER 7:Discovery of the Serenex Hsp90 Inhibitor, SNX5422. **2013**, 198-212

683 The Reciprocal Interaction of Small Molecule Protein Kinase Inhibitors and ATP-Binding Cassette Transporters in Targeted Cancer Therapy.

682 Immunokinases. 329-336

681 Domain Specific Targeting of Cancer. **2014**, 299-310

680 Molecular Docking and Molecular Dynamics Simulations of the Kinase Domain Inhibitor for an Epidermal Growth Factor Receptor. **2013**, 34, 2515-2518

679 Signalling via Single-Pass Transmembrane Proteins.

1

678 An in vitro system to evaluate the scaffold function of the RalA effector protein RalBP1. **2014**, 1120, 207-16

677 Encyclopedia of Cancer. **2014**, 4364-4367

676 Encyclopedia of Cancer. **2014**, 1-5

675 Encyclopedia of Psychopharmacology. **2014**, 1-9

674 Encyclopedia of Cancer. **2014**, 1-4

673 The Role of Mycobacterial Kinases and Phosphatases in Growth, Pathogenesis, and Cell Wall Metabolism. 323-343

672 Sensing, Signal Transduction, and Posttranslational Modification. 224-259

671 Introduction to Pathogenomics. 1-20

670 Targeted Agents in Gynecologic Cancers. **2014**, 1,

669 Overview: Presynaptic Terminal Proteins Orchestrate Stepwise Synaptic Vesicle Phases. **2015**, 3-44

1

668 Encyclopedia of Cancer. **2015**, 1-6

667 Encyclopedia of Cancer. **2015**, 1-4

666 Protein Kinase CK2: Systematic Relationships with Other Posttranslational Modifications. **2015**, 183-196

665 Biomolecular Interfaces Provide Universal Markers for Drug Specificity and Personalized Medicine. **2015**, 217-241

664 The TAM Receptor Family. **2015**, 53-77

663 Case Studies: Selective Inhibitors of Protein Kinases Exploiting Demure Features. 413-434

662 Elucidation of Proto-Oncogene C-Abl Function with the Use of Mouse Models and the Disease Model of Chronic Myeloid Leukemia. **2015**, 59-94

661 Phos-tag Technology for Kinomics. 195-210

660 Development of Species- and Process-Specific Peptide Kinome Arrays with Priority Application to Investigations of Infectious Disease. 211-232

659 Methods for Large-Scale Identification of Protein Kinase Substrate Networks. 255-280

658 Protein Kinases and Caspases: Bidirectional Interactions in Apoptosis. 85-114

657 Global Approaches to Understanding Protein Kinase Functions. 1-45

656 Mycobacterium tuberculosis Serine/Threonine Protein Kinases. 681-708

655 Effect of Physiochemical Properties on Classification Algorithms for Kinases Family. **2016**, 47-57

654 Encyclopedia of Signaling Molecules. **2016**, 1-6

653 Encyclopedia of Signaling Molecules. **2016**, 1-11

652 Encyclopedia of Cancer. **2016**, 1269-1273

651 Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase. **2016**, 249-277

650 Episturctural Informatics for the Drug Designer. **2016**, 267-304

649 Encyclopedia of Cancer. **2016**, 3822-3824

648 Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. **2016**, 27-107

647 An open library of human kinase domain constructs for automated bacterial expression.

646 Ascending the PEAK1 toward targeting TGF β during cancer progression: Recent advances and future perspectives. **2016**, 3,

4

645 Characterization of kinase gene expression and splicing profile in prostate cancer with RNA-Seq data.

644 Could S6K1 immunopositivity be used to distinguish early and advanced stages of endometrioid endometrial adenocarcinoma?. **2016**, 17, 163-7

643 Oncogenes and the Initiation and Maintenance of Tumorigenesis. **2017**, 143-157

642 Proteotype profiling unmask a viral signaling network essential for poxvirus assembly and transcriptional competence.

641 Small Molecule Inhibitors. **2017**, 771-795

640 Data characterization. **2017**, 15-43

639 Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase. **2017**, 1115-1143

638 Encyclopedia of Signaling Molecules. **2017**, 1-9

637 Encyclopedia of Signaling Molecules. **2017**, 1-6

636 [Application of molecular descriptors for recognition of phosphorylation sites in amino acid sequences]. **2017**, 63, 423-427

1

635 Development of Selected Reaction Monitoring Methods to Systematically Quantify Kinase Abundance and Phosphorylation Stoichiometry in Human Samples. **2017**, 1636, 353-369

634 Protein Phosphorylation-Dephosphorylation and Signal Processing in the Archaea. **2017**, 213-234

633 Encyclopedia of Cancer. **2017**, 4549-4555

632 Encyclopedia of Signaling Molecules. **2017**, 1-4

631 Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.

630 Structural characterization of human Vaccinia-Related Kinases (VRK) bound to small-molecule inhibitors identifies different P-loop conformations.

629 ASPEN: A methodology for reconstructing protein evolution with improved accuracy using ensemble models.

628 An Invisible Ubiquitin conformation is required for efficient phosphorylation by PINK1.

627 Global analysis of specificity determinants in eukaryotic protein kinases.

1

626 Computational Modelling of Kinase Inhibitors as Anti-Alzheimer Agents. **2018**, 347-417

1

625 Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasma Agents in ARPE-19 Cells. **2017**, 55, 491-503

2

624 Hierarchical organization endows the kinase domain with regulatory plasticity.

623 Towards simple kinetic models of functional dynamics for a kinase subfamily.

622 High-Throughput Assessment of Kinome-Wide Activation States.

621 Encyclopedia of Signaling Molecules. **2018**, 4279-4286

620 Truncation and Motif Based Pan-Cancer Analysis Highlights Novel Tumor Suppressing Kinases.

619 Encyclopedia of Signaling Molecules. **2018**, 2888-2893

618 Encyclopedia of Signaling Molecules. **2018**, 5973-5976

617 Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

616 Encyclopedia of Signaling Molecules. **2018**, 5965-5973

615 Analysis of the Human Kinome and Phosphatome Reveals Diseased Signaling Networks Induced by Overexpression.

614 Encyclopedia of Signaling Molecules. **2018**, 5955-5965

613 Encyclopedia of Signaling Molecules. **2018**, 4033-4038

612 A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes.

611 Kinome expansion in the *Fusarium oxysporum* species complex driven by accessory chromosomes.

610 New tools for evaluating protein tyrosine sulphation: Tyrosyl Protein Sulphotransferases (TPSTs) are novel targets for RAF protein kinase inhibitors.

609 Analysis of the human kinome and phosphatome reveals diseased signaling networks induced by overexpression.

608 Integrated computational and *Drosophila* cancer model platform captures previously unappreciated chemicals perturbing a kinase network.

607 De novo genome and transcriptome analyses provide insights into the biology of the trematode human parasite *Fasciolopsis buski*.

606 Ancestral Roles of the Fam20C Family of Secreted Protein Kinases Revealed by Functional Analysis in *C. elegans*. 1

605 Kinase Driver Mutations in Protein-protein Structure may associate to Disease by Effecting Kinase Stability.

604 A divergent kinase lacking the glycine-rich loop regulates membrane ultrastructure of the *Toxoplasma* parasitophorous vacuole.

603 Mapping the human kinome in response to DNA damage.

602 Evolution of protein kinase substrate recognition at the active site.

601 Receptors for Targeting Growth Factors for Treatment of Cancers. **2019**, 197-228

600 Phospho-protein Analysis in Adherent Cells Using Flow Cytometry. **2019**, 9, e3395 2

599 Advances in Mass Spectrometry-Based Proteomics and Its Application in Cancer Research. **2019**, 89-112

598 CHAPTER 9. Gold-nanoparticles Interface-based Electrochemical Immunosensors for Tumor Biomarkers. **2019**, 186-218

597 LF4/MOK and a CDK-related kinase regulate the number and length of cilia in *Tetrahymena*.

596 An evolutionary-conserved redox regulatory mechanism in human Ser/Thr protein kinases.

- 595 Dynamics of dual specificity phosphatases and their interplay with protein kinases in immune signaling. 1
- 594 Interaction of Plasmodium falciparum Casein kinase 1 (PfCK1) with components of host cell protein trafficking machinery.
- 593 An atlas of the catalytically active liver and spleen kinases in chicken identified by chemoproteomics.
- 592 Improved detection of gene fusions by applying statistical methods reveals new oncogenic RNA cancer drivers.
- 591 DeepKinZero: Zero-Shot Learning for Predicting Kinase-Phosphosite Associations Involving Understudied Kinases. 1
- 590 An ultrasensitive fiveplex activity assay for cellular kinases.
- 589 An atypical DYRK kinase connects quorum-sensing with posttranscriptional gene regulation in Trypanosoma brucei.
- 588 Design and analysis of the 4-anilino-quin(az)oline kinase inhibition profiles of GAK/SLK/STK10 using quantitative structure activity relationships.
- 587 SKIPHOS: non-kinase specific phosphorylation site prediction with random forests and amino acid skip-gram embeddings.
- 586 Reversed Signaling Flow of a Bacterial Pseudokinase.
- 585 annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions.
- 584 Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis via SYK activation.
- 583 Determination of Phosphohistidine Stoichiometry in Histidine Kinases by Intact Mass Spectrometry. 2020, 2077, 83-91 1
- 582 Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.
- 581 Accurate Prediction of Kinase-Substrate Networks Using Knowledge Graphs.
- 580 Slo2 potassium channel function depends on a SCYL1 protein.
- 579 PhosTransfer: A Deep Transfer Learning Framework for Kinase-Specific Phosphorylation Site Prediction in Hierarchy. 2020, 384-395 1
- 578 Chapter 6:Structure-based PROTAC Design. 2020, 115-134

- 577 Mechanism of the Effect of Protein Phosphorylation on Postmortem Glycolysis. **2020**, 93-121
- 576 3D-QSAR Assisted Design of Novel 7-Deazapurine Derivatives as TNNI3K Kinase Inhibitors Using Molecular Docking and Molecular Dynamics Simulation. **2020**, 17, 155-168 1
- 575 Phosphoproteome profiling provides insight into the mechanisms of ventilator-induced lung injury. **2020**, 19, 3627-3633 2
- 574 A Chemical-genetics and Nanoparticle Enabled Approach for in vivo Protein Kinase Analysis.
- 573 Integrative proteomics reveals principles of dynamic phospho-signaling networks in human erythropoiesis.
- 572 Transcriptional response of human articular chondrocytes treated with fibronectin fragments: an in vitro model of the osteoarthritis phenotype.
- 571 Assessment of mitogen-activated protein kinases as therapeutic targets for the treatment of babesiosis and theileriosis. **2020**, 44, 702-713
- 570 Nucleotide binding, evolutionary insights and interaction partners of the pseudokinase Unc-51-like kinase 4.
- 569 c-Jun and FOXO1 mediate the expression of oncogenic PKC- δ in human prostate cancer cells with an interplay between NF- κ B, IL-8 and ICAM-1. 0
- 568 PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor.
- 567 Genome-Wide Mapping of Cisplatin Damaged Gene Loci.
- 566 Hyperbolic geometry of gene expression.
- 565 Bimodal evolution of Src and Abl kinase substrate specificity revealed using mammalian cell extract as substrate pool. 1
- 564 Pseudokinases repurpose flexibility signatures associated with the protein kinase fold for noncatalytic roles. **2021**, 0
- 563 In-silico Pharmacokinetic and Affinity Studies of Piperazine/Morpholine Substituted Quinolines in complex with GAK as promising anti-HCV agent. 0
- 562 Targeting PINK1 Using Natural Products for the Treatment of Human Diseases. **2021**, 2021, 4045819 0
- 561 Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer. **2021**, 11, 5
- 560 The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. **2021**, 9, 4

- 559 A Radioactive-free Kinase Inhibitor Discovery Assay Against the Glycogen Synthase Kinase-3 short (GSK-3s). **2020**, 10, e3493
- 558 Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. **2020**, 125-153
- 557 Chapter 15:Canonical Phosphoproteomics: Phosphoserine, Phosphothreonine, and Phosphotyrosine. **2020**, 452-489
- 556 Introduction to Kinases, Cellular Signaling, and Kinase Inhibitors. **2020**, 1-12
- 555 Lipid Mediated Regulation of Protein Kinases. **2020**, 147-191
- 554 Epilepsy kinase CDKL5 is a DNA damage sensor which controls transcriptional activity at DNA breaks.
- 553 Protein Tyrosine Phosphorylation in Plants. **2020**, 459-478
- 552 Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo. **2020**, 21, 996-1008
- 551 The landscape of kinase domain duplication in Chinese lung cancer patients. **2020**, 8, 1642 3
- 550 pdCSM-GPCR: predicting potent GPCR ligands with graph-based signatures.. **2021**, 1, vbab031 o
- 549 Mass spectrometry for human kinome analysis. **2022**, 191-216 o
- 548 multiSLIDE: a web server for exploring connected elements of biological pathways in multi-omics data.
- 547 Novel Peptide-Based Inhibitors of Protein Kinases. **2020**, 169-206 o
- 546 Developing Kinase Inhibitors Using Computer-Aided Drug Design Approaches. **2020**, 81-108
- 545 In depth analysis of kinase cross screening data to identify CAMKK2 inhibitory scaffolds. o
- 544 Translation and Post-translational Modifications in Protein Biosynthesis. **2020**, 595-665 1
- 543 Chapter 10:Visualization of Dynamic Intermolecular Interactions in Living Cells. **2020**, 232-247
- 542 Protein Kinase Interactions with Regulatory and Effector Proteins. **2020**, 61-80

541 CHAPTER 8:Chemical Probes for Kinases. **2020**, 182-213

540 Understanding the mechanism of action of pyrrolo[3,2-]quinoxaline-derivatives as kinase inhibitors. **2020**, 11, 665-675 0

539 Chapter 14:Noncanonical Phosphoproteomes. **2020**, 393-451

538 The serine-threonine kinase TAO3 promotes cancer invasion and tumor growth by facilitating trafficking of endosomes containing the invadopodia scaffold TKS5 0

537 A Legionella effector kinase is activated by host inositol hexakisphosphate. 0

536 An Inherent Structural Difference Between Serine and Threonine Phosphorylation: Phosphothreonine Prefers an Ordered, Compact, Cyclic Conformation. 1

535 Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 As Candidate Therapeutic Target. 0

534 The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer's Disease-Induced Cognitive Dysfunction. **2020**, 24, 64-80 3

533 Targeting the water network in cyclin G associated kinase (GAK) with 4-anilino-quin(az)oline inhibitors.

532 STK32A is a dual-specificity AGC kinase with a preference for acidic substrates. 0

531 Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives. **2021**, 1

530 Regulation of PP2A, PP4, and PP6 holoenzyme assembly by carboxyl-terminal methylation. 0

529 Identification and comparison of plant-derived scaffolds as selective CDK5 inhibitors against standard molecules: Insights from umbrella sampling simulations. **2021**, 348, 118015 4

528 DFG-1 residue controls inhibitor binding mode and affinity providing a basis for rational design of kinase inhibitor selectivity.

527 Phosphoproteomic Identification of Vasopressin-Regulated Protein Kinases in Collecting Duct Cells.

526 Analysis of Kinase Inhibitors and Druggability of Kinase-Targets Using Machine Learning Techniques. 937-947

525 Phosphorylation-Dependent Regulation of Voltage-Gated Ca²⁺ Channels. **2005**, 168-182

524 Inter- and Supramolecular Interactions of Protein Kinase CK2 and their Relevance for Genome Integrity. **2005**, 315-342

523 Protein Kinases and Phosphatases. **2007**, 187-205

522 Novel Therapeutic Strategies For Posterior Segment Neovascularization. **2008**, 445-526

521 Annotating the Human Proteome. **2008**, 211-235

520 Tyrosine Kinase Inhibitors. **2007**, 477-508

519 Targeting ATM/ATR in the DNA Damage Checkpoint. **2008**, 93-116

518 Renal Cell Carcinoma. **2008**, 241-261

517 Endothelin Signaling in the Cardiomyocyte. **2008**, 14-45

516 BCR-ABL-Negative Chronic Myeloid Leukemia. **2007**, 219-233

515 Computational Proteomics of Biomolecular Interactions in Sequence and Structure Space of the Tyrosine Kinome: Evolutionary Constraints and Protein Conformational Selection Determine Binding Signatures of Cancer Drugs. **2007**, 604-611

514 Context-Specific Independence Mixture Modelling for Protein Families. **2007**, 79-90

1

513 Phosphorylation-dependent sub-functionalization of the calcium-dependent protein kinase CPK28.

512 [In silico profiling of protein kinases inhibitors]. **2020**, 36 Hors s  rie n   1, 38-41

511 De Novo Design of Allosteric Control into Rotary Motor V1-ATPase by Restoring Lost Function.

0

510 Evolution of kinase polypharmacology across HSP90 drug discovery.

509 Diurnal Dynamics of the Arabidopsis Rosette Proteome and Phosphoproteome.

1

508 Proteasome Regulation by Reversible Tyrosine Phosphorylation at the Membrane.

507 Signaling-based neural networks for cellular computation.

2

506 JAK1 palmitoylation by ZDHHC3/7 is Essential for Neuropoietic Cytokine Signaling and DRG Neuron Survival.

505	The proteomic landscape of resting and activated CD4+ T cells reveal insights into cell differentiation and function.	0
504	Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms.	0
503	Correction of the Taxonomic Composition of Human Gut Microbiota: Serine-Threonine Protein Kinases as Biotargets. 2020 , 10, 495-506	
502	Kinase-substrate Edge Biomarkers Provide a More Accurate Prognostic Prediction in ER-negative Breast Cancer. 2020 , 18, 525-538	
501	Optimization of immobilized gallium (III) ion affinity chromatography for selective binding and recovery of phosphopeptides from protein digests. 2008 , 19, 296-310	16
500	Characterization and evolution of the cell cycle-associated mob domain-containing proteins in eukaryotes. 2007 , 3, 121-58	10
499	NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. 2007 , 2, 93-106	6
498	Simultaneous protein expression and modification: an efficient approach for production of unphosphorylated and biotinylated receptor tyrosine kinases by triple infection in the baculovirus expression system. 2010 , 21, 9-17	7
497	The role of tau kinases in Alzheimer's disease. 2010 , 13, 595-603	83
496	Two-dimensional immobilized metal affinity electrophoresis for capturing a phosphoprotein. 2010 , 21, 160-2	3
495	Protein multifunctionality: principles and mechanisms. 2008 , 3, 99-136	4
494	PEAK1, a novel kinase target in the fight against cancer. 2010 , 1, 219-23	14
493	Importance of manual validation for the identification of phosphopeptides using a linear ion trap mass spectrometer. 2011 , 22, 10-20	5
492	Systems approaches to polypharmacology and drug discovery. 2010 , 13, 297-309	108
491	Comparison of modulation of Kv1.3 channel by two receptor tyrosine kinases in olfactory bulb neurons of rodents. 2004 , 10, 25-36	35
490	RSK2 Binding Models Delineate Key Features for Activity. 2010 , 2, 587-598	2
489	New Test System for Serine/Threonine Protein Kinase Inhibitors Screening: E. coli APHVIII/Pk25 design. 2010 , 2, 110-21	
488	Burn injury-induced IRS-1 degradation in mouse skeletal muscle. 2013 , 3, 37-48	8

487	Specific differentiation of mesenchymal stem cells by small molecules. 2012 , 1, 22-30	11
486	Biomarkers of head and neck cancer, tools or a gordian knot?. 2015 , 8, 10340-57	26
485	Evaluation of discoidin domain receptor-2 (DDR2) expression level in normal, benign, and malignant human prostate tissues. 2015 , 10, 356-63	11
484	Correlation between microRNA-421 expression level and prognosis of gastric cancer. 2015 , 8, 15128-32	17
483	Comparative analysis of the human and zebrafish kinomes: focus on the development of kinase inhibitors. 2015 , 10, 49-75	2
482	Effects of T208E activating mutation on MARK2 protein structure and dynamics: Modeling and simulation. 2014 , 3, 149-164	1
481	[RNA interference library research progress and its application in cancer research]. 2013 , 16, 102-6	
480	EphA10 and EphB3 are prognostic markers in gallbladder squamous cell/adenosquamous carcinomas and adenocarcinomas. 2018 , 11, 512-525	2
479	SNRK: a metabolic regulator with multifaceted role in development and disease. 2020 , 4,	
478	How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors. 2021 , 53, 116534	0
477	Function and regulation of phosphatase 1 in healthy and diseased heart. 2021 , 90, 110203	1
476	SGK1, autophagy and cancer: an overview. 2021 , 1	1
475	Transforming growth factor β latency: A mechanism of cytokine storage and signalling regulation in liver homeostasis and disease.. 2022 , 4, 100397	2
474	A human kinase yeast array for the identification of kinases modulating phosphorylation-dependent protein-protein interactions.	0
473	6-Benzyladenine increasing subsequent waterlogging-induced waterlogging tolerance of summer maize by increasing hormone signal transduction. 2021 ,	1
472	Potential Replacements for Antibiotic Growth Promoters in Poultry: Interactions at the Gut Level and Their Impact on Host Immunity. 2022 , 1354, 145-159	2
471	Diving into the dark kinome: lessons learned from LMTK3. 2021 ,	0
470	Regulation of PP2A, PP4, and PP6 holoenzyme assembly by carboxyl-terminal methylation. 2021 , 11, 23031	0

469	CSNK2 in cancer: pathophysiology and translational applications. 2021 ,	1
468	Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4. 2021 ,	4
467	PHOrming the inflammasome: phosphorylation is a critical switch in inflammasome signalling. 2021 ,	4
466	Modulating undruggable targets to overcome cancer therapy resistance.. 2021 , 60, 100788	2
465	Kinomic comparison of snap frozen and ex vivo-cultured head and neck tumors. 2021 , 123, 105603	0
464	Analysis of protein phosphorylation combining capillary electrophoresis with ATP analog labeling technique. 2021 ,	0
463	Phospho zinc finger protein: A promising serum biomolecule as noninvasive diagnostic marker of chronic Hepatitis B related liver diseases including liver cancer. 2021 , 12, 147	0
462	Cadherin-11 Regulates Cell Proliferation via the PDGFR/ERK1/2 Signaling Pathway in Human Mesenchymal Stem Cells.. 2022 , 40, 165-174	0
461	Comprehensive kinomic study via a chemical proteomic approach reveals kinome reprogramming in hepatocellular carcinoma tissues.. 2021 , e2100141	
460	An Update on the Effectiveness of Probiotics in the Prevention and Treatment of Cancer.. 2022 , 12,	3
459	Calculation of centralities in protein kinase A.	
458	The Rho guanine nucleotide exchange factor PLEKHG1 is activated by interaction with and phosphorylation by Src family kinase member FYN.. 2022 , 101579	0
457	ARN25068, a versatile starting point towards triple GSK-3 β /FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.. 2021 , 229, 114054	1
456	The active kinome: The modern view of how active protein kinase networks fit in biological research.. 2021 , 62, 117-129	2
455	Protein phosphatase 2A in the healthy and failing heart: New insights and therapeutic opportunities.. 2021 , 91, 110213	0
454	Prospects for Targeted Kinase Inhibition in Cancer: Neurofibromatosis Type 1-Related Neoplasia. 2021 ,	
453	Factors modulating the avian immune system. 2022 , 419-435	
452	A community challenge for a pancancer drug mechanism of action inference from perturbational profile data.. 2022 , 3, 100492	5

451	Tracking mutation and drug-driven alterations of oncokinase conformations. 1	0
450	Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses.	0
449	STK35 Gene Therapy Attenuates Endothelial Dysfunction and Improves Cardiac Function in Diabetes.. 2021 , 8, 798091	
448	Multiple subcellular localizations and functions of protein kinase C α in liver cancer.. 2022 , 28, 188-198	0
447	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
446	Interrogating Kinase-Substrate Relationships with Proximity Labeling and Phosphorylation Enrichment.. 2022 ,	2
445	Mutations in the helix E of the catalytic domain from the EGFR affect its activity in cervical cancer cell lines.. 2022 , 23, 71	
444	Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.. 2022 , 14,	2
443	Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from (L.) Millsp.. 2022 , 23,	0
442	Kinase inhibitors involved in the regulation of autophagy: Molecular concepts and clinical implications.. 2022 ,	1
441	Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.. 2022 , 2022, 4889807	2
440	Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.. 2021 , 106037	22
439	In-Silico Screening of Novel Synthesized Thienopyrimidines Targeting Fms Related Receptor Tyrosine Kinase-3 and Their In-Vitro Biological Evaluation.. 2022 , 15,	3
438	A blend of microencapsulated organic acids and botanicals reduces necrotic enteritis via specific signaling pathways in broilers.. 2022 , 101, 101753	2
437	New insights into the roles for DYRK family in mammalian development and congenital diseases. 2022 ,	0
436	A Review of Potential Role of Capsule Endoscopy in the Work-Up for Chemotherapy-Induced Diarrhea.. 2022 , 10,	0
435	The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors.. 2021 , 1877, 188666	4
434	Kinase Function of Brassinosteroid Receptor Specified by Two Allosterically Regulated Subdomains.. 2021 , 12, 802924	0

433	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. 2022 ,	3
432	Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.. 2022 , 15, 103-116	1
431	Orchestrating serine/threonine phosphorylation and elucidating downstream effects by short linear motifs.. 2022 , 479, 1-22	1
430	PCTAIRE1 promotes mitotic progression and resistance against antimitotic and apoptotic signals.. 2022 ,	0
429	Single cell imaging of ERK and Akt activation dynamics and heterogeneity induced by G protein-coupled receptors.. 2022 ,	2
428	Putative dual inhibitors of mTOR and RET kinase from natural products: Pharmacophore-based hierarchical virtual screening. 2022 , 350, 118562	0
427	Analysis of protein kinases by Phos-tag SDS-PAGE.. 2022 , 104485	1
426	EMBER: Multi-label prediction of kinase-substrate phosphorylation events through deep learning.. 2022 ,	3
425	Tousled-like kinase 2 targets ASF1 histone chaperones through client mimicry.. 2022 , 13, 749	0
424	Effect of pH on the structure and function of cyclin-dependent kinase 6.. 2022 , 17, e0263693	0
423	Discovery of Novel Inhibitors of CDK2 Using Docking and Physics-based Binding Free Energy Calculation.. 2022 ,	0
422	An explainable unsupervised framework for alignment-free protein classification using sequence embeddings.	
421	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.. 2021 ,	10
420	Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.. 2021 , 4, e2138793	12
419	Cancer gene mutation frequencies for the U.S. population. 2021 , 12, 5961	15
418	Design and Synthesis of New Thiophene/Thieno[2,3-]pyrimidines along with Their Cytotoxic Biological Evaluation as Tyrosine Kinase Inhibitors in Addition to Their Apoptotic and Autophagic Induction.. 2021 , 27,	2
417	Co-expression of recombinant RIPK3:MLKL complexes using the baculovirus-insect cell system.. 2022 , 667, 183-227	0
416	Development of a phos-tag-based fluorescent biosensor for sensitive detection of protein kinase in cancer cells.. 2022 ,	0

- 415 Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. **2022**, 1-17
- 414 A narrative review of ERBB2 in non-small cell lung carcinoma. **2022**, 5, 97
- 413 Computational tools and resources for pseudokinase research.. **2022**, 667, 403-426 o
- 412 Biology and pathophysiology of central nervous system metastases. **2022**, 55-78
- 411 A human kinase yeast array for the identification of kinases modulating phosphorylation-dependent protein-protein interactions.. **2022**, 18, e10820 1
- 410 Glycogen Synthase Kinase 3βInvolvement in Neuroinflammation and Neurodegenerative Diseases.. **2022**, 1
- 409 Regulatory spine RS3 residue of protein kinases: a lipophilic bystander or a decisive element in the small-molecule kinase inhibitor binding?. **2022**,
- 408 Using publicly available transcriptomic data to identify mechanistic and diagnostic biomarkers in azoospermia and overall male infertility.. **2022**, 12, 2584 1
- 407 Targeting Protein Kinases and Epigenetic Control as Combinatorial Therapy Options for Advanced Prostate Cancer Treatment.. **2022**, 14, 1
- 406 Distinct PEAK3 interactors and outputs expand the signaling potential of the PEAK pseudokinase family.. **2022**, 15, eabj3554 1
- 405 Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.. **2022**, 14, o
- 404 The C. elegans ASPP homolog APE-1 is a junctional protein phosphatase 1 modulator.
- 403 Drug Repurposing and De Novo Drug Discovery of Protein Kinase Inhibitors as New Drugs against Schistosomiasis.. **2022**, 27, o
- 402 The Pseudokinase TRIB1 in Immune Cells and Associated Disorders.. **2022**, 14, o
- 401 Identification of Sorafenib as a Treatment for Type 1 Diabetes.. **2022**, 13, 740805
- 400 Deciphering the Role of Protein Phosphatases in Apicomplexa: The Future of Innovative Therapeutics?. **2022**, 10,
- 399 Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1.. **2022**, 13, 862504 1
- 398 Proteomic Analyses Identify Therapeutic Targets in Hepatocellular Carcinoma.. **2022**, 12, 814120 o

- 397 The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter.. **2022**, 13, 861642 0
- 396 Silencing of A-kinase anchor protein 4 inhibits the metastasis and growth of non-small cell lung cancer.. **2022**, 13, 6895-6907 0
- 395 Effective Reaction-Based Strategy for Kinase Targets: A Case Study on MERTK Inhibitors.. **2022**, 0
- 394 Divergent kinase WNG1 is regulated by phosphorylation of an atypical activation sub-domain. 0
- 393 High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators.. **2022**, 0
- 392 Identification of Pharmacophoric Fragments of DYRK1A Inhibitors Using Machine Learning Classification Models.. **2022**, 27, 0
- 391 A concise review on tyrosine kinase targeted cancer therapy. **2022**, 17, 0
- 390 CK1 Is a Druggable Regulator of Microtubule Dynamics and Microtubule-Associated Processes.. **2022**, 14, 1
- 389 Demystifying the O-GlcNAc Code: A Systems View.. **2022**, 3
- 388 Dark kinase annotation, mining and visualization using the Protein Kinase Ontology. 1
- 387 The proteogenomic subtypes of acute myeloid leukemia.. **2022**, 5
- 386 Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase .. **2021**, 0
- 385 A Recent Update on Small-molecule Kinase inhibitors for Targeted Cancer Therapy and Their Therapeutic Insights from Mass Spectrometry-based Proteomic Analysis.. **2022**, 3
- 384 Small Molecule Modulation of the Archetypal UbiB protein COQ8. 0
- 383 Protein kinases and protein phosphatases encoded in the Ciona robusta genome.. **2022**, e23471 0
- 382 Comparative analysis of the kinomes of Plasmodium falciparum, Plasmodium vivax and their host Homo sapiens.. **2022**, 23, 237 1
- 381 Switch Pocket Kinase: An Emerging Therapeutic Target for the Design of Anticancer Agents.. **2022**, 0
- 380 Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.. **2022**, 188725 1

379	ChemInformatics Model Explorer (CIME): exploratory analysis of chemical model explanations.. 2022 , 14, 21	0
378	Phosphoproteome Profiling of the Receptor Tyrosine Kinase MuSK Identifies Tyrosine Phosphorylation of Rab GTPases.. 2022 , 100221	1
377	Web support for the more efficient discovery of kinase inhibitors.. 2022 ,	
376	Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in vitro and in vivo.. 2022 , 233, 114215	3
375	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.. 2022 , 178, 106156	2
374	Unraveling the Roles of Protein Kinases in Autophagy: An Update on Small-Molecule Compounds for Targeted Therapy.. 2022 ,	1
373	Synthesis and biological evaluation of Haspin inhibitors: Kinase inhibitory potency and cellular activity.. 2022 , 236, 114369	0
372	Structural and Enzymological Evidence for an Altered Substrate Specificity in Okur-Chung Neurodevelopmental Syndrome Mutant CK2β 2022 , 9, 831693	0
371	Cyclin-dependent kinases in DNA damage response.. 2022 , 188716	7
370	The Potential Role of Curcumin in Modulating the Master Antioxidant Pathway in Diabetic Hypoxia-Induced Complications.. 2021 , 26,	5
369	Influence of the Season and Region Factor on Phosphoproteome of Stallion Epididymal Sperm.. 2021 , 11,	
368	Computational Saturation Mutagenesis of SARS-CoV-1 Spike Glycoprotein: Stability, Binding Affinity, and Comparison With SARS-CoV-2.. 2021 , 8, 784303	2
367	Phosphoproteomic Analysis Reveals Downstream PKA Effectors of AKAP Cypher/ZASP in the Pathogenesis of Dilated Cardiomyopathy.. 2021 , 8, 753072	1
366	Fam20C in Human Diseases: Emerging Biological Functions and Therapeutic Implications.. 2021 , 8, 790172	0
365	Active Site Sequence Representations of Human Kinases Outperform Full Sequence Representations for Affinity Prediction and Inhibitor Generation: 3D Effects in a 1D Model.. 2021 ,	1
364	Fam20C Overexpression Predicts Poor Outcomes and is a Diagnostic Biomarker in Lower-Grade Glioma.. 2021 , 12, 757014	0
363	Plant Phosphoproteomics: Known Knowns, Known Unknowns, and Unknown Unknowns of an Emerging Systems Science Frontier. 2021 , 25, 750-769	1
362	Structural conservation of WEE1 and its role in cell cycle regulation in plants.. 2021 , 11, 23862	1

361	SGC-CK2-1 Is an Efficient Inducer of Insulin Production and Secretion in Pancreatic β Cells.. 2021 , 14,	0
360	KANPHOS: A Database of Kinase-Associated Neural Protein Phosphorylation in the Brain.. 2021 , 11,	0
359	The role of necroptosis in disease and treatment.. 2021 , 2, 730-755	1
358	An overview of kinase downregulators and recent advances in discovery approaches.. 2021 , 6, 423	3
357	Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.. 2021 ,	1
356	E-Cadherin Phosphorylation by Protein Kinase D1/Protein Kinase C α s Associated with Altered Cellular Aggregation and Motility in Prostate Cancer. 2005 , 65, 483-492	35
355	Analysis of human Tribbles 2 (TRIB2) pseudokinase.. 2022 , 667, 79-99	0
354	Histone Deacetylase Inhibitor I3 Induces Differentiation of Acute Myeloid Leukemia Cells with T(8;21) or MLL Gene Translocation and Leukemic Stem-Like Cells.	
353	Production and analysis of titin kinase: Exploiting active/inactive kinase homologs in pseudokinase validation.. 2022 , 667, 147-181	1
352	CRISPR deletions in cell lines for reconstitution studies of pseudokinase function.. 2022 , 667, 229-273	
351	Posttranslational Modifications: Key Players in Health and Disease. 2022 ,	
350	The pseudokinase domain in receptor guanylyl cyclases.. 2022 , 667, 535-574	
349	Cardiac complications of cancer therapies. 2022 ,	0
348	Detecting endogenous TRIB2 protein expression by flow cytometry and Western blotting.. 2022 , 667, 59-77	
347	Biologically Mediated RAFT Polymerization for Electrochemical Sensing of Kinase Activity.. 2022 ,	3
346	Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry.. 2022 , 11,	1
345	Discovery of moiety preference by Shapley value in protein kinase family using random forest models.. 2022 , 23, 130	
344	Phosphorylation analysis of the Hippo-YAP pathway using Phos-tag.. 2022 , 104582	0

343	EXPLICIT-Kinase: a gene expression predictor for dissecting the functions of the Arabidopsis kinome.. 2022 ,	0
342	The Ascension of Targeted Covalent Inhibitors.. 2022 ,	3
341	Challenges and Opportunities Associated With Platelets in Pancreatic Cancer.. 2022 , 12, 850485	1
340	CHAPTER 17. Allosteric Inhibition of Abl Kinase. 381-403	
339	Image_1.tif. 2019 ,	
338	Presentation_1.pdf. 2019 ,	
337	Table_2.csv. 2019 ,	
336	Data_Sheet_1.pdf. 2020 ,	
335	Table_1.DOCX. 2020 ,	
334	Table_2.DOCX. 2020 ,	
333	Image_1.jpeg. 2019 ,	
332	Image_2.jpeg. 2019 ,	
331	Image_3.jpeg. 2019 ,	
330	Table_1.xls. 2019 ,	
329	Table_10.xls. 2019 ,	
328	Table_11.xls. 2019 ,	
327	Table_12.xls. 2019 ,	
326	Table_13.xls. 2019 ,	

325 Table_2.xls. **2019**,

324 Table_3.xls. **2019**,

323 Table_4.xls. **2019**,

322 Table_5.xls. **2019**,

321 Table_6.xls. **2019**,

320 Table_7.xls. **2019**,

319 Table_8.xls. **2019**,

318 Table_9.xls. **2019**,

317 Image1.pdf. **2018**,

316 Table1.xlsx. **2018**,

315 Data_Sheet_1.docx. **2020**,

314 Data_Sheet_1.docx. **2020**,

313 Table_1.DOCX. **2020**,

312 Table_1.doc. **2019**,

311 DataSheet_1.docx. **2020**,

310 Image_1.tif. **2020**,

309 Table_1.PDF. **2018**,

308 Data_Sheet_1.fasta. **2018**,

307 Data_Sheet_2.fasta. **2018**,

306 Data_Sheet_3.zip. **2018**,

305 Presentation_1.pdf. **2018**,

304 Table_1.xlsx. **2018**,

303 Table_2.xlsx. **2018**,

302 Table_4.xlsx. **2018**,

301 Table_5.xlsx. **2018**,

300 Identification of 3-(piperazinylmethyl)benzofuran derivatives as novel type II CDK2 inhibitors: design, synthesis, biological evaluation, and insights.. **2022**, 37, 1227-1240

4

299 Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing. 25,

298 Tio4n2'Complexes Formed with 1,10-Phenanthroline Ligands Containing a Donor-Acceptor Hydrogen Bond Site: Synthesis, Cytotoxicity and Docking Experiments.

297 Nanobodies identify an activated state of the TRIB2 pseudokinase.

296 Recent Progress in Fluorescent Chemosensors for Protein Kinases.. **2022**,

295 An integrated network representation of multiple cancer-specific data for graph-based machine learning.. **2022**, 8, 14

0

294 Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases.. **2022**, e202200983

1

293 Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset Of Resistance Mutations in Kinases.

292 Recent Progress on the Localization of PLK1 to the Kinetochore and Its Role in Mitosis.. **2022**, 23,

0

291 Kinome-wide polypharmacology profiling of small molecules by multi-task graph isomorphism network approach. **2022**,

0

290 Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. **2022**, 12, 685

- 289 Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.. **2022**, e0039822 0
- 288 PKD autoinhibition in trans regulates activation loop autophosphorylation in cis.
- 287 KiSSim: Predicting Off-Targets from Structural Similarities in the Kinome.. **2022**, 0
- 286 F/YGG-motif is an intrinsically disordered nucleic-acid binding motif.. **2022**, 19, 622-635 0
- 285 Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge.. **2022**, 1 0
- 284 Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.. **2022**, 128764 0
- 283 An In Silico Approach for Potential Natural Compounds as Inhibitors of Protein CDK1/Cks2. **2021**, 8,
- 282 Characterization and clustering of kinase isoform expression in metastatic melanoma.. **2022**, 18, e1010065 1
- 281 Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations. **2022**, 12, 14865-14882 0
- 280 Looking lively: emerging principles of pseudokinase signaling.. **2022**, 1
- 279 Validation of an allosteric binding site of Src kinase identified by unbiased ligand binding simulations. **2022**, 167628 1
- 278 Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.. **2022**, 1
- 277 RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2.. **2022**, 0
- 276 Sbk2, a Newly Discovered Atrium-Enriched Regulator of Sarcomere Integrity.. **2022**, 101161CIRCRESAHA121319300
- 275 Targeting the altered tyrosine kinases in colorectal cancer: From inhibitors to drugs. **2022**, 361-391 1
- 274 Drug discovery for cancer therapy with special reference to inhibitors of protein kinase pathway. **2022**, 71-96 1
- 273 Kinase inhibitors: An overview. **2022**, 1-22
- 272 Src kinase: An attractive therapeutic target for prostate cancer. **2022**, 479-503

271	Utilization of Landscape of Kinases and Phosphosites To Predict Kinase-Substrate Association.	
270	Phos-tag-based phosphate affinity chromatographic techniques. 2022 , 100051	
269	O-GlcNAc modification of leucyl-tRNA synthetase 1 integrates leucine and glucose availability to regulate mTORC1 and the metabolic fate of leucine. 2022 , 13,	0
268	Therapeutic Targeting the Allosteric Cysteine of RAS and Kinase Families. 2022 , 167626	0
267	Ancient Origins of Cytoskeletal Crosstalk: Spectraplakins-like Proteins Precede the Emergence of Cortical Microtubule Stabilization Complexes as Crosslinkers. 2022 , 23, 5594	0
266	GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond.	0
265	Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma.	1
264	A global atlas of substrate specificities for the human serine/threonine kinome.	1
263	Bayesian analysis of dynamic phosphoproteomic data identifies protein kinases mediating GPCR responses. 2022 , 20,	1
262	A journey from phosphotyrosine to phosphohistidine and beyond. 2022 ,	1
261	Deciphering the conformational transitions of LIMK2 active and inactive states to ponder specific druggable states through microsecond scale molecular dynamics simulation.	
260	TiO ₄ N ₂ complexes formed with 1,10-phenanthroline ligands containing a donor-acceptor hydrogen bond site: synthesis, cytotoxicity and docking experiments. 2022 , 121036	0
259	Dissecting the role of protein phosphorylation: a chemical biology toolbox.	3
258	The Microenvironment of Site-Specific Metastasis. 2022 , 107-115	
257	Identification of pan-kinase-family inhibitors using graph convolutional networks to reveal family-sensitive pre-moieties. 2022 , 23,	0
256	Exploring kinase family inhibitors and their moiety preferences using deep SHapley additive exPlanations. 2022 , 23,	1
255	The Nitrogen Mustards. 2022 , 74, 552-599	2
254	CDK6 activity in a recurring convergent kinase network motif.	

253 An open source plant kinase chemogenomics set.

252 Synthesis of 4,5-Dihydro-1H-[1,2]dithiolo[3,4-c]quinoline-1-thione Derivatives and Their Application as Protein Kinase Inhibitors. **2022**, 27, 4033

251 PROTACs: great opportunities for academia and industry (an update from 2020 to 2021). **2022**, 7, 9

250 Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model. **2022**, 23, 6427

249 Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides as Novel Potential Anticancer Agents: Cytotoxic and Genotoxic Activities In Vitro. **2022**, 27, 3761

248 Interpretable machine learning identification of arginine methylation sites. **2022**, 105767

247 Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. **2022**, 12, 878

246 Maximizing the integration of virtual and experimental screening in hit discovery. 1-12

245 Therapeutic Inhibitors: Natural Product Options through Computer-Aided Drug Design.

244 Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1.

243 Update and elucidation of Plasmodium kinomes: Prioritization of kinases as potential drug targets for malaria. **2022**, 20, 3708-3717

242 Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics. 9,

241 Restoration of EGC trafficking improves the lysosome function in Gaucher's disease.

240 New Perspectives on the Role of Integrin-Linked Kinase (ILK) Signaling in Cancer Metastasis. **2022**, 14, 3209

239 Comparative kinase activity profiling of pathogenic influenza A viruses reveals new anti- and pro-viral protein kinases. **2022**, 103,

238 Docking-Based Virtual Screening Enables Prioritizing Protein Kinase Inhibitors With In Vitro Phenotypic Activity Against Schistosoma mansoni. 12,

237 MST4 negatively regulates type I interferons production via targeting MAVS-mediated pathway. **2022**, 20,

236 KinasePhos 3.0: Redesign and expansion of the prediction on kinase-specific phosphorylation sites. **2022**,

- 235 Dissecting the roles of Haspin and VRK1 in histone H3 phosphorylation during mitosis. **2022**, 12, 0
- 234 Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells. 1
- 233 Harnessing systematic protein-ligand interaction fingerprints for drug discovery. **2022**, 2
- 232 Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy. **2022**, 100358 2
- 231 Immune-related adverse events of cancer immunotherapies targeting kinases. **2022**, 108250 0
- 230 The *C. elegans* ASPP homolog APE-1 is a junctional protein phosphatase 1 modulator. 0
- 229 Investigation of the role of endogenous miRNAs in determining sterility in triploid Pacific oysters (*Crassostrea gigas*). **2022**, 738606
- 228 Dysregulated Protein Phosphorylation in a Mouse Model of FTLD-Tau.
- 227 Grass carp (*Ctenopharyngodon idella*) DYRK2 modulates cell apoptosis through phosphorylating p53. **2022**, 127, 542-548 0
- 226 EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. **2022**, 110, 109031 2
- 225 Perturbation of biological processes with small molecule kinase inhibitors. **2022**, 70, 102185
- 224 Recent advances in targeting protein kinases and pseudokinases in cancer biology. 10, 1
- 223 Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition.
- 222 Epinephrine inhibits PI3K alpha via the Hippo kinases.
- 221 Nonreceptor Protein Kinases and Phosphatases Necessary for Auditory Function.
- 220 Multi-omics analysis reveals expression complexity and functional diversity of mouse kinome. 2200120
- 219 Negative regulation of receptor tyrosine kinases by ubiquitination: Key roles of the Cbl family of E3 ubiquitin ligases. 13,
- 218 Structural characterization and expression analysis of novel MAPK1 transcript variants with the development of a multiplexed targeted nanopore sequencing approach. **2022**, 106272 0

- 217 Beyond controlling cell size: functional analyses of S6K in tumorigenesis. **2022**, 13,
- 216 The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review. **2022**, 10, 31 o
- 215 Exploring the roles of the Cdc2-like kinases in cancers. **2022**, 70, 116914 o
- 214 Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications. **2022**, 218, 394-408 1
- 213 Drug-Target Affinity Prediction Based on Multi-channel Graph Convolution. **2022**, 533-546
- 212 Precision Medicine in Therapy of Non-solid Cancer. **2022**,
- 211 Developing A Multi-task Edge-attention based Graph Deep Learning Algorithm for Kinase Polypharmacology Profiling. **2022**,
- 210 Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma. **2022**, 2,
- 209 Paladin, overexpressed in colon cancer, is required for actin polymerisation and liver metastasis dissemination. **2022**, 11, o
- 208 All-in-One Luminescent Lanthanide Coordination Polymer Nanoprobe for Facile Detection of Protein Kinase Activity. **2022**, 94, 10730-10736 o
- 207 ATP-competitive inhibitors modulate the substrate binding cooperativity of a kinase by altering its conformational entropy. **2022**, 8, 1
- 206 Structural basis for the calmodulin-mediated activation of eukaryotic elongation factor 2 kinase. **2022**, 8, 1
- 205 Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: What's New?. **2022**, 29,
- 204 CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. **2022**, 41,
- 203 Heavy Metal Stress-Induced Activation of Mitogen-Activated Protein Kinase Signalling Cascade in Plants. o
- 202 Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site. **2022**, 65, 10975-10991
- 201 Genome-wide characterization of the common bean kinome: catalog and insights into expression patterns and genetic organization. o
- 200 A small molecule screen reveals the essentiality of p38 kinase for choanoflagellate cell proliferation.

- 199 Analysis of the potential role of fission yeast PP2A in spindle assembly checkpoint inactivation. **2022**, 36,
- 198 Divergent kinase WNG1 is regulated by phosphorylation of an atypical activation sub-domain.
- 197 The Omnipresence of DYRK1A in Human Diseases. **2022**, 23, 9355 1
- 196 Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. **2022**, 183, 106362 0
- 195 Insight into the C-terminal SH3 domain mediated binding of Drosophila Drk to Sos and Dos. **2022**, 625, 87-93
- 194 Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy. **2022**, 99, 110434 1
- 193 Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment. **2022**, 128, 106071
- 192 Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. **2004**, 3, 21-27 5
- 191 Identification of an integrated kinase-related prognostic gene signature associated with tumor immune microenvironment in human uterine corpus endometrial carcinoma. 12, 0
- 190 Engineered kinases as a tool for phosphorylation of selected targets in vivo. **2022**, 221, 0
- 189 Phosphoproteomics data-driven signalling network inference: does it work?. 0
- 188 Biosensors for the detection of protein kinases: Recent progress and challenges. **2022**, 182, 107961 0
- 187 Therapeutic peptides targeting protein kinase: progress, challenges, and future directions, featuring cancer and cardiovascular disease. **2022**, 333-356 0
- 186 Molecular Principles, Components, Technology, and Concepts: Proteins [Posttranslational Modifications: Key Players in Health and Disease. **2022**, 0
- 185 Phosprof: pathway analysis database of drug response based on phosphorylation activity measurements. **2022**, 2022, 0
- 184 Protein Sequence Determination: Methodology and Evolutionary Implications. **2022**, 0
- 183 PTMs: A Missing Piece for Schizophrenia Studies. **2022**, 119-127 0
- 182 Oxidative Stress in Cancer: Therapeutic Implications of Small-Molecule Kinase Inhibitors. **2022**, 3809-3825 0

- 181 Process-biomimetic macromolecular materials for in vivo applications. **2023**, 131, 101015 o
- 180 Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells. **2022**, 2022, 1-13 1
- 179 Heterocycles in Breast Cancer Treatment: The use of Pyrazole Derivatives. **2022**, 29, o
- 178 Inferring kinase activity from phosphoproteomic data: Tool comparison and recent applications. 1
- 177 Research progress on the relationship between the TOR signaling pathway regulator, epigenetics, and tumor development. 13, o
- 176 Mechanisms of Regulation in Intraflagellar Transport. **2022**, 11, 2737 1
- 175 Protein kinase CK2 Diverse roles in cancer cell biology and therapeutic promise. 1
- 174 Systematic Review of the Role of Alpha-Protein Kinase 1 in Cancer and Cancer-Related Inflammatory Diseases. **2022**, 14, 4390 o
- 173 A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation-regulated kinase 2 (DYRK2) in human tumors. **2022**, 12, o
- 172 Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKB/AKT2 inhibitory and in vitro anti-glioma activity. **2022**, 54, 2549-2561 o
- 171 Evolutionary and cellular analysis of the dark pseudokinase PSKH2. o
- 170 Phosphorylation, compartmentalization, and cardiac function. o
- 169 The two facets of receptor tyrosine kinase in cardiovascular calcification: Can tyrosine kinase inhibitors benefit cardiovascular system?. 9, 1
- 168 Nanobodies identify an activated state of the TRIB2 pseudokinase. **2022**, o
- 167 Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. 12, o
- 166 AXL kinase inhibitors- A prospective model for medicinal chemistry strategies in anticancer drug discovery. **2022**, 1877, 188786 o
- 165 Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome. **2022**, 74, 1136-1145 o
- 164 Mitochondrial protein dysfunction in pathogenesis of neurological diseases. 15, 2

163	Pyrazolo[3,4- d]pyrimidine scaffold: A review on synthetic approaches and EGFR and VEGFR inhibitory activities.	0
162	Imaging strategies for receptor tyrosine kinase dimers in living cells.	0
161	Monitoring drug-target interactions through target engagement-mediated amplification on arrays and in situ.	0
160	Emerging insights into serine/threonine-specific phosphoprotein phosphatase function and selectivity. 2022 , 135,	1
159	Comparative and evolutionary analysis of RIP kinases in immune responses. 13,	1
158	The pathogenesis of organ fibrosis: Focus on necroptosis.	0
157	Exploring the Mechanism of Action of Taoren Honghua Decoction in the Treatment of Cardiac Arrhythmias Based on Network Pharmacology and Molecular Docking. 2022 , 12, 9243-9254	0
156	Exploration of cancer predictive biomarkers: Comprehensive kinase activity assay with three-dimension peptide array. 2022 , 66, 47-51	0
155	Identification of multi-kinase allosteric inhibitors of oncogenic targets EGFR1, PI3 & BRAF Kinase. 2022 , 19,	0
154	CRISPRi screens in human iPSC-derived astrocytes elucidate regulators of distinct inflammatory reactive states. 2022 , 25, 1528-1542	1
153	Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. 2022 , 15, 1322	0
152	An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function.	0
151	Rational Design, Synthesis and Biological Evaluation of Novel Pyrazoline-Based Antiproliferative Agents in MCF-7 Cancer Cells. 2022 , 15, 1245	0
150	Genome-Wide Analysis of AGC Kinases Reveals that MoFpk1 Is Required for Development, Lipid Metabolism, and Autophagy in Hyperosmotic Stress of the Rice Blast Fungus <i>Magnaporthe oryzae</i> .	0
149	Oncogenes. 1-25	1
148	Phosphorylation-mediated PI3K-Akt signalling pathway as a therapeutic mechanism in the hydrogen-induced alleviation of brain injury in septic mice.	0
147	Cellular and physiological roles of the conserved atypical MAP kinase ERK7.	0
146	Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. 9,	0

145	Small-molecule inhibition of the archetypal UbiB protein COQ8.	0
144	Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases. 2022 , 27, 7124	0
143	A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAFV600Ecolorectal tumors.	0
142	Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules. 2022 , 102656	0
141	In silico approaches uncovering the systematic function of N-phosphorylated proteins in human cells. 2022 , 106280	0
140	HIPK2 in cancer biology and therapy: Recent findings and future perspectives. 2023 , 101, 110491	4
139	Molecular mechanisms of hormonal activity. I. receptors. neuromediators. systems with second messengers. 2005 , 70, 24-39	0
138	De novo transcriptome assembly and identification of G-Protein-Coupled-Receptors (GPCRs) in two species of monogenean parasites of fish. 2022 , 29, 51	1
137	Construction of a phos-tag-directed self-assembled fluorescent magnetobiosensor for simultaneous detection of multiple protein kinases.	0
136	Pyrophosphoproteomics: extensive protein pyrophosphorylation revealed in human cell lines.	0
135	Identification of novel kinases of Tau using fluorescence complementation mass spectrometry (FCMS)*. 2022 , 100441	0
134	Competition between electrostatic interactions and halogen bonding in the protein-ligand system: structural and thermodynamic studies of 5,6-dibromobenzotriazole-hCK2 complexes. 2022 , 12,	0
133	Systematic analysis of the MAPK signaling network reveals MAP3K-driven control of cell fate. 2022 , 13, 885-894.e4	1
132	The Power of Biocatalysts for Highly Selective and Efficient Phosphorylation Reactions. 2022 , 12, 1436	0
131	Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes. 2023 , 38, 84-99	3
130	Regulation of alphaherpesvirus protein via post-translational phosphorylation. 2022 , 53,	0
129	Functional annotation of proteins for signaling network inference in non-model species.	0
128	Function and inhibition of Haspin kinase: targeting multiple cancer therapies by antimitosis.	0

127	Targeting Gatekeeper Mutations for Kinase Drug Discovery.	1
126	Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. 2022 , 106552	6
125	Phosphorylation-Based Molecular Switches. 2022 , 381-400	0
124	Mass Spectrometry-based Methodologies for Studying Proteolytic Networks and the Degradome. 2016 , 396-410	0
123	The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer. 2023 , 114, 109581	0
122	Phosphoproteomics data-driven signalling network inference: Does it work?. 2023 , 21, 432-443	0
121	Genome-wide characterization of the common bean kinome: Catalog and insights into expression patterns and genetic organization. 2023 , 855, 147127	0
120	Mixed lineage kinase domain-like pseudokinase: Conventional (necroptosis) and unconventional (necroptosis-independent) functions and features. 2022 ,	0
119	Quantitative phosphoproteomic analysis of chitin-triggered immune responses in the plasma membrane of Arabidopsis. 2022 ,	0
118	Multi-omics analysis identifies drivers of protein phosphorylation.	0
117	Evaluation of Quantification and Normalization Strategies for Phosphoprotein Phosphatase Affinity Proteomics: Application to Breast Cancer Signaling.	0
116	An open source plant kinase chemogenomics set. 2022 , 6,	0
115	Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.	0
114	Regulation of eukaryotic protein kinases by Pin1, a peptidyl-prolyl isomerase. 2022 , 100938	0
113	Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content.	0
112	Evolutionary Divergence of Phosphorylation to Regulate Interactive Protein Networks in Lower and Higher Species. 2022 , 23, 14429	0
111	Neuroprotective and anticancer effects of 7-Methoxyheptaphylline via the TAK1 pathway. 2022 , 49,	0
110	Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. 2022 , 22,	0

- 109 Multilayered allosteric modulation of coupled folding and binding by phosphorylation, peptidyl-prolyl cis/trans isomerization, and diversity of interaction partners. **2022**, 157, 235102 ○
- 108 De novo linear phosphorylation site motifs for BCR-ABL kinase revealed by phospho-proteomics in yeast. ○
- 107 A receptor tyrosine kinase regulated by the transcription factor VAB-3/PAX6 pairs with a pseudokinase to trigger immune signalling upon oomycete recognition in *C. elegans*. ○
- 106 Phosphorylation of enteroviral 2A pro at Ser/Thr125 benefits its proteolytic activity and viral pathogenesis. **2023**, 95, ○
- 105 High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors. **2022**, 14, 6061 ○
- 104 Evolutionary and cellular analysis of the 'dark' pseudokinase PSKH2. ○
- 103 Structure and regulation of full-length human leucine-rich repeat kinase 1. ○
- 102 The Role of Bromodomain and Extraterminal (BET) Proteins in Controlling the Phagocytic Activity of Microglia In Vitro: Relevance to Alzheimer's Disease. **2023**, 24, 13 1
- 101 Nucleosome assembly protein 1-like 5 alleviates Alzheimer's disease-like pathological characteristics in a cell model. 15, ○
- 100 Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy. **2022**, 14, 2706 1
- 99 A novel leaky surface acoustic wave biosensor for detection of PKA activity in cell lysates based on peptide biomineralized metal nanoclusters. **2022**, 114107 ○
- 98 A Review: Meridianins and Meridianins Derivatives. **2022**, 27, 8714 ○
- 97 Structural perspective on the design of selective DYRK1B inhibitors.. ○
- 96 Cdc37 as a Co-chaperone to Hsp90. **2023**, 141-158 ○
- 95 Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia. ○
- 94 Drug Repositioning Applied to Cardiovascular Disease in Mucopolysaccharidosis. **2022**, 12, 2085 ○
- 93 Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management. **2022**, 23, 15693 ○
- 92 The Stiffness-sensitive Transcriptome of Human Tendon Stromal Cells. 2101216 ○

91	Network-based approach for targeting human kinases commonly associated with amyotrophic lateral sclerosis and cancer. 15,	0
90	Tree visualizations of protein sequence embedding space enable improved functional clustering of diverse protein superfamilies.	1
89	Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. 2023 , 15, 403	0
88	Redefining pseudokinases: A look at the untapped enzymatic potential of pseudokinases.	0
87	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. 13,	0
86	The Role of JAK/STAT Pathway in Fibrotic Diseases: Molecular and Cellular Mechanisms. 2023 , 13, 119	0
85	Dynamic conformational states of apo, ATP and cabozantinib bound TAM kinases to differentiate active-inactive kinetic models. 1-21	0
84	An atlas of substrate specificities for the human serine/threonine kinome.	3
83	Targeting Death-Associated Protein Kinases for Treatment of Human Diseases: Recent Advances and Future Directions.	0
82	Targets mapped for almost all human kinase enzymes.	0
81	Regulating eEF2 and eEF2K in skeletal muscle by exercise. 1-12	0
80	Cordycepin and kinase inhibition in cancer. 2023 , 28, 103481	0
79	Kinases control of regulated cell death revealing druggable targets for Parkinson's disease. 2023 , 85, 101841	1
78	From phosphorylation to phenotype Recent key findings on kinase regulation, downstream signaling and disease surrounding the receptor tyrosine kinase MuSK. 2023 , 104, 110584	0
77	Protein Kinase CK2 Contributes to Glucose Homeostasis by Targeting Fructose-1,6-Bisphosphatase 1. 2023 , 24, 428	0
76	Affimer-Mediated Locking of a PAK5 Intermediate Activation State Reveals a Novel Mechanism of Kinase Inhibition.	0
75	Cyclic AMP Responsive Element Binding Protein 3-like 4/AarF Domain Containing Kinase 5 Axis Facilitates Proliferation, Migration and Invasion of Lung Adenocarcinoma Cells by Modulating the TGF β Pathway.	0
74	Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development and lung metastasis.	0

- 73 Identification of a Class of WNK Isoform-Specific Inhibitors Through High-Throughput Screening. Volume 17, 93-105 o
- 72 Voltage-Gated T-Type Calcium Channel Modulation by Kinases and Phosphatases: The Old Ones, the New Ones, and the Missing Ones. **2023**, 12, 461 o
- 71 Comparative Analysis of Dasatinib Effect between 2D and 3D Tumor Cell Cultures. **2023**, 15, 372 1
- 70 Master mitotic kinases regulate viral genome delivery during papillomavirus cell entry. **2023**, 14, o
- 69 EFMC Trends that Link Medicinal Chemistry and Chemical Biology to Translational Drug Discovery. o
- 68 In silico approaches in the repurposing of bioactive natural products for drug discovery. **2023**, 125-147 o
- 67 Molecular characterization, expression and function analysis of Epinephelus coioides PKC- γ response to Singapore grouper iridovirus (SGIV) infection. **2023**, 142, 104646 o
- 66 New Biological Evaluation of Thienoquinolines as Disruptors of the PKC δ /RACK2 Protein-Protein Interaction. **2022**, 77, S46-S54 o
- 65 Regulation of secretory pathway kinase or kinase-like proteins in human cancers. 14, o
- 64 Kinase Degraders, Activators, and Inhibitors: Highlights and Synthesis Routes to the Chemical Probes on opnMe.com, Part 1. o
- 63 Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3 β and DYRK1A Kinases: A Structural Perspective. **2023**, 66, 4009-4024 o
- 62 Protein kinase D3 conditional knockout impairs osteoclast formation and increases trabecular bone volume in male mice. **2023**, 116759 o
- 61 Strategies for Competitive Activity-Based Protein Profiling in Small Molecule Inhibitor Discovery and Characterization. o
- 60 Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy. **2023**, 299, 104572 o
- 59 Protein phosphorylation database and prediction tools. **2023**, 24, o
- 58 Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily. **2023**, 115347 o
- 57 Phosformer: an explainable transformer model for protein kinase-specific phosphorylation predictions. **2023**, 39, o
- 56 Computational Approaches to Enzyme Inhibition by Marine Natural Products in the Search for New Drugs. **2023**, 21, 100 o

- 55 Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. o
- 54 KinFams: De-Novo Classification of Protein Kinases Using CATH Functional Units. **2023**, 13, 277 o
- 53 Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. **2023**, 83, 803-818.e8 o
- 52 The NLRP3 Inflammasome Works as a Sensor for Detecting Hypoactivity of the Mitochondrial Src Family Kinases. **2023**, 210, 795-806 o
- 51 Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. **2023**, 189, 106642 o
- 50 Role of Protein Kinase A Activation in the Immune System with an Emphasis on Lipopolysaccharide-Responsive and Beige-like Anchor Protein in B Cells. **2023**, 24, 3098 o
- 49 In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation. **2023**, 23, o
- 48 Role of Fyn in hematological malignancies. o
- 47 A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors. **2023**, 4, 240-256 o
- 46 Mass spectrometry analysis of phosphotyrosine-containing proteins. o
- 45 Trans-activating mutations of the pseudokinase ERBB3. o
- 44 Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario. **2023**, 15, 664 o
- 43 Network-based elucidation of colon cancer drug resistance by phosphoproteomic time-series analysis. o
- 42 Palbociclib (PD 0332991) Interaction with Kinases. Theoretical and Comparative Molecular Docking Study. **2023**, 20, o
- 41 HER Receptor, Current, and Emerging Therapeutic Targets. **2023**, 1-32 o
- 40 Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases. **2023**, 15, 568 o
- 39 Strategy toward Kinase-Selective Drug Discovery. **2023**, 19, 1615-1628 o
- 38 Protein kinases: Role of their dysregulation in carcinogenesis, identification and inhibition. **2023**, 73, 189-199 o

- 37 Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning. ○
- 36 Comparative genomics studies on the stk gene family in vertebrates: From the bighead carp (*Hypophthalmichthys nobilis*) genome. **2023**, 135, 108642 ○
- 35 Self-Assembly of the Tetraphenylethylene-Capped Diserine through a Hierarchical Assembly Process. **2023**, 34, 562-571 ○
- 34 FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. **2023**, 26, 106309 ○
- 33 Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase. 11, ○
- 32 Functional molecular evolution of a GTP sensing kinase: PI5P4K○ ○
- 31 Edmond Fischer's kinase legacy: History of the protein kinase inhibitor and protein kinase 'A. **2023**, 75, 311-323 ○
- 30 A Mouse Systems Genetics Approach Reveals Common and Uncommon Genetic Modifiers of Hepatic Lysosomal Enzyme Activities and Glycosphingolipids. **2023**, 24, 4915 ○
- 29 Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles. **2023**, 24, 5088 ○
- 28 CDK6 activity in a recurring convergent kinase network motif. **2023**, 37, ○
- 27 Spinocerebellar ataxia type 11 (SCA11): TTBK2 variants, functions and associated disease mechanisms. ○
- 26 Evolutionary history of MEK1 illuminates the nature of cancer and RASopathy mutations. ○
- 25 Multiplex single-cell chemical genomics reveals the kinase dependence of the response to targeted therapy. ○
- 24 Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. **2023**, 22, 511-523 ○
- 23 Drug discovery processes: When and where the rubber meets the road. **2023**, 339-415 ○
- 22 Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. **2023**, 24, 5821 ○
- 21 2-5A-Mediated decay (2-5AMD): from antiviral defense to control of host RNA. 1-15 ○
- 20 The Cucumber Kinome: genome-wide, identification, characterisation and expression analysis of the *Cucumis sativus* protein kinases in response to Powdery Mildew, *Alternaria* Leaf Spot and Root-Knot Nematode. ○

- 19 Mapping the Protein Kinome: Current Strategy and Future Direction. **2023**, 12, 925 ○
- 18 Rigid Scaffolds are Promising for Designing Macrocyclic Kinase Inhibitors. ○
- 17 Poincaré maps for visualization of large protein families. ○
- 16 Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. **2023**, ○
- 15 Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily. ○
- 14 Deciphering the complete human-monkeypox virus interactome: Identifying immune responses and potential drug targets. 14, ○
- 13 The promotion action of AURKA on post-ischemic angiogenesis in diabetes-related limb ischemia. **2023**, 29, ○
- 12 LRRK2 Structure-Based Activation Mechanism and Pathogenesis. **2023**, 13, 612 ○
- 11 Mechanistic and evolutionary insights into isoform-specific "supercharging" in DCLK family kinases. ○
- 10 Comprehensive proteome, phosphoproteome and kinome characterization of luminal A breast cancer. 13, ○
- 9 NEK Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types. **2023**, 15, 2067 ○
- 8 Drug-target affinity prediction method based on consistent expression of heterogeneous data. **2022**, ○
- 7 De Novo Linear Phosphorylation Site Motifs for BCR-ABL Kinase Revealed by Phospho-Proteomics in Yeast. ○
- 6 Development of a cell-permeable adenine-derived probe for capture of nucleotide-binding proteins in living cells. **2023**, 108455 ○
- 5 Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. **2023**, 106774 ○
- 4 NRBP1 Promotes the Malignant Phenotypes of Glioblastoma by Regulating PI3K/Akt Activation. ○
- 3 Target proteins profiling of irreversible kinase inhibitor pelitinib and discovery of degradation of PRDX4 by label free chemoproteomics. **2023**, 230, 115398 ○
- 2 MKK4 Inhibitors Recent Development Status and Therapeutic Potential. **2023**, 24, 7495 ○

- 1 Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome.
Publish Ahead of Print,

o